thalidomide has been researched along with lenalidomide in 2367 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 437 (18.46) | 29.6817 |
| 2010's | 1769 (74.74) | 24.3611 |
| 2020's | 161 (6.80) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, H; Hashimoto, Y; Miyachi, H; Miyajima, A; Noguchi, T; Sano, H | 1 |
| Abbasian, M; Carmel, G; Cathers, B; Chen, R; Chopra, R; Daniel, TO; Evans, JF; Gaidarova, S; Gandhi, AK; Handa, H; Ito, T; Jackson, P; Kang, J; Karasawa, S; Lopez-Girona, A; Mahmoudi, A; Mendy, D; Miller, K; Rychak, E; Schafer, PH | 1 |
| Babusis, D; Capone, L; Chen, R; Corral, L; Kang, J; Man, HW; Moghaddam, MF; Muller, GW; Parton, A; Ruchelman, AL; Schafer, PH; Shirley, MA; Tang, Y; Zhang, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abraham, LJ; Callus, BA; Diepeveen, LA; Dwyer, BJ; Elsegood, CL; Finch-Edmondson, ML; Kampmann, SS; Kong, GS; Olynyk, JK; Passman, AM; Stewart, SG; Tirnitz-Parker, JE; Woo, K; Yeoh, GC; Yeung, SY | 1 |
| Bahlis, NJ; Derksen, DJ; Gorobets, E; MacCallum, JL; Maity, R; Muniyat, MI; Neri, P; Papatzimas, JW | 1 |
| Bär, K; Giannis, A; Hartmann, MD; Heim, C; Hernandez Alvarez, B; Mousavizadeh, F; Pliatsika, D | 1 |
| Cao, F; Chen, D; de Weerd, S; Dekker, FJ; van der Wouden, PE; Zwinderman, MRH | 1 |
| Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
| Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT | 1 |
| Che, J; Jones, LH; Kong, NR; Liu, H | 1 |
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Chen, Y; Freedman, VH; Kaplan, G; Mangaliso, B; Muller, G; Stirling, D; Tsenova, L | 1 |
| Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D | 1 |
| Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J | 1 |
| Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M | 1 |
| Anderson, KC | 7 |
| Hanekom, WA; Haslett, PA; Kaplan, G; Muller, G | 1 |
| Bennett, BL; Mercurio, F; Schafer, PH; Stirling, DI; Zeldis, JB | 1 |
| Mehta, J; Singhal, S | 2 |
| Hattori, Y | 1 |
| Anderson, KC; Burger, R; Catley, LP; Chauhan, D; Cheema, P; Hideshima, T; LeBlanc, R; Mitsiades, C; Mitsiades, N; Munshi, NC; Richardson, PG; Shringarpure, R | 1 |
| Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J | 1 |
| Barlogie, B | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K | 1 |
| Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Ng, SS; Parker, C; Tohnya, TM; Wright, JJ; Zeldis, J | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Mitsiades, CS; Mitsiades, N | 1 |
| Anderson, K; Richardson, P | 1 |
| Anderson, KC; Antin, JH; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, P; Stirling, DI | 1 |
| Kyle, RA; Rajkumar, SV | 2 |
| Dahut, WL; Figg, WD; Fine, HA; Hwang, K; Lepper, ER; Sparreboom, A; Tohnya, TM; Venitz, J | 1 |
| Chen, RS; Haley, M; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Akman, HO; Batuman, OA; Berenson, JR; Braunstein, M; Chen, L; Dai, K; Hussain, MM; Klueppelberg, U; Maroney, J; Norin, AJ; Ozçelik, T; Smith, EL; Vakil, V; Zhang, H | 1 |
| Aul, C; Boultwood, J; Germing, U; Giagounidis, AA; Wainscoat, JS | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Cazzola, M; Malcovati, L | 1 |
| Buresh, A; Fuchs, D; Heaton, R; Knight, R; Kurtin, S; List, A; Mahadevan, D; Rimsza, L; Roe, DJ; Zeldis, JB | 1 |
| Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K; Horsfall, R; Lu, L; Muller, G; Robinson, SP; Schafer, P; Shirley, MA; Stirling, D; Tang, Y; Zhang, LH | 1 |
| List, A; Sekeres, MA | 2 |
| Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B; Strupp, C | 1 |
| Chng, WJ | 1 |
| Ganser, A; Stadler, M | 1 |
| Rajkumar, SV | 6 |
| Knight, R | 1 |
| List, AF | 7 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Czuczman, MS; Hernandez-Ilizaliturri, FJ; Holkova, B; Ottman, E; Reddy, N | 1 |
| Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR | 1 |
| Teo, SK | 1 |
| Silver, R | 1 |
| Richardson, P | 3 |
| Bartlett, JB; Stirling, D; Tozer, A; Zeldis, JB | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Bockman, J; Rice, MC | 1 |
| Elice, F; Tricot, G; Zangari, M | 1 |
| Hellström-Lindberg, E | 1 |
| Crane, E; List, A | 2 |
| Anderson, KC; Prince, HM | 1 |
| Greipp, P | 1 |
| Hussein, MA | 1 |
| Anderson, KC; Bae, J; Breitkreutz, I; Catley, L; Chauhan, D; Coffey, R; Grewal, IS; Hideshima, T; Li, XF; Munshi, NC; Podar, K; Richardson, P; Schlossman, R; Song, W; Tai, YT; Treon, SP | 1 |
| Aul, C; Germing, U; Giagounidis, AA | 1 |
| Hammond, JM; Maier, SK | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 1 |
| Murakami, H | 1 |
| Badros, A; Deng, A; Gaspari, A; Harvey, V; Junkins-Hopkins, JM; Oghilikhan, M; Samuels, A; Sina, B; Strobel, D | 1 |
| Gandhi, AK; Kang, J; Naziruddin, S; Parton, A; Schafer, PH; Stirling, DI | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Hussein, MA; Srkalovic, JG; Suppiah, R | 1 |
| Beal, MF; Calingasan, NY; Chen, J; Choi, DK; Gardian, G; Hensley, K; Kiaei, M; Kipiani, K; Muller, GW; Petri, S; Schafer, P; Stewart, C | 1 |
| Coiteux, V; Facon, T; Leleu, X | 1 |
| Chang, DH; Dhodapkar, MV; Hassoun, H; Jagannath, S; Klimek, V; Liu, N; Mazumder, A; Nimer, SD | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Allred, JB; Byrne, C; Cortes, J; Giles, F; Hogan, WJ; Jones, D; Kantarjian, HM; Ketterling, RP; Lasho, TL; Litzow, MR; McClure, RF; Mesa, RA; Tefferi, A; Thomas, D; Verstovsek, S; Zeldis, JB | 1 |
| DeLap, RJ; Knight, R; Zeldis, JB | 1 |
| Hess, U | 1 |
| Blood, E; Rajkumar, SV | 1 |
| Awada, A; de Castro, G | 1 |
| Nimer, SD | 1 |
| Chanan-Khan, A; Porter, CW | 1 |
| Kumar, S; Rajkumar, SV | 1 |
| Galili, N; Raza, A | 3 |
| Barlogie, B; Crowley, J; Durie, BG; Hussein, MA; McCoy, J; Zonder, JA | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Daines, CA; Dalgleish, AG; Knight, RD; O'Byrne, KJ; Sharma, RA; Steward, WP | 1 |
| Davis, MD; Hoverson, AR; Weenig, RH; Wolanskyj, AP | 1 |
| Davies, MJ | 2 |
| Barrick, M | 1 |
| Fortenbaugh, C | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 2 |
| Doss, DS | 1 |
| Fennessey, S; Finn, KT; Rosenzweig, M; Sanchorawala, V; Seldin, DC; Skinner, M; Wright, DG; Zeldis, JB | 1 |
| Harousseau, JL | 7 |
| Moreau, P | 1 |
| Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J | 1 |
| Curtiss, FR | 1 |
| Li, CY; Mesa, RA; Steensma, DP; Tefferi, A | 1 |
| Jagannath, S; Mazumder, A | 1 |
| Allred, JB; Dispenzieri, A; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kabat, B; Kumar, SK; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR | 1 |
| Anderson, KC; Hideshima, T; Raje, N | 1 |
| Bennett, J; Dewald, G; Feldman, E; Giagounidis, A; Greenberg, P; Knight, R; List, A; Patin, J; Powell, B; Raza, A; Reeder, C; Schmidt, M; Stone, R; Thomas, D; Wride, K; Zeldis, J | 1 |
| Okamoto, S | 1 |
| Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Dreicer, R; Elson, P; Garcia, JA; Jinks, HA; Mekhail, TM; Rini, BI; Thakkar, SG | 1 |
| Kale, V; List, AF | 1 |
| Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P | 1 |
| Kenealy, M; Prince, HM | 1 |
| Zangari, M | 1 |
| Borden, E; Bukowski, R; Cline-Burkhardt, M; Davis, M; Dowlati, A; Dreicer, R; Kalmadi, S; Mekhail, T; O'Keefe, S; Pelley, RJ | 1 |
| Aul, C; Giagounidis, AA; Göhring, G; Haase, S; Heinsch, M; Schlegelberger, B | 1 |
| Fenaux, P; Kelaidi, C | 1 |
| Dewald, GW; Fink, SR; Paternoster, SF; Reeder, CB; Smoley, SA; Stockero, KJ; Tefferi, A; Tun, HW; Zou, YS | 1 |
| Angelotta, C; Bennett, CL; Evens, AM; Raisch, DW; Richardson, P; Yarnold, PR; Zonder, JA | 1 |
| Darabi, K; Kantamnei, S; Wiernik, PH | 1 |
| Le Beau, MM; Olney, HJ | 1 |
| Ribatti, D; Vacca, A | 1 |
| Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ | 1 |
| Hirsh, J | 1 |
| Lancet, JE; List, AF; Moscinski, LC | 1 |
| Brady, HA; Chan, KW; Chen, R; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Lopez-Girona, A; Moutouh-de Parseval, L; Mueller, JH; Muller, GW; Schafer, PH; Verhelle, D; Wong, K | 1 |
| Baker, AF; Bellamy, W; Green, S; List, AF | 1 |
| Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ | 1 |
| Kurtin, S; Sokol, L | 1 |
| Barlogie, B; Colla, S; Epstein, J; Shaughnessy, JD; Stephens, O; Wu, X; Xiong, W; Xu, H; Yaccoby, S; Zhan, F | 1 |
| Kale, V; List, A; Melchert, M | 1 |
| Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM | 1 |
| Hussar, DA | 1 |
| Dreicer, R | 1 |
| Dimopoulos, MA; Kastritis, E | 2 |
| Steensma, DP; Tefferi, A | 1 |
| Deeg, HJ; Mhyre, AJ | 1 |
| Schiffer, CA | 2 |
| Baz, R; Kalmadi, S; Mahindra, A | 1 |
| Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R | 1 |
| List, A; Melchert, M; Williams, C | 1 |
| Davies, FE; Jenner, M; Morgan, GJ; Phekoo, KJ; Schey, SA; Srikanth, M; Wu, P | 1 |
| Hanson, CA; Ketterling, RP; Lasho, TL; Mesa, RA; Pardanani, A; Tefferi, A | 1 |
| Case, D; Harmon, M; Hurd, D; Lesser, G; Melin, SA; Miller, AA; Savage, P | 1 |
| Kurtin, S | 1 |
| Molica, S | 1 |
| Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Hulin, C | 1 |
| Chanan-Khan, AA; Lee, K | 1 |
| Christian, MS; Hoberman, A; Laskin, OL; Latriano, L; Sharper, V; Stirling, DI | 1 |
| Boultwood, J; Cattan, H; Christensson, B; Emanuelsson, EK; Forsblom, AM; Hellström-Lindberg, E; Jädersten, M; Merup, M; Nilsson, L; Pellagatti, A; Samuelsson, J; Sander, B; Wainscoat, JS | 1 |
| Binder, M; Bornhäuser, M; Ehninger, G; Mohr, B; Platzbecker, U; Schetelig, J; von Bonin, M | 1 |
| Buadi, FK; Dispenzieri, A; Fonseca, R; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Litzow, MR; Rajkumar, SV; Roy, V | 1 |
| Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Benson, DM; Smith, MK | 1 |
| Davis-Lorton, M; Hindenburg, A; Kujawa, J; Phillips, J | 1 |
| Cooper, A; Forbes, A; Hawkey, CJ; Hawthorne, AB; Manning, DC; Mansfield, JC; Parkes, M; Perowne, RC; Probert, CS; Zeldis, JB | 1 |
| Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI | 1 |
| Dispenzieri, A; Klein, CJ; Mauermann, ML | 1 |
| Fassas, AB; Tricot, G | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Jalbrzikowski, J; Jayabalan, D; Lent, R; Leonard, JP; Mark, T; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Zafar, F | 1 |
| Rivera, C; Stein, EM | 1 |
| Bensinger, W | 1 |
| Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R | 1 |
| Shah, SR; Tran, TM | 1 |
| Tariman, JD | 1 |
| Rao, KV | 1 |
| Anderson, KC; Breitkreutz, I; Raab, MS | 1 |
| Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Laffitte, E | 1 |
| De Aloe, G; Fimiani, M; Flori, ML; Rubegni, P; Sbano, P | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Oestreicher, P | 1 |
| Alatakis, S; Bishton, MJ; Januszewicz, H; Liew, MS; Prince, HM | 1 |
| Carwile, J; El Rassi, FA; Tam, CS; Verstovsek, S | 1 |
| Bennett, JM; Curtin, PT; Deeg, HJ; Dewald, GW; Dreisbach, L; Feldman, EJ; Greenberg, PL; Klimek, VM; Knight, RD; List, AF; Raza, A; Reeves, JA; Schiffer, CA; Schmidt, M; Shammo, JM; Stone, RM; Thomas, D; Wride, K; Zeldis, JB | 1 |
| Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG | 1 |
| List, A; Ortega, J | 1 |
| Bergsagel, PL; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Chen, N; Knight, R; Kong, L; Kumar, G; Laskin, OL; Lau, H; Zeldis, JB | 1 |
| Ganser, A; Peest, D | 1 |
| DeLap, RJ; Knight, RD; Moutouh-de Parseval, LA; Weiss, L; Zeldis, JB | 1 |
| Dammacco, F; Merchionne, F; Perosa, F | 1 |
| Bagchi, S | 1 |
| Browne, R; Chen, J; Hussain, S; Parekh, S | 1 |
| Green, J; McCormack, C; Prince, HM; Upjohn, E; Zeldis, J | 1 |
| Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F | 1 |
| Czuczman, MS; Deeb, G; Hernandez-Ilizaliturri, FJ; Knight, J; Reddy, N; Roth, M; Vaughn, M; Wallace, P | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Abonour, R; Alsina, M; Badros, A; Comenzo, R; Durie, B; Giralt, S; Hussein, M; Jakubowiak, A; Lonial, S; Mehta, J; Munshi, NC; Niesvizky, R; Orlowski, R; Siegel, D; Singhal, S; Stadtmauer, EA; Vescio, R; Vesole, DH; Wang, M; Zangari, M | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB | 1 |
| Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Jagannath, S; Kaufman, J; Lonial, S; Mazumder, A; Niesvizky, R; Vesole, D | 1 |
| Albert, PS; Duic, JP; Figg, WD; Fine, HA; Kim, L; Ma, H; Royce, C; Tohnya, T; Zhang, W | 1 |
| Faiman, B | 1 |
| Wiley, KE | 1 |
| Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D | 1 |
| Dimopoulos, M; Kastritis, E | 1 |
| Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F | 1 |
| Habermann, T; Menon, S; Witzig, T | 1 |
| Colado, E; García-Sanz, R; Mateos, MV; Olazábal, J; San-Miguel, J | 1 |
| Handa, H; Murakami, H; Saitoh, T | 2 |
| Tsukagoshi, S | 1 |
| Chou, T | 1 |
| Shimazaki, C | 1 |
| Takatoku, M | 1 |
| Richards, TA; Thomas, SK; Weber, DM | 1 |
| Decaudin, D; Kirova, YM; Marchand, V; Servois, V | 1 |
| Miwa, A | 2 |
| Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA | 1 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L | 1 |
| Alexander, HR; Blansfield, JA; Caragacianu, D; Libutti, SK; Lorang, D; Morita, SY; Muller, G; Royal, RE; Schafer, P; Stirling, D; Tangrea, MA | 1 |
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Sloand, EM | 1 |
| Garcia-Manero, G; Jagasia, M; Yang, AS | 1 |
| Bergsagel, PL; Boesiger, J; Cabou, S; Dueck, A; Ehlenbeck, C; Fonseca, R; Leis, JF; Paripati, H; Pirooz, N; Reeder, C; Slack, J; Stewart, AK; Torloni, AS; Zepeda, VJ | 1 |
| Eclache, V; Fenaux, P; Kelaidi, C | 1 |
| Drach, J; Einsele, H; Miguel, JS; Moreau, P; Morgan, G; Palumbo, A; Sonneveld, P | 1 |
| Bargou, R; Cosgrove, D; Einsele, H; Knop, S; List, A | 1 |
| Da Rocha, A; Eclache, V; Fenaux, P; Le Roux, G | 1 |
| Cripe, L; Fenaux, P; Giagounidis, A; Mufti, GJ; Muus, P; Platzbecker, U; Sanz, G; Von Lilienfeld-Toal, M; Wells, RA | 1 |
| Bosco, J; Ebert, BL; Galili, N; Golub, TR; Ladd-Acosta, C; Mak, R; Pretz, J; Raza, A; Stone, R; Tamayo, P; Tanguturi, S | 1 |
| Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV | 1 |
| Lonial, S | 3 |
| Chanan-Khan, AA; Cheson, BD | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
| Mitani, K | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Litzow, MR; Rajkumar, SV | 1 |
| Cohen, EN; Estrov, Z; Faderl, S; Ferrajoli, A; Gao, H; Keating, MJ; Lee, BN; Li, C; O'Brien, SM; Reuben, JM; Schlette, EJ; Wen, S; Wierda, WG | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
| Nand, S; Portell, C | 1 |
| Andritsos, LA; Awan, F; Blum, W; Byrd, JC; Chen, CS; Jarjoura, D; Johnson, AJ; Kefauver, C; Knight, RD; Lapalombella, R; Lehman, A; Lozanski, G; May, SE; Raymond, CA; Ruppert, AS; Smith, LL; Wang, DS | 1 |
| D'Auria, F; Guariglia, R; Lerose, R; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O; Zonno, A | 1 |
| Awais, A; Cortes, J; Duvic, M; Ferrajoli, A; Keating, MJ; Kontoyiannis, D; Tam, CS | 1 |
| Gertz, MA | 1 |
| Anderson, KC; Boccadoro, M; Palumbo, A; Raje, N; Vallet, S | 1 |
| Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V | 1 |
| Armoiry, X; Aulagner, G; Facon, T | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Cutting, R; Dalley, C; Ezaydi, Y; Snowden, JA; Winfield, D | 1 |
| Garderet, L; Gorin, NC; Isnard, F | 1 |
| Barron, L; Batchelor, TT; Black, PM; Ciampa, A; David, K; Doherty, L; Drappatz, J; Kesari, S; Lafrankie, DC; Norden, A; Ostrowsky, L; Ramakrishna, N; Sceppa, C; Schiff, D; Smith, ST; Weiss, S; Wen, PY; Wong, ET; Zimmerman, J | 1 |
| Burwick, N; Ghobrial, IM; Leleu, X; Roccaro, AM | 1 |
| Gieseler, F | 1 |
| Musch, A | 1 |
| Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Boccadoro, M; Cavallo, F; Falco, P; Larocca, A; Liberati, AM; Musto, P; Palumbo, A | 1 |
| Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Blum, W; Byrd, JC; Gorgün, G; Gribben, JG; Johnson, AJ; Le Dieu, R; Lee, AM; Ramsay, AG | 1 |
| Burwik, N; Dupire, S; Gay, J; Ghobrial, IM; Hatjiharissi, E; Leleu, X; Moreau, AS; Robu, D; Roccaro, AM | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Ballester, O | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Cazzola, M | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D | 1 |
| Bloem, AC; Bogers-Boer, L; Lokhorst, HM; van de Donk, NW; van der Spek, E; van Kessel, B | 1 |
| Adams, M; Bartlett, JB; Carter, T; Chen, R; Muller, G; Schafer, P; Stirling, D; Wu, L | 1 |
| Akin, C; Ferenc, V; Kluin-Nelemans, HC; Peters, WG; Valent, P; van Doormaal, JJ; van Iperen, C | 1 |
| Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Barlogie, B; Burington, B; Crowley, J; Shaughnessy, JD; Zhan, F | 1 |
| Berenson, JR; Yellin, O | 1 |
| Brandenburg, NA; Bwire, R; Castaneda, CP; Freeman, J; Quigley, C; Zeldis, JB | 1 |
| Blum, KA; Byrd, JC; Dalton, JT; Farley, KL; Grever, MR; Hofmeister, CC; Johnson, AJ; Liu, Q; Muthusamy, N; Phelps, MA; Schaaf, LJ | 1 |
| Paydas, S | 1 |
| Martínez-Baños, DM; Niesvizky, R | 1 |
| Andritsos, L; Blum, W; Butchar, JP; Byrd, JC; Chen, CS; Johnson, AJ; Lapalombella, R; Lee, LJ; Lee, RJ; Lehman, A; Liu, Q; Lozanski, G; Marcucci, G; Muthusamy, N; Ramanunni, A; Smith, LL; Triantafillou, G; Tridandapani, S; Wang, DS; Yu, B | 1 |
| Attal, M; Dimopoulos, M; Harousseau, JL; Hussein, M; Knop, S; Ludwig, H; Palumbo, A; San Miguel, J; Sonneveld, P; von Lilienfeld-Toal, M | 1 |
| Bangia, N; Chanan-Khan, AA; Lee, K; Porter, CW; Whitworth, A | 1 |
| Aarts, T; Emmelot, M; Lokhorst, HM; Minnema, MC; Mutis, T; van der Veer, MS | 1 |
| Dyer, C | 2 |
| Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Bartlett, JB; Chen, RS; Hariri, RJ; Hughes, CC; Lu, L; Man, HW; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Czuczman, MS; O'Connor, OA | 1 |
| Abboud, CN; Blum, W; Byrd, JC; Fehniger, TA; Kefauver, C; Marcucci, G; Payton, JE; Vij, R | 1 |
| Miyazawa, K | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Fonseca, R; Rajkumar, SV | 1 |
| Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Agrawal, YP; Cesarman, E; Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furman, RR; Jayabalan, D; Lee, JW; Lent, R; Leonard, JP; Mark, T; Matthew, S; Mazumdar, M; Niesvizky, R; Pearse, RN; Wang, YL | 1 |
| Lin, TS | 2 |
| Anderson, KC; Attal, M; Cavo, M; Gertz, MA; Giralt, S; Ludwig, H; Morgan, GJ | 1 |
| Anderson, KC; Balk, SP; Catley, L; Exley, MA; Munshi, NC; Podar, K; Prabhala, R; Shammas, MA; Song, W; Tai, YT; van der Vliet, HJ; Wang, R | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Burcheri, S; Chaury, MP; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Hoarau, N; Laurent, G; Legros, L; Mbida, RM; Prebet, T; Ravoet, C; Stamatoullas, A; Vey, N | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Nomdedeu, B | 1 |
| Bartlett, JB; Chen, R; Dalgleish, AG; Dredge, K; Galustian, C; Henry, J; Klaschka, D; Labarthe, MC; Meyer, B; Muller, G; Schafer, P; Stirling, D; Todryk, S | 1 |
| Bako, J; Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Horvath, N; Krishnamurthi, S; Nock, C; Remick, SC; Sanborn, SL | 1 |
| Wiernik, PH | 3 |
| Mohamedali, A; Mufti, GJ | 1 |
| Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C | 1 |
| Giagounidis, AA; Knight, R; List, AF; Maciejewski, JP; Raza, A; Sekeres, MA; Wride, K | 1 |
| Alexandrescu, DT; Dasanu, CA | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| Bacher, U; Haferlach, C; List, A; Maciejewski, JP; Tiu, R | 1 |
| Kumar, G; Laskin, O; Lau, H | 1 |
| Stone, RM | 2 |
| Brandenburg, NA; Burton, GH; Bwire, R; Castaneda, CP; Zeldis, JB | 1 |
| Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP | 1 |
| Ambrus, JL; Islam, A | 1 |
| Estey, E; Scott, BL | 1 |
| Tuscano, JM | 1 |
| Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC | 1 |
| Dmoszyńska, A | 1 |
| Fricker, J | 1 |
| Anderson, KC; Baron, AD; Branagan, AR; Chu, L; Hunter, ZR; Hyman, PM; Ioakimidis, L; Kash, JJ; Munshi, NC; Musto, P; Nawfel, EL; Nunnink, JC; Patterson, CJ; Sharon, DJ; Soumerai, JD; Terjanian, TO; Treon, SP | 1 |
| Borrello, I | 1 |
| Berthou, C; De Braekeleer, M; Ianotto, JC; Marion, V; Morel, F; Tempescul, A | 1 |
| Hellström-Lindberg, E; Jädersten, M | 1 |
| Cantalapiedra, A; Conde, J; Garcia Frade, LJ; Peñarrubia, MJ; Silvestre, LA | 1 |
| Hanson, CA; Ketterling, RP; Knudson, RA; Mesa, RA; Schwager, S; Tefferi, A | 1 |
| Ehninger, G; Mohr, B; Oelschlaegel, U; Platzbecker, U; Stewart, MM; Thiede, C | 1 |
| Bargou, RC; Einsele, H; Falk, K; Gerecke, C; Glasmacher, A; Knop, S; Liebisch, P; Maeder, U; Platzbecker, U; Sezer, O; Topp, MS; Vollmuth, C | 1 |
| Byrd, JC; Caligiuri, MA; Chen, CS; Cheney, C; Gowda, A; Johnson, AJ; Joshi, T; Lapalombella, R; Lehman, A; Mehter, N; Muthusamy, N; Tridandapani, S | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Gore, SD | 1 |
| Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A | 1 |
| Jonásová, A; Neuwirtová, R; Novotová, E; Spicka, I; Straub, J | 1 |
| Dalgleish, A; Galustian, C | 2 |
| Brandenburg, NA; Bwire, R; Freeman, J; Knight, RD; Salomon, ML; Yang, X; Zeldis, JB | 1 |
| Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB | 1 |
| Albrecht, J; Bonilla-Martinez, Z; Okawa, J; Rose, M; Rosenbach, M; Shah, A; Werth, VP | 1 |
| Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Hussein, K; Tefferi, A | 1 |
| Bergsagel, PL; Buadi, F; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y | 1 |
| Croce, CM; Gorgun, G; Gribben, JG; Holderried, TA; Le Dieu, R; Liu, F; Quackenbush, J; Ramsay, AG; Zahrieh, D | 1 |
| Cavenagh, J; Lonial, S | 1 |
| Akobeng, AK; Srinivasan, R | 1 |
| Akobeng, AK; Stokkers, PC | 1 |
| Basile, FG | 1 |
| Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R | 1 |
| Meijer, E; Sonneveld, P | 1 |
| Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Dalgleish, AG; Liu, WM; Nizar, S | 1 |
| Bowcock, SJ; Patrick, HE | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Aragon-Ching, JB; Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Tohnya, TM; Ventiz, J; Woo, S; Wright, JJ | 1 |
| Fenaux, P; Itzykson, R | 1 |
| Byrd, J; Chen, X; Dewald, G; Djeu, JY; Epling-Burnette, PK; Lawrence, N; List, A; Liu, Q; Maciejewski, J; Pireddu, R; Rocha, K; Sokol, L; Wei, S; Williams, A | 1 |
| Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J | 1 |
| Attolico, I; Cifarelli, RA; Cimminiello, M; Discepoli, G; Olivieri, A | 1 |
| Kurtin, SE; List, AF | 1 |
| Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB | 1 |
| Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D | 1 |
| Burkhard, R; Dürr, D; Hirschi, A; Honegger, H; Hummel, Y; O'Meara, A; Siciliano, RD | 1 |
| Bartlett, JB; Cai, Z; Qian, Z; Sun, L; Wang, H; Wang, M; Yi, Q; Zhang, L | 1 |
| Kist, JM; Rosenbach, M; Thieu, KP; Xu, X | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR | 1 |
| Barnett, DB; Boysen, M; Chung, H; Gajraj, E; Longson, C | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Q; Zhang, Z | 1 |
| Asch, J; Ford, CD; Konopa, K; Petersen, FB | 1 |
| Bolton, TB; Dalgleish, AG; Galustian, C; Henry, JY; Laux, H; Liu, WM | 1 |
| Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Christie, S | 1 |
| Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B | 1 |
| Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F | 1 |
| Erdel, M; Fiegl, M; Kilga-Nogler, S; Köck, L; Schennach, H; Sun, WL; Walder, A | 1 |
| Das, B; Goel, S; Heuck, C; Kotla, V; Nischal, S; Verma, A; Vivek, K | 1 |
| Abruzzo, L; Borthakur, G; Bueso-Ramos, C; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J | 1 |
| Medeiros, BC; Pretz, J | 1 |
| Harada, H; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Takeshita, K; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y | 1 |
| Blum, S; Cavassini, M; Fayet, A; Jotterand, M; Lambert, JF; Schapira, M | 1 |
| Machálková, K; Maisnar, V | 1 |
| Chanan-Khan, A; Lee, K; Miller, KC; Sher, T | 1 |
| Adès, L; Boehrer, S; Eclache, V; Fenaux, P; Gardin, C; Leroux, G; Martiat, P | 1 |
| Figg, WD; Gardner, ER; Sissung, TM; Thordardottir, S | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM | 1 |
| Scott, BL | 1 |
| Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E | 1 |
| Gribben, JG; Ramsay, AG | 1 |
| Aue, G; Boss, C; Gibellini, F; Hughes, T; Keyvanfar, K; McCoy, JP; Njuguna, N; Pittaluga, S; Samsel, L; Soto, S; Tian, X; Valdez, J; Vire, B; Wiestner, A; Wilson, WH | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Layzer, R; Wolf, J | 1 |
| Arabi, H; Penumetcha, R; Sethi, S; Tageja, N | 1 |
| Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL | 1 |
| Bokemeyer, C; Honecker, F; Oechsle, K | 1 |
| Galanopoulos, A; Giannikou, K; Hatzimichael, E; Kartasis, Z; Klaus, M; Kokoris, S; Korkolopoulou, P; Liapi, D; Papadaki, HA; Pappa, V; Parcharidou, A; Pontikoglou, C; Psyllaki, M; Sambani, C; Symeonidis, A; Ximeri, M | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| List, A | 1 |
| Calaminici, M; Clear, AJ; Fatah, R; Gribben, JG; Kelly, G; Lee, AM; Lister, TA; Macdougall, F; Matthews, J; Ramsay, AG | 1 |
| San Miguel, JF | 1 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| Boultwood, J; Göhring, G; Hellström-Lindberg, E; Jädersten, M; Pellagatti, A; Porwit, A; Saft, L; Schlegelberger, B; Wainscoat, JS | 1 |
| Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB | 1 |
| Ravikumar, K; Sridhar, B | 1 |
| Abonour, R; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, M; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME | 1 |
| Gay, F; Palumbo, A | 3 |
| Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M | 1 |
| Kurtin, SE | 1 |
| Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U | 1 |
| Böll, B; Borchmann, P; Engert, A; Hänel, M; Naumann, R; Reiners, KS; Topp, MS | 1 |
| Aprile, L; Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Rondoni, M | 1 |
| Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL | 1 |
| Powles, R; Sirohi, B | 1 |
| Berthold, A; Fredericks, R; Shumaker, G; Sumrall, A | 1 |
| Dimopoulos, MA; Fink, L; Finlayson, A; Fu, T; Knight, R; Niesvizky, R; Polavaram, L; Tricot, G; Weber, D; Zangari, M; Zhan, F | 1 |
| Dereure, O; Guillot, B; Michot, C | 1 |
| Copplestone, JA; Dyer, MJ; Eve, HE; Richardson, SJ; Rule, SA | 1 |
| Bonkowski, J; Kolesar, JM; Vermeulen, LC | 1 |
| Rowan, K | 1 |
| Hussein, M; Srkalovic, G | 1 |
| Ozaki, S | 1 |
| Ishikawa, T | 2 |
| Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
| Bhattacharya, N; Döhner, H; Giannopoulos, K; Idler, I; Mertens, D; Nothing, M; Stilgenbauer, S; Zenz, T | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Andritsos, L; Blum, KA; Blum, W; Browning, R; Byrd, JC; Chen, CS; Ford, R; Jarjoura, D; Johnson, AJ; Lapalombella, R; Lehman, A; Liu, Q; May, SE; Mo, X; Muthusamy, N; Pham, LV; Rader, C; Ramanunni, A; Raymond, CA; Smith, LL | 1 |
| Anderson, KC; Chauhan, D; Ciccarelli, B; Palladino, MA; Richardson, PG; Singh, AV | 1 |
| Bazargan, A; Tam, CS | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Ghobrial, IM; Stewart, AK | 1 |
| Sekeres, MA | 1 |
| Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Jain, P | 1 |
| Amoroso, B; Arcamone, M; Becchimanzi, C; Capobianco, G; Corazzelli, G; Crisci, S; De Filippi, R; De Rosa, V; Frigeri, F; Iaccarino, G; Lastoria, S; Marcacci, G; Pinto, A; Russo, F | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Awan, FT; Byrd, JC; Fischer, B; Hu, W; Johnson, AJ; Lapalombella, R; Lucas, M | 1 |
| Bilgrami, SA; Block, AW; Chanan-Khan, AA; Czuczman, MS; Hernandez-Ilizaliturri, F; Lawrence, D; Lawrence, W; Lee, K; Miller, A; Miller, KC; Sher, T; Sood, R; Whitworth, A; Wood, MT | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Berzins, SP; Chan, AC; Godfrey, DI; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; Wittebol, S | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Bartlett, JB; Capone, L; Fang, W; Gandhi, AK; Hampton, G; Kang, J; Lopez-Girona, A; Mendy, D; Parton, A; Sapinoso, L; Schafer, P; Tran, T; Wu, L; Xu, S; Zhang, LH | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Hogan, WJ; Kumar, S; Lacy, MQ | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Chen, W; Fan, L; Li, W; Liu, L; Liu, X; Xiong, B; Zou, P | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Curran, JJ; Lin, RJ; Niewold, TB; Song, J; Sweiss, NJ; Zimmerman, TM | 1 |
| Kishimoto, M; Kondo, T; Matsuoka, A; Nakahara, T; Tasaka, T; Tochigi, A; Tohyama, K; Tohyama, Y; Tsujioka, T | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| Dufva, IH; Risum, M | 1 |
| Alessandrino, PE; Angelucci, E; Barosi, G; Billio, A; Di Maio, M; Finelli, C; Locatelli, F; Marchetti, M; Morra, E; Musto, P; Santini, V; Tura, S; Visani, G | 1 |
| Assaf, M; Chen, N; Choudhury, S; Laskin, OL; Lau, H; Wang, X | 1 |
| Carraway, HE; Gore, SD; Loaiza-Bonilla, A | 1 |
| Chen, Y; Kiatsimkul, P; Nugent, K; Raj, R | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Psimenou, E; Roussou, M; Terpos, E | 1 |
| de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E | 1 |
| Jädersten, M | 1 |
| Bizzari, JP; Jacques, C; Knight, RD; Tozer, A; Zeldis, JB | 1 |
| Belkaid, M; Campo, E; Carrió, A; Costa, D; Coutinho, R; Muñoz, C; Nomdedeu, B; Vidal, A | 1 |
| Chon, SY; Silapunt, S | 1 |
| Compagnone, R; De Sanctis, JB; Garmendia, J; Mijares, M; Moreno, D; Salazar-Bookaman, M; Suárez, A | 1 |
| Ludwig, H; Zojer, N | 1 |
| Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA | 1 |
| O'Connor, OA | 1 |
| Tobinai, K | 1 |
| Komrokji, RS; List, AF | 4 |
| Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G | 1 |
| Iida, S | 1 |
| Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
| Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
| Adam, Z; Germáková, Z; Hájek, R; Kovárová, L; Krejcí, M; Kren, L; Krivanová, A; Mardová, J; Mayer, J; Moulis, M; Nedbálková, M; Pour, L; Stepánková, S; Svobodová, I; Veselý, K; Zahradová, L | 1 |
| Clima, J; Galili, N; Quddus, F; Raza, A; Sajjad, G; Seedham, H | 1 |
| Kuwabara, S | 3 |
| Cook, R; Cunningham, K; Gardler, M; Hummel, K; Luger, SM; Mangan, PA; Nazha, A; O'Doherty, U; Porter, DL; Schuster, S; Siegel, D; Stadtmauer, EA; Vogl, DT | 1 |
| Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Niscola, P; Perrotti, A; Siniscalchi, A; Tendas, A | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Kumar, S | 3 |
| Komrokji, RS; Lancet, JE; List, AF | 1 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Koppel, A; Schiller, G | 1 |
| Sirulnik, LA; Stone, RM | 1 |
| Gotlib, J; Oh, ST | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A | 1 |
| Dougherty, DW; Friedberg, JW | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Baiocchi, RA; Bakan, CE; Becknell, B; Benson, DM; Byrd, JC; Caligiuri, MA; Devine, SM; Efebera, Y; Greenfield, CN; Hofmeister, CC; Lozanski, G; Mishra, A; Porcu, P; Rotem-Yehudar, R; Smith, MK; Yu, J; Zhang, J | 1 |
| Attal, M; Chen, C; Corso, A; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Hájek, R; Holánek, M | 1 |
| Mateos, MV | 2 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S | 1 |
| Calandra, G; Gandhi, PJ; Ho, AD; Klein, LM; Marulkar, S; McSweeney, PA; Micallef, IN | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; D'Errigo, MG; Finelli, C; Galimberti, S; Ghio, R; Iacopino, P; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Poloni, A; Ronco, F; Specchia, G | 1 |
| Einsele, H; Kortuem, M | 1 |
| Feilchenfeldt, J; Györik, S; Lerch, E; Mazzucchelli, L; Quadri, F | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Kolonic, SO; Mandac, I | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH | 1 |
| Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE | 1 |
| Higginson, I; Schey, S | 1 |
| Czuczman, MS; Leonard, JP; Williams, ME | 1 |
| Boyd, K; Corderoy, S; Davies, FE; Hazel, B; Jenner, M; Ladon, D; Morgan, GJ; Phekoo, K; Ramasamy, K; Schey, SA | 1 |
| Chou, T; Hatake, K; Hotta, T; Iida, S; Lau, H; Murakami, H; Nagai, H; Okamoto, S; Shimizu, K; Takagi, T; Takatoku, M; Takeshita, K | 1 |
| Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA | 1 |
| Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; van der Jagt, R; White, D | 1 |
| Hoffman, M; Mittelman, M; Neumann, D; Oster, HS | 1 |
| Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Dauguet, N; Fournié, JJ; Poupot, M; Poupot, R | 1 |
| Brown, JR | 1 |
| Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Chetaille, B; Chuto, G; Coso, D; Fezoui, H; Ivanov, V; Rey, J; Schiano, JM; Stoppa, AM; Tabouret, E | 1 |
| Fielding, K; Neeson, P; Quach, H; Ritchie, DS | 1 |
| Chen-Kiang, S; Coleman, M; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Jayabalan, DS; Kumar, S; Kyle, RA; Lacy, MQ; Leonard, J; Lust, JA; Mark, T; Niesvizky, R; Pearse, R; Rajkumar, SV; Roy, V; Stewart, AK; Witzig, TE | 1 |
| Dumas, PY; Milpied, N; Pigneux, A; Tabrizi, R | 1 |
| Anderson, KC; Bandi, M; Calabrese, E; Cirstea, D; Fabre, C; Görgün, G; Hideshima, T; Hu, Y; Mimura, N; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Soydan, E; Tai, YT | 1 |
| Cripe, LD; Li, CY; Litzow, M; Mesa, RA; Paietta, E; Rowe, JM; Tallman, MS; Tefferi, A; Yao, X | 1 |
| Aguilar, C; de la Rubia, J; del Campo, R; García, I; González, N; Ibáñez, A; Martínez, R; Palomera, L; Picón, I; Rodríguez, JN; Roig, M; Sanz, MA; Vera, JA | 1 |
| Chanan-Khan, A; Miller, KC; Musial, L; Whitworth, A | 1 |
| Dember, LM; Fennessey, S; Finn, KT; Sanchorawala, V; Seldin, DC; Shelton, A; Specter, R; Zeldis, JB | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Fine, DM; Holanda, DG; Huff, CA; Lipson, EJ; McDevitt, MA | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS | 1 |
| Alakl, M; Benboubker, L; Bridoux, F; Fermand, JP; Harousseau, JL; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Moreau, P; Planche, L; Roussel, M; Royer, B; Salles, G | 1 |
| Bardet, V; Dreyfus, F; Park, S; Vassilieff, D; Viguié, F | 1 |
| Biemond, BJ | 1 |
| de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N | 1 |
| Bowen, DT; Chen, C; Giagounidis, AA; Haase, S; Schlegelberger, B; Wright, EG | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
| Hagemeister, FB | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A | 1 |
| Anderson, K; Astrand-Grundström, I; Buza-Vidas, N; Dhanda, RS; Ferry, H; Göhring, G; Hast, R; Hellström-Lindberg, E; Horvat, A; Jacobsen, SE; Johansson, B; List, A; Mead, AJ; Mizukami, T; Nilsson, L; Rydén, T; Schlegelberger, B; Strömbeck, B; Tehranchi, R; Vyas, P; Woll, PS | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Azaceta, G; Bonafonte, E; Calasanz, MJ; Dourdil, V; Izquierdo, I; Palomera, L | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Doros, G; Fennessey, S; Finn, KT; Sanchorawala, V; Seldin, DC; Shelton, A; Zeldis, JB | 1 |
| Adams, M; Bartlett, JB; Lu, L; Parton, A; Schafer, P; Wu, L | 1 |
| Goldschmidt, H; Heiss, C; Hielscher, T; Ho, AD; Klein, U; Neben, K | 1 |
| Bassett, R; Bedikian, A; Hwu, P; Hwu, WJ; Kim, KB; Knight, RD; Papadopoulos, NE; Patnana, M | 1 |
| Tefferi, A | 1 |
| Grivas, PD; Saloura, V | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, S; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Zeldenrust, S | 1 |
| Gajra, A; Singh, A | 1 |
| Abidi, MH; Barlogie, B; Bolejack, V; Crowley, J; Durie, BG; Hussein, MA; Moore, DF; Whittenberger, BF; Zonder, JA | 1 |
| Rummel, M | 1 |
| Ahmadi, T; Carver, JR; Chong, EA; Nasta, S; Schuster, SJ; Stonecypher, M; Wheeler, JE | 1 |
| Eve, HE; Rule, SA | 1 |
| Mey, UJ | 1 |
| Dalgleish, AG; Gravett, AM; Liu, WM | 1 |
| Egner, JR; Khaliq, W; Konchanin, RP; Sapiente, RA; Uzoaru, I | 1 |
| Theodorescu, D; Wilson, SS | 1 |
| Chmarzyńska, E; Dwilewicz-Trojaczek, J; Jędrzejczak, WW; Koperski, Ł; Pastwińska, A; Paszkowska-Kowalewska, M; Ziarkiewicz, M; Ziarkiewicz-Wróblewska, B | 1 |
| Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y | 1 |
| Carter, T; Chopra, R; Heise, C; Schafer, P | 1 |
| Amadori, D; Asioli, S; Cangini, D; Ceccolini, M; Fattori, PP; Giannini, MB; Matteucci, F; Musuraca, G; Ronconi, S | 1 |
| Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X | 1 |
| Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M | 1 |
| Harrison, SJ; Hsu, AK; Neeson, P; Prince, HM; Quach, H; Ritchie, DS; Smyth, MJ; Tai, T; Trapani, JA | 1 |
| Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Arellano-Rodrigo, E | 1 |
| Cai, Z; Qian, Z; Sun, L; Wang, H; Wang, M; Yi, Q; Zhang, L | 1 |
| Abboud, CN; Cashen, AF; Demland, J; DiPersio, JF; Fehniger, TA; Nelson, AD; Stockerl-Goldstein, KE; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Afable, M; Englehaupt, R; List, AF; Maciejewski, JP; O'Keefe, C; Paulic, K; Sekeres, MA | 1 |
| Borchmann, P; Eichenauer, DA; Engert, A; Fuchs, M | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Guglielmelli, T; Palumbo, A; Petrucci, MT; Saglio, G | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Büsche, G; Fenaux, P; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, HH; Schlegelberger, B | 1 |
| Bakker, JM; de Weers, M; Lokhorst, HM; Mutis, T; Parren, PW; van der Veer, MS; van Kessel, B; Wittebol, S | 1 |
| Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG | 1 |
| Bwire, R; Freeman, J; Houn, F | 1 |
| San-Miguel, JF | 1 |
| Baz, R; Davies, F | 1 |
| Dimopoulos, MA; Terpos, E | 1 |
| Morgan, G | 1 |
| Fennessey, S; Finn, KT; Sanchorawala, V; Seldin, DC; Shelton, A; Tapan, U; Zeldis, JB | 1 |
| Ershler, WB; Ferrucci, L; Goetzl, EJ; Greig, NH; Huang, MC; Longo, DL; Luo, W; Schwartz, JB; Tweedie, D | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Richardson, PG | 1 |
| Blaney, SM; Boyett, JM; Fangusaro, J; Goldman, S; Jakacki, R; Kun, LE; Macdonald, T; Packer, R; Pollack, IF; Schaiquevich, P; Stewart, CF; Wallace, D; Warren, KE | 1 |
| Adamson, PC; Ayello, J; Berg, SL; Blaney, SM; Cairo, MS; Chen, N; Ingle, AM; Lau, H; Russell, H | 1 |
| Basinko, A; Berthou, C; Bovo, C; De Braekeleer, M; Douet-Guilbert, N; Eveillard, JR; Guéganic, N; Herry, A; Le Bris, MJ; Morel, F | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Asmis, LM; Kaech, A; Leikauf, MS; Madon, J; Ruf, W; Valsami, S | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Bjorklund, CC; Davis, RE; Kornblau, SM; Kuhn, DJ; Ma, W; Orlowski, RZ; Shah, JJ; Wang, M; Wang, ZQ | 1 |
| Bergsagel, PL; Brandwein, J; Chen, CI; Dave, N; Gibson, S; Hernandez, T; Johnston, J; Kukreti, V; Lau, A; Leung-Hagesteijn, C; Li, ZH; Pantoja, M; Paul, H; Spaner, D; Trudel, S; Wei, E; Xu, W | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Bisconte, MG; Bossio, S; Caruso, N; De Stefano, L; Franzese, S; Gentile, C; Gentile, M; Gigliotti, V; Lucia, E; Madeo, A; Mazzone, C; Morabito, F; Morabito, L; Recchia, AG; Servillo, P; Vigna, E | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Bouabdallah, R; Buckstein, R; Czuczman, MS; Ervin-Haynes, AL; Guo, P; Haioun, C; Pietronigro, D; Polikoff, JA; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Alimena, G; Barzotti, R; Breccia, M; Cannella, L; Ferretti, A; Latagliata, R; Loglisci, G; Nanni, M; Oliva, EN; Santopietro, M | 1 |
| Kristinsson, SY | 1 |
| Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C | 1 |
| Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB | 1 |
| Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K | 1 |
| Jädersten, M; Karsan, A | 1 |
| Bauer, F; Dasanu, CA; Davis, LK; Reale, MA; Schwartz, RA; Silver, JS | 1 |
| Attal, M; Beksaç, M; da Costa, FL; Davies, FE; Delforge, M; Dimopoulos, MA; Einsele, H; Hajek, R; Harousseau, JL; Ludwig, H; Mellqvist, UH; Morgan, GJ; Palumbo, A; San-Miguel, JF; Sonneveld, P; Zweegman, S | 1 |
| Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A | 1 |
| Haan, J; Molendijk, WJ; Tannemaat, MR; Vries, EP | 1 |
| Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J | 1 |
| Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL | 1 |
| Komrokji, R; List, AF; Padron, E | 2 |
| Kay, NE; O'Brien, S | 1 |
| Abou-Nassar, K; Brown, JR | 1 |
| Lacy, MQ | 2 |
| Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Schots, R | 1 |
| Alimena, G; Breccia, M; Cannella, L; Latagliata, R; Loglisci, G; Oliva, EN; Salaroli, A; Santopietro, M | 1 |
| Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC | 1 |
| Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA | 1 |
| Blum, KA; Byrd, JC; Gordon, AL; Herman, SE; Johnson, AJ; Jones, J; Lannutti, BJ; Lapalombella, R; Muthusamy, N; Puri, KD; Ramanunni, A; Zhang, X | 1 |
| Galson, DL; Lentzsch, S; Li, S; Mapara, M; Monaghan, SA; Ouyang, H; Pal, R; Schafer, P | 1 |
| Baer, MR; Gojo, I | 1 |
| Bosi, A; Maratea, D; Messori, A; Nozzoli, C | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Boué, F; Castilla, MA; Kirstetter, M; Martinez, V; Melica, G; Tateo, M | 1 |
| Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA | 1 |
| Bello, C; Komrokji, RS; Lancet, JE; List, AF; Wetzstein, GA; Yu, D; Zhu, W | 1 |
| Adès, L; Fenaux, P | 3 |
| Tageja, N | 1 |
| Giorgadze, T; Tageja, N; Zonder, J | 1 |
| Anderson, KC; Bandi, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Hu, Y; Mahindra, A; Munshi, NC; Nelson, EA; Patel, K; Pozzi, S; Raje, N; Rodig, S; Santo, L; Squires, M; Unitt, C; Vallet, S | 1 |
| Sanchez, JF | 1 |
| González Rodríguez, AP | 1 |
| García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E | 1 |
| Chopra, R; Hussein, M; Knight, R; Muller, G; Zeldis, JB | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Calabrese, C; Calabrese, LH; Faiman, B; Martin, D; Reu, F | 1 |
| Komrokji, RS; List, AF; Sekeres, MA | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 2 |
| Frosch, P; Grape, J | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, KM; Mandrekar, SJ; Rajkumar, SV; Witzig, TE | 1 |
| Wendtner, CM | 2 |
| Engelhardt, M; Finke, J; Jakob, T; Technau, K; Wäsch, R | 1 |
| Czuczman, MS; Deeb, G; Goy, A; Hernandez-Ilizaliturri, FJ; Macon, WR; Malik, F; Pileri, SA; Witzig, TE; Zinzani, PL | 1 |
| Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Endo, I; Miura, A; Murata, Y; Ohashi, K | 1 |
| Argnani, L; Baccarani, M; Berti, E; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Kim, JH; Scialli, AR | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Gahrton, G | 1 |
| Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Rubenstein, JL; Stewart, PJ; Treseler, PA | 1 |
| Rexer, H | 1 |
| Chanan-Khan, A; Czuczman, MS; Hernandez-Illatazurri, F; Lawrence, D; Lee, K; Miller, A; Miller, KC; Padmanabhan, S; Wallace, PK; Zeldis, JB | 1 |
| Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A | 1 |
| Al-Shahrour, F; Dutt, S; Ebert, BL; Hurst, S; McAuley, JR; McConkey, M; Narla, A; Neuberg, D | 1 |
| Kyle, RA | 2 |
| Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P | 1 |
| Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F | 1 |
| Brown, K; Clayton, W; Figaro, MK; Jagasia, S; Kassim, A; Lakhani, VT; Usoh, C | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Advani, A; Appelbaum, FR; Gundacker, H; Lancet, J; Liesveld, J; List, AF; Mulford, D; Norwood, T; Petersdorf, S; Sekeres, MA; Willman, CL | 1 |
| Carter, JS; Downs, LS | 1 |
| Alegre, A; Calle, C; Calvo-Villas, JM; García-Sánchez, R; Hernández, MT; Ramírez, G | 1 |
| Ikezoe, T; Kubota, T; Kuwayama, Y; Sakai, M; Yokoyama, A | 1 |
| Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM | 1 |
| Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; Pierce, S; Thomas, D; Verstovsek, S; Zhou, L | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Cuzzola, M; Ferretti, A; Girmenia, C; Latagliata, R; Loglisci, G; Oliva, EN; Santopietro, M; Volpicelli, P; Vozella, F | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR | 1 |
| Ben-Yehuda, D; Boccadoro, M; Bringhen, S; Cafro, AM; Calabrese, E; Caravita, T; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Crippa, C; Liberati, AM; Lupo, B; Milone, G; Montefusco, V; Musto, P; Nagler, A; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Peccatori, J; Petrucci, MT; Rossini, F | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T; Sanada, Y | 1 |
| Cheson, BD | 1 |
| Elloumi, M; Fenaux, P; Hadiji Mseddi, S; Jedidi, I; Kallel, F; Kassar, O; Sennana, H | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Lahiri, DK; Luo, W; Salcedo, I; Tweedie, D; Yu, QS | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Lust, J; Madan, S; Rajkumar, SV; Zeldenrust, S | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Goldschmidt, H; Hegenbart, U; Herth, I; Ho, AD; Hose, D; Hundemer, M; Klein, B; Neuber, B; Schoenland, S; Tolliver, C; Witzens-Harig, M | 1 |
| Arumainathan, A; Kalakonda, N; Pettitt, AR | 1 |
| Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S | 1 |
| Bari, A; Civallero, M; Cosenza, M; Sacchi, S | 1 |
| Bartlett, JB; Bolomsky, A; Brady, H; Chopra, R; Daniel, T; Gaidarova, S; Gisslinger, H; Heintel, D; Hilgarth, B; Jäger, U; Lopez-Girona, A; Ludwig, H; Mendy, D; Schafer, PH; Schreder, M; Zhang, LH; Zojer, N | 1 |
| Buckstein, R; Czuczman, MS; Ervin-Haynes, A; Li, J; Pietronigro, D; Polikoff, J; Reeder, CB; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Adès, L; Banos, A; Beyne-Rauzy, O; Blanc, M; de Botton, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Guerci, A; Kelaidi, C; Lamy, T; Le Bras, F; Rea, D; Schmidt, A; Sebert, M; Turlure, P; Vey, N; Visanica, S | 1 |
| Astermark, J; Dufva, IH; Dybedal, I; Ejerblad, E; Garelius, H; Grønbæk, K; Hellström-Lindberg, E; Jädersten, M; Jansson, M; Kjeldsen, L; Lindberg, EH; Linder, O; Möllgård, L; Nilsson, L; Nørgaard, JM; Porwit, A; Saft, L; Treppendahl, MB; Vestergaard, H | 1 |
| Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; Kornblau, SM; Lee, BN; O'Brien, SM; Reuben, J; Sivina, M; Wen, S; Wierda, WG | 1 |
| Barker, A; Coates, S; Spurgeon, S | 1 |
| Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D | 1 |
| Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
| Aul, C; Beyne-Rauzy, O; Bowen, D; Cazzola, M; Del Cañizo, C; Fenaux, P; Francis, J; Fu, T; Ganser, A; Giagounidis, A; Guerci-Bresler, A; Hellström-Lindberg, E; Knight, R; Lübbert, M; Mittelman, M; Mufti, G; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; Te Boekhorst, P | 1 |
| Sekeres, MA; Tiu, RV | 1 |
| Aguilar, JL; Baumann, T; Calvo, X; Cervantes, F; Colomer, D; Costa, D; Díaz-Beyá, M; Esteve, J; Maffioli, M; Martínez-Trillos, A; Nomdedeu, B; Nomdedeu, M; Rozman, M | 1 |
| Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, H; Lange, K; Morgan, M; Nielsen, KV; Roy, L; Schlegelberger, B | 1 |
| Larsen, LH; Lund, T; Plesner, T; Vilholm, OJ | 1 |
| Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L | 1 |
| Fukushima, T; Iwao, H; Nakamura, T; Umehara, H | 1 |
| Aue, G; Cullinane, AM; McCoy, P; Nelson Lozier, J; Samsel, L; Soto, S; Tian, X; Wiestner, A | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Koureas, A; Migkou, M; Nikitas, N; Roussou, M; Terpos, E; Tsokou, E; Zagouri, F | 1 |
| Braunstein, I; Goodman, NG; Kovarik, CL; Krathen, M; Luning Prak, E; Okawa, J; Rosenbach, M; Shah, A; Werth, VP | 1 |
| Katayama, Y | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Benson, DM; Byrd, JC; Chan, KK; Chen, CS; Chen, P; Farag, SS; Garr, CL; Grever, MR; Hade, EM; Hicks, WJ; Hofmeister, CC; Ji, J; Johnson, AJ; Kraut, EH; Lee, S; Liu, Z; Phelps, MA; Pichiorri, F; Rozewski, DM; Schaaf, LJ; Yang, X | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB | 1 |
| Demierre, MF; Goldberg, LJ; Kuohung, V | 1 |
| Sucak, GT; Suyanı, E; Yağcı, M | 1 |
| Basinko, A; De Braekeleer, E; De Braekeleer, M; Douet-Guilbert, N; Le Bris, MJ; Morel, F | 1 |
| Boileau, J; Goetz, J; Gorse, A; Martin, T; Stoll-Keller, F | 1 |
| Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L | 1 |
| Agliano, A; Bertolini, F; Calleri, A; Calvo, A; Gregato, G; Marighetti, P; Martin-Padura, I; Prior, C; Redrado, M | 1 |
| Badoux, X; Cohen, EN; Estrov, Z; Faderl, SH; Ferrajoli, A; Gao, H; Keating, MJ; Lee, BN; Reuben, JM; Wierda, WG | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Haug, JL; Henderson, KJ; Jacobus, SJ; Kumar, SK; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Falk, RH | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Möller, J; Murthy, A; Nicklasson, L | 1 |
| Tokuhira, M | 1 |
| Ohmachi, K | 1 |
| Adam, Z; Chovancová, J; Hájek, R; Klabusay, M; Koukalová, R; Krejčí, M; Mayer, J; Pour, L; Rehák, Z; Stehlíková, O; Szturz, P; Zahradová, L | 1 |
| Horiike, S; Kuroda, J; Nagoshi, H; Taniwaki, M | 1 |
| Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Henderson, KJ; Jacobus, SJ; Kumar, S; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA; Williams, ME | 1 |
| Bodera, P; Stankiewicz, W | 1 |
| Dimeski, G; Wood, P | 1 |
| Cavo, M | 2 |
| Bolesta, S; Boruah, PK; Shetty, SM | 1 |
| Knop, S | 1 |
| Bartlett, NL; Blum, KA; Carson, KR; Cashen, AF; Fehniger, TA; Fenske, TS; Goy, A; Hurd, DD; Keppel, CR; Larson, S; Schneider, SE; Siegel, MJ; Trinkaus, K; Wagner-Johnston, ND | 1 |
| Garcia-Manero, G | 2 |
| Cairoli, A; Voutsadakis, IA | 1 |
| Aul, C; Büsche, G; Germing, U; Giagounidis, AA; Göhring, G; Haase, S; Kulasekararaj, A; Mufti, GJ; Petersen, P; Platzbecker, U; Radkowski, R | 1 |
| Glasmacher, A; Gorschlüter, M; Schmidt-Wolf, IG; Schwamborn, K | 1 |
| Adams, M; Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Lu, L; Meyer, B | 1 |
| Hata, H | 1 |
| Tohyama, K | 2 |
| Alsina, M; Nishihori, T | 1 |
| Cox, MC; Lionetto, L; Mannino, G; Naso, V; Simmaco, M; Spiriti, MA | 1 |
| Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E | 1 |
| Gorin, NC; Isnard, F; Malak, S; Perot, C; Rubio, MT; Scherman, E | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Hamnvik, OP; Larsen, PR; Marqusee, E | 1 |
| Bangia, N; Borrello, I; Chanan-Khan, AA; Chitta, K; Czuczman, MS; Ersing, N; Lee, K; Mashtare, TL; Masood, A; Paulus, A; Sher, T; Swaika, A; Wallace, PK; Wilding, G | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| Andre, P; Bakan, CE; Benson, DM; Bléry, M; Bonnafous, C; Caligiuri, MA; Clever, D; Collins, SM; Efebera, Y; Farag, SS; Hofmeister, CC; Liang, J; Romagne, F; Srivastava, S; Zhang, J; Zhang, S | 1 |
| Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM | 1 |
| Abdel-Wahab, O; Berube, C; Bhattacharya, S; Coutre, S; Figueroa, ME; Gallegos, L; Gotlib, JR; Kohrt, HE; Levine, R; Liedtke, M; Medeiros, BC; Melnick, A; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Hogan, WJ; Kumar, SK; Lacy, MQ; Micallef, IN; Rajkumar, SV; Sinha, S | 1 |
| Chen, N; Kumar, G; Lau, H; Surapaneni, S; Wen, L | 1 |
| Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R | 1 |
| Balzarotti, M; Bonfichi, M; Bottelli, C; Brusamolino, E; De Luca, S; Fanin, R; Levis, A; Monagheddu, C; Orsucci, L; Pileri, SA; Ravelli, E; Ria, R; Rusconi, C; Sabattini, E; Salvi, F; Tucci, A; Vacca, A; Vitolo, U; Volpetti, S; Zaja, F | 1 |
| Giraldo, P; Lecumberri, R; Nistal, S; Tomás, JF | 1 |
| Fenaux, P; Freeman, J; Palumbo, A; Weiss, L | 1 |
| Adam, Z; Cervinek, L; Hájek, R; Hermanová, M; Koukalová, R; Král, Z; Krejcí, M; Kren, L; Mayer, J; Mechl, M; Moulis, M; Pour, L; Prásek, J; Rehák, Z; Sprláková, A; Szturz, P; Zahradová, L | 1 |
| Cives, M; Dammacco, F; Milano, A; Silvestris, F | 1 |
| Colman, H; Conrad, CA; de Groot, J; Dhamne, M; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Ictech, SE; Kang, SL; Levin, VA; Liu, V; Loghin, M; Puduvalli, VK; Yung, WK | 1 |
| Giannopoulos, K; Mertens, D; Stilgenbauer, S | 1 |
| Adam, Z; Chovancová, J; Hájek, R; Klabusay, M; Koukalová, R; Krejčí, M; Mayer, J; Pour, L; Rehák, Z; Slaisová, R; Stehlíková, O; Szturz, P | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Berg, SL; Dauser, RC; Gibson, BW; McGuffey, LH; Muscal, JA; Nuchtern, JG; Sun, Y | 1 |
| Brosseau, C; Colston, K; Dalgleish, AG; Galustian, C | 1 |
| Barlett, B; Dalgleish, AG; Fryer, RA; Galustian, C | 1 |
| Bischoff, M | 1 |
| Ashida, T; Emoto, M; Hirase, C; Matsumura, I; Morita, Y; Ojima, M; Rai, S; Serizawa, K; Shimada, T; Taniguchi, Y; Tatsumi, Y; Yamaguchi, T | 1 |
| Jena, RK; Kansurkar, SS; Swain, M; Swain, TR | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Landgren, O; Mailankody, S; Thomas, A | 1 |
| Allegra, A; Alonci, A; Cannavò, A; D'Angelo, A; Musolino, C; Penna, G; Petrungaro, A; Romeo, G; Russo, S | 1 |
| Reece, D; Scott, E | 1 |
| Appel, A | 1 |
| Ailawadhi, S; Borrelo, I; Chanan-Khan, A; Chitta, K; Ersing, N; Khan, AN; Lee, KP; Manfredi, D; Masood, A; Miller, KC; Paulus, A; Sher, T | 1 |
| Harada, H; Jinnai, I; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y | 1 |
| Himmelmann, A; Tchinda, J | 1 |
| Constans, T; Cottier, JP; Dardaine, V; Eudo, C; Hommet, C; Mondon, K; Petit, A; Rippault, H | 1 |
| Chen, DT; Epling-Burnette, PK; Fulp, W; List, AF; McDaniel, JM; Zou, JX | 1 |
| Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM | 1 |
| Iino, M | 1 |
| Hajek, R; Kovarova, L; Muthu Raja, KR | 1 |
| Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E | 1 |
| Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C | 1 |
| Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N | 1 |
| Moehler, T | 1 |
| Gribben, JG; Ramsay, AG; Riches, JC | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Borrello, I; Emerling, A; Ferguson, A; Huff, CA; Noonan, K; Pasetti, MF; Rudraraju, L | 1 |
| Greig, N; Sandoval, F; Shannon, E; Stagg, P | 1 |
| Figueiredo, A; João, C; Martins, HF | 1 |
| Esteves, GV; Mariz, JM | 1 |
| Anderson, KC; Bernett, MJ; Cemerski, S; Chen, H; Chu, SY; Desjarlais, JR; Horton, HM; Karki, S; Kong, SY; Lazar, GA; Muchhal, US; Munshi, NC; Nguyen, DH; Pong, E; Tai, YT | 1 |
| Awan, F; Bunner, P; Craig, M; Cumpston, A; Deremer, D; Hamadani, M; Jillella, A; Kochuparambil, ST; Kota, V; Leadmon, S; Morrison, D; Osman, S; Speir, E; Watkins, K | 1 |
| Chang, H; Chen, MH; Qi, CX; Saha, MN | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A | 1 |
| Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T | 1 |
| Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D | 1 |
| Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M | 1 |
| Brandenburg, N; Dimopoulos, MA; Morgan, GJ; Niesvizky, R; Richardson, PG; Weber, DM; Yu, Z | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC | 1 |
| Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Akuthota, P; Kelly, E; Roberts, DH; Rosenthal, ES; Theisen-Toupal, J; Zwicker, JI | 1 |
| Miyazaki, Y | 2 |
| Anand, P; Bello, E; Bendarz, U; Bilotti, E; McBride, L; McNeill, A; Olivo, K; Siegel, DS; Tufail, M; Vesole, DH | 1 |
| Cragin, LS; Khan, ZM; Pashos, CL | 1 |
| Carson, D; Endo, T; Gast, SM; Kim, Y; Lu, D; Schmidt-Wolf, IG | 1 |
| Ramchandren, R | 1 |
| Adami, F; Briani, C; Citton, V; Lessi, F; Manara, R; Zambello, R | 1 |
| Afable, M; Guinta, K; Jankowska, A; Jerez, A; List, AF; Maciejewski, J; Makishima, H; McGraw, KL; O'Keefe, CL; Sekeres, MA; Sugimoto, Y; Szpurka, H; Tiu, R; Traina, F; Visconte, V | 1 |
| Jin, X; Zhang, YZ | 1 |
| Chanan-Khan, AA; Kasyapa, CS; Sher, T | 1 |
| Kolesar, JM; Simondsen, KA | 1 |
| Mizutani, M; Ohya, E; Sekine, T | 1 |
| Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J | 1 |
| Akpek, G; Brauer, DL; Edelman, B; Hess, JR; Rapoport, AP | 1 |
| Alexandrescu, DT; Dasanu, CA; Mitsis, D | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Duran, S; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Ladaique, P; Lemarie, C; Oudin, C; Schiano De Colella, JM; Stoppa, AM | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA | 1 |
| Fujita, Y; Furuta, N; Ikeda, M; Okamoto, K; Tashiro, Y | 1 |
| Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Křikavová, L; Matýšková, M; Mayer, J; Navrátil, M; Nebeský, T; Neuman, C; Pour, L; Rehák, Z; Szturz, P; Tomíška, M | 1 |
| Tsuda, H; Tsuji, T; Yamasaki, H; Yokoo, E | 1 |
| Domján, G; Gadó, K | 1 |
| Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S | 1 |
| Abbas, J; Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, A; McDonald, K; Shoptaw, K; Stuart, RK | 1 |
| Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B | 1 |
| Dispenzieri, A; Gertz, MA | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Papatheodorou, A; Terpos, E | 1 |
| Finsterer, J; Höftberger, R; Regele, H; Stöllberger, C; Wöhrer, A | 1 |
| Allred, J; Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, KM; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Zeldenrust, SR | 1 |
| Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF | 1 |
| Habermann, TM | 1 |
| Fonseca, R | 1 |
| Giralt, S | 1 |
| Braggio, E; Cesarman-Maus, G; Fonseca, R | 1 |
| Diez-Campelo, M; Giraldo, P; Hernández, MT; López-Corral, L; Matarraz, S; Mateos, MV; Orfao, A; Paiva, B; Pérez, E; San Miguel, JF | 1 |
| Apostolou, T; Boletis, I; Delimpasi, S; Dimopoulos, MA; Gavriatopoulou, M; Gkortzolidis, G; Kastritis, E; Marinaki, S; Michalis, E; Nikitas, N; Pamboukas, C; Roussou, M; Terpos, E | 1 |
| Dong, M; Hua, Y; Jones, KR; Li, L; Li, Q; Ren, J; Smith, DT; Yuan, M | 1 |
| Billingsley, D; Caceres, G; Chen, X; Clark, J; Djeu, J; Eksioglu, EA; Epling-Burnette, PK; Fortenbery, N; Komrokji, R; Lancet, J; List, A; Maciejewski, JP; McGraw, K; Sallman, D; Sekeres, M; Sokol, L; Wang, H; Wei, S; Zhang, L; Zhou, J | 1 |
| Boccia, R; Brown, GL; Galili, N; Garcia-Manero, G; Lyons, RM; Mesa, RA; Mulford, D; Raza, A; Sekeres, MA; Smith, SE; Steensma, DP | 1 |
| Clear, AJ; Fatah, R; Gribben, JG; Ramsay, AG | 1 |
| Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C | 1 |
| Caravita, T; De Bellis, A; de Fabritiis, P; Dentamaro, T; Morino, L; Musto, P; Perrotti, A; Siniscalchi, A; Tendas, A | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M | 1 |
| Anderson, KC; Barry, S; Bashey, A; Bennett, E; Bressler, L; Callander, NS; Devine, SM; Gabriel, DA; Gentile, T; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Kelly, M; Landau, H; Levitan, D; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Postiglione, J; Qazilbash, MH; Richardson, PG; Rosenbaum, C; Schlossman, R; Seiler, M; Shea, TC; Stadtmauer, EA; Van Besien, K; Vij, R; Weisdorf, DJ | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Decaux, O; Dumontet, C; Facon, T; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Payen, C; Pegourie, B; Roussel, M; Stoppa, AM; Vekemans, MC; Voillat, L | 1 |
| Badros, AZ | 1 |
| Matsuoka, A; Tohyama, K; Tohyama, Y; Tsujioka, T | 1 |
| Brown, RE; Dhanasiri, S; Schey, S; Stern, S | 1 |
| Jimenez-Zepeda, VH; John, R; Trudel, S; Vajpeyi, R | 1 |
| Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Arita, M; Hotta, M; Ishida, T; Kunimasa, K; Maeda, T; Ueda, T | 1 |
| Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K | 1 |
| Segler, A; Tsimberidou, AM | 1 |
| Nabhan, C; Petrylak, DP | 1 |
| Belickova, M; Caniga, M; Cechova, E; Cermak, J; Dostalova Merkerova, M; Jonasova, A; Krejcik, Z; Michalova, K; Neuwirtova, R; Vesela, J; Votavova, H; Zemanova, Z | 1 |
| Alegre, A; Dimopoulos, MA; Goldschmidt, H; Mark, T; Niesvizky, R; Terpos, E | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Bari, A; Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Roat, E; Sacchi, S | 1 |
| Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T | 1 |
| Kalff, A; Quach, H; Spencer, A | 1 |
| Janakiraman, N; Munoz, J | 1 |
| Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R | 1 |
| Caraffa, P; Caravita, T; de Fabritiis, P; Gentili, S; Leoni, P; Offidani, M; Perrotti, A; Siniscalchi, A | 1 |
| Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S | 1 |
| Badillo, M; Bejarano, M; Bell, N; Byrne, C; Cabanillas, F; Champlin, R; Chen, W; Chen, Y; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hartig, K; Kwak, L; McLaughlin, P; Neelapu, SS; Newberry, KJ; Romaguera, J; Samaniego, F; Sun, L; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zeldis, J; Zhang, L | 1 |
| Dawar, R; Hernandez-Ilizaliturri, F | 1 |
| Geisler, CH | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Balasubramanian, S; Buggy, JJ; Ceribelli, M; Emre, NC; Ferrer, M; Guha, R; Kohlhammer, H; Mathews, LA; Platig, J; Powell, J; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, C; Waldmann, TA; Wright, G; Xiao, W; Xu, W; Yang, Y; Young, RM; Zhang, M; Zhao, H | 1 |
| Benath, G; Bornhäuser, M; Ehninger, G; Ferrer, RA; Hofbauer, LC; Platzbecker, U; Rauner, M; Schmitz, M; Wehner, R; Wobus, M | 1 |
| Moskowitz, AJ | 2 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Somani, N | 1 |
| Jinesh, GG; Kamat, AM; Lee, EK; Tran, J | 1 |
| Aerts, JL; Allard, SD; De Keersmaecker, B; Lacor, P; Schots, R; Thielemans, K | 1 |
| Anderson, KC; Arnason, J; Avigan, D; Glotzbecker, B; Joyce, RM; Kufe, D; Kufe, T; Levine, JD; Luptakova, K; Mills, H; Rosenblatt, J; Stroopinsky, D; Tzachanis, D; Vasir, B; Zwicker, JI | 1 |
| Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Cluzeau, T; Fenaux, P | 1 |
| Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H | 1 |
| Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W | 1 |
| Deeks, SG; Ferrucci, L; Goetzl, EJ; Greig, N; Hesdorffer, CS; Kane, L; Lim, H; Schwartz, JB | 1 |
| Takamatsu, Y | 1 |
| Lentzsch, S; Pan, B | 1 |
| Bahner, J; Kanavy, H; Korman, NJ | 1 |
| Brunetti, O; Cives, M; Longo, V; Silvestris, F; Simone, V | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Abboud, CN; Bernabe, N; Cashen, AF; DiPersio, JF; Monahan, R; Ramsingh, G; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Brower, V | 2 |
| Ay, C; Pabinger, I; Thaler, J | 1 |
| Gertz, M | 1 |
| Boccadoro, M; Bringhen, S; Cerrato, C; Gay, F; Palumbo, A; Pautasso, C | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Burchert, A; Hansen, T; Hildebrandt, Y; Klyuchnikov, E; Kröger, N; Kropff, M; Pflüger, KH; Schilling, G; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR | 1 |
| Marschner, N; Zaiss, M | 1 |
| Berenson, JR; Eshaghian, S | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 2 |
| Auer, RL; Bullard, SH; Carey, S; Eve, HE; Heise, CC; Mamidipudi, V; Radford, JA; Richardson, SJ; Rule, SA; Shi, T | 1 |
| Kimby, E | 1 |
| Dolak, W; Kiesewetter, B; Lukas, J; Müllauer, L; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Buckstein, R; Leitch, HA; Shamy, A; Storring, JM | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C | 1 |
| Medeiros, BC; Ungewickell, A | 1 |
| Advani, AS; Afable, M; Cuthbertson, D; Englehaupt, R; Jerez, A; Juersivich, J; Komrokji, R; Lancet, J; List, AF; Maciejewski, JP; Makishima, H; Paleveda, J; Paquette, R; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Cockwell, P; Cook, M; Stringer, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Caceres, G; Deeg, HJ; Karsan, A; List, AF; Nevill, TJ; Platzbecker, U; Scott, BL; Sokol, L; Sung, S; Venner, CP; Woltosz, JW | 1 |
| Liu, LR; Qian, SX | 1 |
| Chen, N; Komrokji, RS; Lancet, JE; List, AF; Lush, R; Paleveda, J; Saba, HI; Swern, AS | 1 |
| Chen, N; Kasserra, C; Lau, H; Liu, L; Reyes, J | 1 |
| Byrd, JC; Gao, Y; Herman, SE; Jarjoura, D; Johnson, AJ; Li, X; Mahoney, E; Phelps, MA; Rozewski, DM; Shin, JD; Stefanovski, MR; Towns, WH; Yang, X | 1 |
| Hiddemann, W; Seiler, TM | 1 |
| Kortuem, KM; Stewart, AK; Zhu, YX | 1 |
| Suzuki, K | 2 |
| Abouyahya, I; Alhan, C; Coenen, JL; de Kruijf, EJ; de Wolf, JT; Heyning, FH; Huls, GA; Imholz, AL; Kappers-Klunne, MC; Koedam, J; Koene, HR; Muus, P; Ossenkoppele, GJ; Planken, EV; Segeren, CM; te Boekhorst, PA; van de Loosdrecht, AA; van der Velden, AM; Vasmel, WL; Velders, GA; Veth, G; Westers, TM | 1 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Perlini, S; Russo, P | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; Finelli, C; Galimberti, S; Ghio, R; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Rigolino, C; Rodà, F; Sanpaolo, G; Volpe, A | 1 |
| Usmani, SZ | 2 |
| Arima, N; Kawada, H | 1 |
| Fontana, RJ; Konda, A; Nojkov, B; Signori, C | 1 |
| Espinal-Witter, R; Geyer, JT; Knowles, DM; Mathew, S; Orazi, A; Racchumi, J; Subramaniyam, S; Verma, S; Wang, YL | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML | 1 |
| Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC | 1 |
| Hansson, L; Karlsson, C; Lundin, J; Mozaffari, F; Norin, S; Österborg, A; Porwit, A; Rossmann, E; Sylvan, SE | 1 |
| Giagounidis, AA | 1 |
| Atanackovic, D; Ayuk, F; Dreger, P; Hegenbart, U; Heinzelmann, M; Hildebrandt, Y; Kröger, N; Schönland, S; Stübig, T; Wolschke, C; Zander, A | 1 |
| Furtado, M; Harding, S; Levoguer, A; Rule, S; Shah, N | 1 |
| Barley, K; Chari, A; Jagannath, S; Osman, K | 1 |
| Dhodapkar, KM; Dhodapkar, MV; Miesowicz, F; Monesmith, T; Nair, S; Neparidze, N; Richter, J; Sundaram, R; Zhang, L | 1 |
| Alachkar, H; Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Dorrance, AM; Eiring, AM; Fehniger, TA; Garzon, R; Hickey, CJ; Lee, LJ; Maharry, K; Marcucci, G; Mishra, A; Mrózek, K; Nicolet, D; Perrotti, D; Radomska, HS; Santhanam, R; Schwind, S; Vij, R; Walker, A; Whitman, SP; Wu, LC; Wu, YZ; Zhao, X | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Banglawala, S; Lentz, EM; Reece, DE; Seki, JT | 1 |
| Giralt, S; Landau, H; Rosenzweig, M | 1 |
| Blaise, D; Charbonnier, A; Gelsi-Boyer, V; Mozziconacci, MJ; Prebet, T; Vey, N | 1 |
| Allegra, A; Alonci, A; Catena, S; Musolino, C; Rizzotti, P; Rotondo, F; Russo, S | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Boccadoro, M; Cavallo, F; Larocca, A; Mina, R; Palumbo, A | 1 |
| Ogura, M | 1 |
| Fu, J; Lentzsch, S; Li, S; Ma, H; Mapara, MY | 1 |
| Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ | 1 |
| Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I | 1 |
| Patel, JM; Sanchorawala, V; Seldin, DC; Shelton, AC; Sloan, JM; Zeldis, JB | 1 |
| Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Gertz, MA; Hayman, SR; Sher, T | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Gandhi, S; Hu, K; Larson, RA; Liu, D; Lyons, RM; Matei, C; Scott, B; Wang, ES; Yang, AS | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP | 1 |
| Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M | 1 |
| Beckers, MM; Huls, G | 1 |
| Santini, V | 2 |
| Locke, FL; Morgan, GJ | 1 |
| Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E | 1 |
| Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Rizzieri, DA | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| He, Y; Li, W; Li, X; Liu, F; Liu, X; You, Y; Zhang, M; Zheng, J; Zou, P | 1 |
| Chopra, R; Heise, C; Kosek, J; Schafer, PH; Wang, M; Zhang, LH | 1 |
| Chen, CI | 1 |
| Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Fuchida, S; Haruyama, H; Hatsuse, M; Murakami, S; Okano, A; Shimazaki, C | 1 |
| Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF | 1 |
| Alexanian, R; Delasalle, K; Wang, M | 1 |
| Mahindra, A; Saini, N | 2 |
| Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG | 1 |
| Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R | 1 |
| Corradini, P; Farina, L; Rezzonico, F; Spina, F | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F | 1 |
| Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Siegel, D | 1 |
| Ganesh, N; Senthilkumar, CS | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Lonial, S; Miguel, JF | 1 |
| McCarthy, PL | 1 |
| Mina, R; Palumbo, A | 1 |
| Borthakur, G; Chen, Y | 1 |
| Berry, L; Boe, M; Chesi, M; Del Rosario, G; Du, C; Ebens, A; Friedman, LS; Leif Bergsagel, P; Mariathasan, S; Munugalavadla, V; Slaga, D; Sun, L; Yan, Y | 1 |
| Fujisawa, S; Fujita, H; Imai, N; Ishigatsubo, Y; Matsuura, S; Ogusa, E; Taguchi, J; Tomita, N | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G | 1 |
| Ansari, A; Ansari, SA; Gupta, A; Hasnain, MS; Joshi, P; Rao, S; Sen, P; Singh, MK; Vig, N | 1 |
| Evans, R; Gribben, JG; Hogg, N; Kiaii, S; Ramsay, AG; Svensson, L | 1 |
| Benson, DM | 1 |
| Curto Barredo, L; Gallardo, F; Garcia, M; Pujol, RM; Salar, A | 1 |
| Adel, N; Chen, X; Chimento, D; Chung, DJ; Comenzo, R; Giralt, S; Hassoun, H; Landau, H; Lendvai, N; Lesokhin, A; Pozotrigo, M; Reich, L; Riedel, E | 1 |
| Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C | 1 |
| Döhner, H; Dürr, C; Lichter, P; Schulz, A; Seiffert, M; Stilgenbauer, S; Zenz, T | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Dalgleish, AG; Dasgupta, P; Galustian, C; Henry, JY; Labarthe, MC; Meyer, B | 1 |
| Abruzzo, L; Cortes, J; Kantarjian, H; Pierce, S; Takahashi, K; Verstovsek, S | 1 |
| Niu, S; Sheng, Z; Wang, H; Xu, J; Yu, J; Zou, Y | 1 |
| Li, J; Zhou, DB | 1 |
| Cirstea, D; Eda, H; Fulciniti, M; Mahindra, A; Nemani, N; Patel, K; Raje, N; Santo, L; Scullen, T; Vallet, S; Yee, A | 1 |
| Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V | 1 |
| Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A | 1 |
| Ades, L; Bally, C; Chesnais, V; Dreyfus, F; Fenaux, P; Fontenay, M; Kaltenbach, S; Kosmider, O; Leschi, C; Park, S; Rouquette, A; Santini, V; Sardnal, V; Toma, A | 1 |
| Asher, C; Furnish, T | 1 |
| Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF | 1 |
| Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Mori, F; Niimi, A; Ri, M; Suzuki, T; Yoshida, T | 1 |
| Amraoui, K; Belhadj, K; Dupuis, J; Jannière-Nartey, C; Maître, B | 1 |
| Kizaki, M; Tokuhira, M; Watanabe, R | 1 |
| Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Dwyer, MA; Fayad, LE; Glenn, MJ; Gockerman, JP; Gordon, LI; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Naganuma, M; Porcu, P; Press, O; Pro, B; Reddy, N; Sokol, L; Swinnen, L; Tsien, C; Vose, JM; Wierda, WG; Yahalom, J; Zafar, N; Zelenetz, AD | 1 |
| García-Muñoz, R; Muñoz-Rodríguez, A; Rabasa, P; Robles-de-Castro, D | 1 |
| Bowen, D; Call, TG; Hanson, CA; Jelinek, DF; Kay, NE; LaPlant, B; Leis, JF; Pettinger, A; Ramsay, AG; Shanafelt, TD; Tun, HW; Zent, CS | 1 |
| Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
| Chen, C; Chu, CM; Jiang, H; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Trudel, S; Young, T | 1 |
| Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Z | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Triozzi, P; Tyler, A | 1 |
| Lu, H; Sheng, Z; Yu, J; Zou, Y | 1 |
| Matsumura, I; Morita, Y; Tanaka, H | 1 |
| Abe, M; Fujii, S | 1 |
| Berno, T; Briani, C; Campagnolo, M; Candiotto, L; Cavaletti, G; Ermani, M; Lucchetta, M; Padua, L; Torre, CD; Zambello, R | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
| Burgstaller, S; Fridrik, M; Gisslinger, H; Hojas, S; Kühr, T; Ludwig, H; Mayrbäurl, B; Pöhnl, R; Pötscher, M; Schlögl, E; Thaler, J; Zauner, D | 1 |
| Minvielle, S; Moreau, P | 1 |
| Skarbnik, AP; Smith, MR | 1 |
| Anderson, KC; Carter, SL; Giralt, S; Horowitz, MM; Laport, GG; McCarthy, PL; Pasquini, MC; Rajkumar, SV; Richardson, PG; Stadtmauer, EA | 1 |
| Gaspari, AA; Liu, H; Schleichert, R | 1 |
| Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L | 1 |
| Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T | 1 |
| Ysebaert, L | 1 |
| Bolomsky, A; Caltagirone, S; Gisslinger, H; Heintel, D; Jäger, U; Ludwig, H; Palumbo, A; Pfeifer, S; Rocci, A; Schreder, M; Zojer, N | 1 |
| Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Anwer, S; Collings, F; Sternberg, A; Sun, Y; Trace, K | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Arcila, ME; Babu, D; Chimento, D; Chung, DJ; Devlin, SM; Giralt, S; Hassoun, H; Landau, H; Lendvai, N; Lesokhin, A; Weltz, J; Zamarin, D | 1 |
| Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Takeuchi, K | 1 |
| Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E | 1 |
| Argnani, L; Derenzini, E; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Blau, IW; Böhme, A; Braulke, F; Brümmendorf, TH; Bug, G; Detken, S; Ganster, C; Germing, U; Giagounidis, AA; Götze, K; Haase, D; Hofmann, WK; Jentsch-Ullrich, K; Jung, K; Lübbert, M; Metz, M; Müller-Thomas, C; Ottmann, O; Pfeiffer, S; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schmidt, B; Seraphin, J; Shirneshan, K; Stadler, M; Trümper, L | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M | 1 |
| Chang, MN; Hou, W; Jung, SH; Li, Y | 1 |
| Amiot, M; Bonnaud, S; Gomez-Bougie, P; Gratas, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C | 1 |
| Cavallo, F; Palumbo, A | 1 |
| Ashhab, MU; Gan, N; He, F; Kong, H; Omran, A; Peng, J; Yin, F | 1 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Assaf, MS; Chen, N; Kasserra, C; Liu, L; Palmisano, M; Reyes, J; Ye, Y; Zhou, S | 1 |
| Germing, U; Platzbecker, U | 1 |
| Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kapoor, P; Kumar, S; Kyle, R; Lacy, MQ; McCurdy, A; Rajkumar, SV; Rana, V; Russell, S; Srivastava, G; Zeldenrust, S | 1 |
| Sanchorawala, V; Seldin, DC; Shelton, AC; Zeldis, JB | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Alonso-Llamazares, J; Chimento, SM; Herschthal, J; Spock, C; Vivas, AC | 1 |
| Akinleye, A; Wu, M; Zhu, X | 1 |
| Foschi, FG; Lanzi, A; Marano, G; Savini, P; Stefanini, GF | 1 |
| Johnston, JB | 1 |
| Cerrato, C; Palumbo, A | 2 |
| Chi, XH; Lu, XC; Yang, B; Yu, RL | 1 |
| Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C | 1 |
| Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
| Dalm, VA; van Hagen, PM | 1 |
| Afghahi, A; Arai, S; Dinner, S; Lafayette, R; Liedtke, M; Schrier, SL; Witteles, R; Witteles, W | 1 |
| Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H | 1 |
| Bornhäuser, M; Brocard, B; Ehninger, G; Ferrer, RA; Hofbauer, LC; List, C; Mohr, B; Platzbecker, U; Rauner, M; Schmitz, M; Schönefeldt, C; Stiehler, M; Wehner, R; Wobus, M | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T | 1 |
| Hirata, T; Inagaki, T; Iwai, M; Katayama, Y; Kawano, H; Kimura, S; Kishi, M; Koide, T; Matsui, T; Minagawa, K; Suzuki, T; Takechi, M | 1 |
| Inui, Y; Kanakura, Y; Kataoka, S; Kawata, S; Kubo, M; Maeda, T; Matsunaga, H; Matsuura, N; Ueda, S | 1 |
| Bosly, A; Coiffier, B; Delarue, R; Fitoussi, O; Gabarre, J; Glaisner, S; Haioun, C; Li, J; Lister, J; Morschhauser, F; Quach, H; Thieblemont, C | 1 |
| Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F | 1 |
| Cutucache, CE | 1 |
| Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E | 1 |
| Baladandayuthapani, V; Bjorklund, CC; Jones, RJ; Kuiatse, I; Lin, HY; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Yang, J | 1 |
| Mistrík, M; Roziaková, L | 1 |
| Bateman, S; Cha, SC; Chen, J; Kwak, LW; Lerman, B; Qin, H; Sakamaki, I; Surapaneni, S; Yi, Q | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Garden, BC; Lacouture, ME; Nardone, B; Reich, LM; West, DP; Wu, S | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| Abul, N; Al-Awadhi, A; Al-Jafar, HA; Kumar, N | 1 |
| Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Badoux, XC; Calin, S; Ferrajoli, A; Gao, H; Kantarjian, HM; Keating, MJ; Kornblau, SM; O'Brien, S; Reuben, JM; Strati, P; Wierda, WG | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Scott, LJ; Syed, YY | 1 |
| He, L; Huang, Z; Liu, SQ; Ma, Z; Zhang, RB | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| Cosiglio, FJ; Ordi-Ros, J | 1 |
| Czuczman, MS; Habermann, TM; Li, J; Lossos, IS; Pietronigro, D; Reeder, CB; Tuscano, JM; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| Erskine, L; Figg, WD; Greig, NH; Mahony, C; Niven, J; Vargesson, N | 1 |
| Brunet-Possenti, F; Crickx, B; Descamps, V; Hermine, O; Marinho, E | 1 |
| Gironella, M; López-Andreoni, L; Mallo, M; Martínez-Morgado, N; Ortega, M; Sánchez-Morata, C; Solé, F; Valcárcel, D; Vallespí, T | 1 |
| Galichon, P; Hertig, A; Jamme, M | 1 |
| Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P | 1 |
| Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF | 1 |
| Alaibac, M; Lo Nigro, A; Peserico, A; Russo, I; Stan, R; Zattra, E | 1 |
| Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG | 1 |
| Klánová, M; Špička, I | 1 |
| Kasahara, KH; Miyagishima, T; Oda, H; Sawada, K; Sogabe, S; Tateno, T | 1 |
| Boku, S; Hosoda, T; Kagoo, T; Kudo, M; Ohashi, K; Ueno, H; Yamamoto, R; Yano, T; Yokoyama, A; Yoneda, M | 1 |
| Adu-Gyamfi, B; Buja, LM; Frazier, OH; Mallidi, HR; Meyers, DE; Rice, L; Segura, AM | 1 |
| Desai, M; Newberry, KJ; Ou, Z; Romaguera, J; Wang, M; Zhang, L | 1 |
| Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S | 1 |
| Baer, MR; Davidoff, AJ; Gore, SD; Hendrick, F; Mahmoud, D; McNally, DL; Zeidan, AM | 1 |
| Adam, Z; Hajek, R; Pelcova, J; Plasil, M; Raja, KR; Rihova, L | 1 |
| Burkhard, JA; Carreira, EM; Plancher, JM; Rogers-Evans, M; Wuitschik, G | 1 |
| Delbeuck, X; Facon, T; Le Rhun, E; Leleu, X; Lenfant, P; Mackowiak, MA; Noel, MP; Pasquier, F; Pollet, M; Rollin-Sillaire, A | 1 |
| Arceci, RJ; Atsidaftos, E; Blanc, L; Bodine, DM; Ebert, BL; Ellis, SR; Farrar, JE; Gazda, HT; Landowski, M; Lipton, JM; Liu, JM; Markello, TC; Muir, E; Narla, A; Singh, SA; Vlachos, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Ishida, T | 2 |
| Agnelli, L; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Cascavilla, N; Cavalli, M; D'Arena, G; Di Raimondo, F; Falcone, A; Filardi, N; Guariglia, R; Lerose, R; Levi, A; Mansueto, G; Martorelli, MC; Mina, R; Morabito, F; Musto, P; Neri, A; Nobile, F; Offidani, M; Olivieri, A; Omedè, P; Palumbo, A; Petrucci, MT; Pietrantuono, G; Simeon, V; Todoerti, K; Villani, O | 1 |
| Morgan, GJ | 1 |
| Mark, TM; Meadows, JP | 1 |
| Atienza, JB; McDonnell, CN; Rull, PR; Sánchez Quintana, A | 1 |
| Falchook, G; Ganesan, P; Janku, F; Kies, M; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Zinner, R | 1 |
| Asgharzadeh, S; Liu, WY; Seeger, RC; Sheard, MA; Sposto, R; Sun, J; Tran, HC; Wan, Z; Wu, HW; Xu, Y | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K | 1 |
| Greenberg, AJ; Jelinek, DF; Kumar, SK; Rajkumar, SV; Walters, DK | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Wang, L; Xu, YL; Zhang, XQ | 1 |
| Guron, G; Layne, T; Shaaban, H | 1 |
| Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L | 1 |
| Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M | 1 |
| Fenaux, P; Germing, U; Giagounidis, A; List, A; MacBeth, KJ; Mufti, GJ | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Czuczman, MS; Haioun, C; Li, J; Polikoff, J; Prandi, K; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zhang, L; Zinzani, PL | 1 |
| Alsina, M; Baz, RC; Dalton, WS; Hussein, MA; Lee, JH; Nardelli, LA; Nishihori, T; Nodzon, LA; Ochoa-Bayona, JL; Oliver, EF; Shain, KH; Sullivan, DM; Zhao, X | 1 |
| Berzins, SP; Chan, AC; Godfrey, DI; Harrison, SJ; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K | 1 |
| Al Ali, NH; Basiorka, A; Boultwood, J; Caceres, G; Daugherty, FJ; Fulp, WJ; Johnson, J; Komrokji, RS; Lee, JH; List, AF; Littleton, N; Liu, K; McGraw, K; Pellagatti, A; Smith, LJ; Sokol, L; Wei, S; Wells, RA; Yip, BH; Zhang, L; Zhang, LM | 1 |
| Inoue, Y; Isobe, Y; Kato, M; Miura, I; Nishio, Y; Saito, T; Sakai, H; Sato, K; Suzuki, Y; Takahashi, M; Tsuruoka, Y | 1 |
| Gilbert, JA | 1 |
| Lin, M; Niu, S; Sheng, Z; Zou, Y | 1 |
| Cabanillas, F; Rivera-Rodriguez, N | 1 |
| Montastruc, JL; Olivier-Abbal, P; Teisseyre, AC | 1 |
| Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M | 1 |
| Ballester, G; Ballester, O; Yaqub, S | 1 |
| Merlini, G; Palladini, G | 1 |
| Burnette, BL; Dispenzieri, A; Harris, AM; Kumar, S; Kyle, RA; Rajkumar, SV; Sloan, JA; Tilburt, JC | 1 |
| Pérez-Paredes, MG; Rodríguez-Prieto, MÁ; Ruiz-González, I; Valladares-Narganes, LM | 1 |
| Ahmadi, T; Aqui, NA; Chong, EA; Gordon, A; Mato, AR; Nasta, SD; Schuster, SJ; Svoboda, J | 1 |
| Moreau, P; Touzeau, C | 2 |
| Liu, H; McCarthy, P | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Mabuchi, R; Matsumoto, T; Moriwaki, H; Nakamura, H; Nakamura, N; Shibata, Y; Tsurumi, H | 1 |
| Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Brandt, J; Goldschmidt, H; Herth, I; Heußel, CP; Hundemer, M; Merz, M; Neben, K | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B | 1 |
| Buadi, FK; Dispenzieri, A; Gertz, MA; Kourelis, TV; Kumar, SK; Kyle, RA; Lacy, MQ; Srivastava, G | 1 |
| Cooper, LJ; Kharfan-Dabaja, MA; Wierda, WG | 1 |
| Chen, H; Fu, J; Herzog, BH; McDaniel, JM; Ruan, J; Sheng, M; Song, K; Xia, L | 1 |
| Lentzsch, S; Schecter, J | 1 |
| Acebes-Huerta, A; Gonzalez, S; Gonzalez-García, E; González-Rodríguez, AP; Huergo-Zapico, L; Payer, AR; Villa-Alvarez, M | 1 |
| Avet-Loiseau, H; Bjorklund, C; Calle, Y; Chelliah, R; Chopra, R; Gandhi, AK; Lentzsch, S; Lopez-Girona, A; Madan, A; Mendy, D; Ning, Y; Orlowski, RZ; Schafer, P; Schey, SA; Thakurta, A; Waldman, MF | 1 |
| Adam, P; Fend, F; Goldschmidt, H; Kanz, L; Weisel, K; Zago, M | 1 |
| Ashhab, MU; Gan, N; Kong, H; Omran, A; Peng, J; Yin, F | 1 |
| Bustany, S; Cahu, J; Colomer, D; Martínez, A; Moros, A; Roué, G; Saborit-Villarroya, I; Sola, B | 1 |
| Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL | 1 |
| Bonacorsi, G; Bulgarelli, J; Castelli, I; Cuneo, A; Debbia, G; Fiorcari, S; Forconi, F; Gaidano, G; Laurenti, L; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Palumbo, GA; Rigolin, GM; Rizzotto, L; Rossi, D; Santachiara, R; Vallisa, D | 1 |
| Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
| Bompoint, C; Busson, M; Carmagnat, M; Clave, E; Coman, T; Douay, C; Garderet, L; Glauzy, S; Gorin, NC; Moins-Teisserenc, H; Toubert, A | 1 |
| Kelby, SK; Lestingi, TM; Nabhan, C; Patel, A; Tolzien, K; Villines, D | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E | 1 |
| Chopra, R; Gandhi, AK; Jungnelius, U; Li, M; Romano, A; Schafer, PH; Shi, T; Siena, S; Tabernero, J | 1 |
| Amías-Lamana, V; Cabiró-Badimón, I; Hoyos-Chacón, J; Mesa-Gutiérrez, JC; Porta-Monnet, J; Rouras-López, A | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, R; Hayman, SR; Kapoor, P; Kourelis, TV; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Rajkumar, SV; Russell, SJ; Srivastava, G; Zeldenrust, SR | 1 |
| Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB | 1 |
| Cavallo, F; Cerrato, C; Mina, R; Palumbo, A | 1 |
| Bradner, JE; Kaelin, WG; Lu, G; Middleton, RE; Mitsiades, CS; Naniong, M; Ott, CJ; Sun, H; Wong, KK | 1 |
| Carr, SA; Ciarlo, C; Comer, E; Ebert, BL; Grauman, P; Hartman, E; Heckl, D; Hurst, SN; Krönke, J; Li, X; McConkey, M; Munshi, N; Narla, A; Schenone, M; Schreiber, SL; Svinkina, T; Udeshi, ND | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Psaltopoulou, T; Sergentanis, TN; Terpos, E; Zagouri, F | 1 |
| Abuhejail, RM; Alzoman, NZ; Darwish, IA | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Beguin, Y; Caberg, JH; Caers, J; Hafraoui, K; Keutgens, A; Lambert, F; Tassin, F | 1 |
| Gattermann, N; Germing, U; Haas, R; Kobbe, G | 1 |
| Buadi, FK; Gertz, MA | 1 |
| Leleu, X; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K | 1 |
| Boyapati, A; Khan, S; Mar, A; Sheridan, A | 1 |
| Engelhardt, M; Kleber, M; Knop, S; König, C; Reinhardt, H; Wäsch, R | 1 |
| Hahn, T; McCarthy, PL | 1 |
| Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y | 1 |
| Ando, H; Chopra, R; Conklin, T; Daniel, TO; Gandhi, AK; Handa, H; Havens, CG; Ito, T; Kang, J; Klippel, A; Ning, Y; Schafer, PH; Thakurta, A; Waldman, MF; Wu, L | 1 |
| Ardanaz, MT; Arrizabalaga, B; Azaceta, G; Bargay, J; Cabrero, M; Calabuig, M; Cedena, T; Cerveró, C; Collado, R; del Cañizo, C; Díez-Campelo, M; García, M; Luño, E; Morell, MJ; Muñoz, JA; Nomdedeu, B; Pedro, C; Rodríguez, MJ; Rojas, SM; Simiele, A; Xicoy, B | 1 |
| Dusza, SW; Duvic, M; Guitart, J; Kim, YH; Kuzel, TM; Querfeld, C; Rosen, ST | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Sakurai, T; Yamada, M; Yoshida, M | 1 |
| Kharfan-Dabaja, MA; Komrokji, RS; Zeidan, AM | 1 |
| Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H | 1 |
| Guo, S; Hayes, TG; Lin, D; Munker, R; Shi, R | 1 |
| Cai, Q; Champlin, RE; Desai, M; Fu, K; Huang, H; Jiang, W; Liang, R; Qian, Z; Wang, M; Westin, J; Zhang, L | 1 |
| Abe, M; Fujii, S; Harada, T; Ikegame, A; Itoh, K; Iwasa, M; Kagawa, K; Kawai, S; Kuroda, Y; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Tsuji, D; Udaka, K; Yamada-Okabe, H | 1 |
| Ishikawa, O; Motegi, S; Uchiyama, A; Uehara, A; Yamada, K | 1 |
| Perry, C; Polliack, A | 1 |
| Landgren, O; Mailankody, S | 1 |
| Becker, PS; Bensinger, WI; Burwick, N; Green, DJ | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Kuendgen, A | 1 |
| Stewart, AK | 1 |
| Caraci, MR; Di Raimondo, F; Ferrara, F; Fuligni, F; Gazzola, A; Isidori, A; Laginestra, MA; Loscocco, F; Paolini, S; Piccaluga, PP; Pileri, SA; Riccardi, C; Rocchi, M; Rossi, M; Sparaventi, G; Visani, A; Visani, G | 1 |
| Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L | 1 |
| Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M | 1 |
| Engelhardt, M; Kleber, M; Landgren, O; Wäsch, R | 1 |
| Chennupati, S; Golla, M; Nalla, S; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Attal, M; Einsele, H; Giralt, S; McCarthy, PL | 1 |
| He, J; Hong, B; Lan, Y; Li, H; Lu, Y; Qian, J; Yang, J; Yi, Q; Zhang, M; Zheng, Y | 1 |
| Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S | 1 |
| Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z | 1 |
| Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R | 1 |
| Blum, KA; Maddocks, K | 1 |
| Alousi, A; Di Stasi, A; Hosing, C; Keating, M; Mehta, RS; O'Brien, S; Rezvani, K; Shah, N; Shpall, EJ; Wierda, W | 1 |
| Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Chetaille, B; Coso, D; Esterni, B; Ivanov, V; Olive, D; Schiano, JM; Stoppa, AM | 1 |
| Ebert, BL; Komrokji, RS; List, AF; Padron, E | 1 |
| Al Ustwani, O; Bhat, SA; Bogner, P; Ghani, S; Grassi, M; Khalid, B; Powell, J | 1 |
| Pratt, G | 1 |
| Anderson, K; Barlogie, B; Boccadoro, M; Bringhen, S; Cavo, M; Ciccone, G; Dimopoulos, MA; Evangelista, A; Hajek, R; Kumar, SK; Larocca, A; Lonial, S; Lupparelli, G; McCarthy, PL; Musto, P; Nooka, AK; Offidani, M; Palumbo, A; Petrucci, MT; Richardson, P; Sonneveld, P; Spencer, A; Usmani, S; van der Holt, B; Waage, A; Zweegman, S | 1 |
| Krathen, M; Okawa, J; Okon, L; Propert, K; Rose, M; Rosenbach, M; Werth, V | 1 |
| Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T | 1 |
| Baumann, T; Delgado, J; Montserrat, E; Santacruz, R | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Greil, R; Hartmann, TN; Huemer, M; Melchardt, T; Neureiter, D; Rebhandl, S; Zaborsky, N | 1 |
| Abumiya, M; Fujishima, N; Hagihara, M; Hirokawa, M; Kameoka, Y; Kobayashi, T; Matsumoto, M; Miura, M; Niioka, T; Sawada, K; Shida, S; Tagawa, H; Takahashi, N | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Cea, M; Christie, AL; Craigen, J; Fieles, W; Gliddon, L; Hoang, B; Kung, AL; Mayes, PA; Munshi, NC; Richardson, P; Tai, YT; Tunstead, J; Yates, J; Zhong, MY | 1 |
| Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q | 1 |
| Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Abedi, M; Brunson, A; Chee, K; Dutia, M; O'Donnell, RT; Reed-Pease, C; Tuscano, JM; Welborn, J | 1 |
| Bergsagel, PL; Chen, CI; Dave, N; Kukreti, V; Lau, A; Le, LW; Nong Wei, E; Paul, H; Trudel, S; Wang, T | 1 |
| Besa, EC; Gaballa, MR | 1 |
| Kumar, G; Surapaneni, S; Tong, Z; Yerramilli, U | 1 |
| Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Agarwal, S; Eddins, MJ; Kodrasov, MP; Kumar, S; LaRocque, JP; Marblestone, JG; Mattern, MR; Nicholson, B; Sterner, DE; Wu, J | 1 |
| Dickinson, M; Prince, HM | 1 |
| Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A | 1 |
| Chen, N; Kasserra, C; Kumar, G; Liu, L; Palmisano, M; Reyes, J; Wang, X; Weiss, D; Weiss, L; Zhou, S | 1 |
| Brioli, A; Cavo, M; Davies, FE; Melchor, L; Morgan, GJ; Morilla, R; Pawlyn, C; Stephens, C; Titley, I; Vijayaraghavan, G; Zeisig, A | 1 |
| Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM | 1 |
| Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y | 1 |
| Lichtman, EI; Sanchorawala, V; Seldin, DC; Shelton, A | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Bolomsky, A; Hose, D; Ludwig, H; Meißner, T; Pfeifer, S; Schreder, M; Zojer, N | 1 |
| Flohr, A; Schuelper, N; Trümper, L; Wulf, GG | 1 |
| Brossart, P; Busch, A; Fingerhut, L; Hahn-Ast, C; Janzen, V; Maurer, O; Mügge, LO; von Lilienfeld-Toal, M; Wolf, D; Zeh, D | 1 |
| Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B | 1 |
| Balsas, P; Campo, E; Colomer, D; Martínez, A; Montraveta, A; Moros, A; Normant, E; Pérez-Galán, P; Rodríguez, V; Roué, G; Saborit-Villarroya, I; Sandy, P; Wiestner, A | 1 |
| Borrello, I; Ghosh, N; Huff, CA; Tucker, N; Wozney, J; Zahurak, M | 1 |
| Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N | 1 |
| Bonini, C; Caprioli, C; Cocito, F; Corradini, P; Dalto, S; De Philippis, C; Dodero, A; Farina, L; Galli, M; Maura, F; Montefusco, V; Mussetti, A; Pennisi, M; Perrone, G; Rezzonico, F; Roncari, L; Soldarini, M; Spina, F; Stefanoni, P | 1 |
| Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E | 1 |
| Dong, H; Hu, N; Jiang, S; Jones, KR; Kang, YM; Luo, F; Ren, J; Xiong, L; Zhu, X; Zou, Y | 1 |
| Gomathi, T; Govindarajan, C; Imran, PK; Kim, SK; Rose H R, MH; Sudha, PN; Venkatesan, J | 1 |
| Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R | 1 |
| Diehl, V; von Tresckow, B | 1 |
| Kanz, L; Weisel, K | 1 |
| Govindaraj, C; Kong, YY; Madondo, M; Plebanski, M; Tan, P; Wei, A | 1 |
| Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Lei, W; Li, YF; Zhou, KS | 1 |
| Adams, A; Alsina, M; Becker, PS; Bensinger, W; Giralt, SA; Hari, P; Logan, B; McClune, B; Pasquini, MC; Popplewell, LL; Qazilbash, M; Riches, M; Rowley, S; Stadtmauer, EA; Vesole, DH; Weisdorf, D; Zhong, X | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Benettaib, B; Beyne-Rauzy, O; Bowen, D; del Cañizo, C; Fenaux, P; Fu, T; Ganser, A; Giagounidis, A; Göhring, G; Guerci-Bresler, A; Hellström-Lindberg, E; Lübbert, M; Mittelman, M; Mufti, GJ; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; te Boekhorst, P | 1 |
| Buckstein, R; Chesney, A; Cheung, M; Chodirker, L; Cussen, MA; Davidson, C; Kerbel, R; Lee, CR; Lenis, M; Mamedov, A; Reis, M; Shaked, Y; Wells, RA; Zhang, L | 1 |
| Castells, M; Fanning, L; Laubach, J; Lee, MJ; Richardson, P; Schlossman, R; Wickner, P | 1 |
| Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P | 1 |
| Attias, D; Mishchenko, E; Tadmor, T | 1 |
| Schleiffenbaum, BE | 1 |
| Kalampokis, I; Rabinovich, CE | 1 |
| Demopoulos, AM; Devoe, CE; Li, JY | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M | 1 |
| Burger, J; Faderl, S; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Barrientos, JC; Brown, JR; Castro, JE; Greaves, A; James, DF; Johnson, AJ; Kipps, TJ; Neuberg, D; Rai, KR; Rassenti, LZ; Werner, L; Wierda, WG | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Paumgartten, FJ | 1 |
| Beck, R; Burris, HA; Fandi, A; Garcia, JA; Infante, JR; Jungnelius, U; Li, S; Redman, B; Rini, B | 1 |
| Bergsagel, PL; Braggio, E; Bruins, LA; Champion, MD; Chang, XB; Fonseca, R; Jedlowski, P; Kortuem, KM; Lacy, M; Langlais, P; LaPlant, B; Laumann, K; Luo, M; Mikhael, J; Schmidt, JE; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Foard, D; Gibbs, SD; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Pinney, JH; Rannigan, L; Sachchithanantham, S; Venner, CP; Wechalekar, AD; Whelan, CJ | 1 |
| Agostinelli, C; Biasco, G; Bolondi, L; Leoni, S; Lolli, C; Mandrioli, A; Nannini, M; Pallotti, MC; Pantaleo, MA; Pileri, S; Saponara, M; Scioscio, VD | 1 |
| Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S | 1 |
| Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
| Agostino, NM; Gheith, S; Nair, R; Popescu, D | 1 |
| Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jasielec, J; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Stockerl-Goldstein, K; Vesole, DH; Vij, R | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G | 1 |
| Alexandrescu, DT; Bockorny, B; Dasanu, CA | 1 |
| Bharati, IS; Cathers, B; Corral, LG; Cui, B; Fecteau, JF; Futalan, D; Gaidarova, S; Ghia, EM; Kipps, TJ; Lopez-Girona, A; Messmer, D; Schwaederlé, M | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN | 1 |
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Kizaki, M | 1 |
| Ichinohe, T; Oshima, K | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Terpos, E | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S | 1 |
| Gao, L; Gao, M; Shi, J; Tao, Y; Tompkins, VS; Wu, X; Xu, H; Yang, G; Zhan, F | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P | 1 |
| Acker, V; Beckwith, RE; Böhm, K; Cavadini, S; Fischer, ES; Forrester, WC; Harper, JW; Hassiepen, U; Hild, M; Jenkins, JL; Lingaraju, GM; Lydeard, JR; Nagel, J; Ottl, J; Schebesta, M; Schirle, M; Serluca, F; Stadler, MB; Thomä, NH; Tichkule, RB; Yang, H | 1 |
| Gribben, JG; Riches, JC | 2 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A | 1 |
| Duong, VH; Komrokji, RS; List, AF | 1 |
| Andritsos, LA; Browning, R; Byrd, JC; Flynn, J; Gao, Y; Harper, E; Jiang, Y; Johnson, AJ; Jones, J; Kefauver, C; Maddocks, K; Phelps, MA; Poi, M; Rozewski, DM; Ruppert, AS | 1 |
| Akashi, K; Aoki, T; Ito, Y; Kamimura, T; Miyamoto, T; Yokota, N | 1 |
| Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M | 1 |
| Cheesman, S; D'Sa, S; Dickson, J; Khan, I; Popat, R; Rabin, N; Smith, D; Yong, K | 1 |
| Ando, H; Carmel, G; Cathers, BE; Chamberlain, PP; Chie-Leon, B; Corral, LG; Daniel, TO; Delker, SL; Hakoshima, T; Handa, H; Hirano, Y; Ito, T; Lopez-Girona, A; Miller, K; Mori, T; Pagarigan, B; Ren, YJ; Riley, M; Rychak, E; Wang, M | 1 |
| Afrin, LB; Bentz, TA; Costa, LJ; Fanning, SR; Kistner-Griffin, E; Stephenson, J; Stuart, RK | 1 |
| Alfinito, F; Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Pane, F; Picardi, M; Pisano, I; Risitano, AM | 1 |
| Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE | 1 |
| Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L | 1 |
| Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S | 1 |
| Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL | 1 |
| Egle, A; Kater, AP; Ramsay, AG; Tonino, SH | 1 |
| Amiot, M; Brosseau, C; Dousset, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C; Touzeau, C | 1 |
| Bennett, JM; Dreyfus, F; Fenaux, P; Greenberg, PL; Li, JS; List, AF; Sanz, GF; Sekeres, MA; Sugrue, MM; Swern, AS | 1 |
| Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E | 1 |
| Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ | 1 |
| Avigan, D; Rosenblatt, J | 1 |
| Meers, S | 1 |
| Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Kumar, S; Singla, A | 1 |
| Birgegård, G | 1 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Seiffert, M | 1 |
| Caballero, D; Coiffier, B; d'Amore, F; Dearden, C; Federico, M; Gomes da Silva, M; Jäger, U; Morschhauser, F; Pettengell, R; Tilly, H; Trümper, L; Weidmann, E; Zinzani, PL; Zucca, E | 1 |
| Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E | 1 |
| McCarthy, PL; Palumbo, A | 1 |
| Vincent Rajkumar, S | 1 |
| Badillo, M; Cai, Q; Chen, Y; Huang, H; Jiang, W; Lin, T; Lopez, E; Romaguera, J; Wang, M; Zhang, L; Zhou, S; Zou, D | 1 |
| Koeppen, S | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Tura, S; Vitolo, U; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Abe, T; Fujii, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Sakurai, T; Sato, M; Usami, M; Yamada, M; Yoshida, M | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Fabbro, SK; Kaffenberger, BH | 1 |
| Gałązka, K; Gruchała, A; Jurczak, W; Krawczyk, K; Skotnicki, AB | 1 |
| Bargetzi, M; Mischo, A; Nair, G; Petrausch, U; Pfrommer, S; Renner, C; Samaras, P; Schanz, U; Schmidt, A; Seifert, B; Stenner-Liewen, F; Stupp, R; Taverna, C | 1 |
| Alexander, G; Arezzo, JC; Cooper, A; Harden, RN; Manning, DC; Oaklander, AL; Raja, SN; Rauck, R; Schwartzman, R | 1 |
| Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E | 1 |
| Bokorova, R; Brezinova, J; Cermak, J; Cervinek, L; Fuchs, O; Hajkova, H; Jonasova, A; Kostecka, A; Michalova, K; Mikulenkova, D; Neuwirtova, R; Polak, J; Siskova, M; Sponerova, D; Vostry, M | 1 |
| Belickova, M; Cermak, J; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Merkerova, MD; Michalova, K; Stara, E; Zemanova, Z | 1 |
| Usuki, K | 1 |
| Yamamoto, K | 1 |
| Shibayama, H | 1 |
| Nakaseko, C | 1 |
| Tsurumi, H | 1 |
| Andreyev, HJ; Davies, FE; Kaiser, MF; Khan, MS; Morgan, GJ; Muls, A; Pawlyn, C; Sriskandarajah, P | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Andreadis, C; Gupta, NK | 1 |
| Acebes-Huerta, A; Fernandez-Guizan, A; Gonzalez, S; Gonzalez-Rodriguez, AP; Huergo-Zapico, L; López-Soto, A; Payer, AR | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Blin, N; Caristan, A; Connault, J; Duhamel, E; Graveleau, J; Hamidou, M; Le Gouill, S; Lestang, E; Maisonneuve, H; Masseau, A; Moreau, P; Néel, A; Touzeau, C | 1 |
| Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; Toumishey, E; van der Jagt, R; White, D | 1 |
| Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L | 1 |
| Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H | 1 |
| Bari, A; Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Jain, MK; Menke, DM; Sher, T; Swaika, A | 1 |
| Aziz, M; Braggio, E; Bruins, LA; Champion, M; Jedlowski, P; Keith Stewart, A; Kortuem, KM; Schmidt, JE; Sereduk, C; Shi, CX; Yin, H; Zhu, YX | 1 |
| Bakker, J; de Jong-Korlaar, R; Groen, RW; Lokhorst, HM; Martens, AC; Mutis, T; Nijhof, IS; Noort, WA; Parren, PW; van Bueren, JJ; van de Donk, NW; van Kessel, B | 1 |
| Audrito, V; Bulgarelli, J; Colaci, E; Deaglio, S; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Narni, F; Potenza, L; Zucchini, P | 1 |
| Adam, Z; Autzinger, EM; Greil, R; Heintel, D; Kasparu, H; Kuehr, T; Ludwig, H; Müldür, E; Poenisch, W; Rauch, E; Weißmann, A; Zojer, N | 1 |
| Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB | 1 |
| Anabuki, K; Arakawa, Y; Ikezoe, T; Kubota, T; Sakai, M; Takaoka, M; Togitani, K; Tsukuda, T; Yokoyama, A | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Bornhäuser, M; Ehninger, G; Kramer, M; Mohr, B; Oelschlaegel, U; Parmentier, S; Platzbecker, U; Sockel, K; Thiede, C; van de Loosdrecht, AA; Westers, TM | 1 |
| Buske, C | 1 |
| Baladandayuthapani, V; Claret, LC; Davis, RE; Fanale, MA; Fayad, LE; Feng, L; Fowler, NH; Hagemeister, FB; Kwak, LW; McLaughlin, P; Muzzafar, T; Nastoupil, L; Neelapu, SS; Oki, Y; Orlowski, RZ; Rawal, S; Romaguera, JE; Samaniego, F; Shah, J; Tsai, KY; Turturro, F; Wang, M; Westin, JR | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Dahlman, KB; Hames, ML; Iams, WT; Reddy, NM; Richards, KL; Talbott, MS; Tsai, JP | 1 |
| Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Basiorka, AA; Caceres, G; Clark, J; Heaton, R; Johnson, JO; List, AF; McGraw, KL; Ozawa, Y; Padron, E; Sokol, L; Wei, S | 1 |
| Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 2 |
| Franz, M; Rominger, F; Trapp, O; Walz, S; Weis, S | 1 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Andre, P; Lammerts van Bueren, JJ; Lokhorst, HM; Morel, Y; Mutis, T; Nijhof, IS; Parren, PW; van de Donk, NW; van Kessel, B | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Fagiolari, G; Migliorato, A; Moggio, M; Montagnese, F; Musumeci, O; Portaro, S; Rodolico, C | 1 |
| Choquet, S; Hoang-Xuan, K; Houillier, C; Martin-Duverneuil, N; Mokhtari, K; Navarro, S; Soussain, C; Touitou, V | 1 |
| Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A | 1 |
| Gooding, S; King, AJ; Ramasamy, K | 1 |
| Escudero-Vilaplana, V; Osorio Prendes, S; Sanjurjo Sáez, M | 1 |
| Caivano, A; D'Arena, G; D'Auria, F; Del Vecchio, L; La Rocca, F; Musto, P; Ruggieri, V; Simeon, V; Statuto, T; Telesca, D | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kalapanida, D; Kaldara, E; Kastritis, E; Migkou, M; Ntalianis, A; Pamboucas, C; Psimenou, E; Roussou, M; Tasidou, A; Terpos, E; Toumanidis, ST | 1 |
| Guglielmelli, T; Palumbo, A | 1 |
| Govindarajulu, B; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Du, W; Hasegawa, Y; Hattori, Y; Hozumi, M; Ichikawa, D; Matsuo, K; Matsushita, M; Oikawa, T; Ozaki, Y; Shiheido, H; Tabata, N; Terada, F; Yamada, T; Yanagawa, H | 1 |
| Britton, HC; Loberiza, FR; McGuire, TR; Meza, JL; Schwarz, JK; Talmadge, JE; Wang, J | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Ahmadi, T; Aqui, NA; Chong, EA; Mato, AR; Nasta, SD; Schuster, SJ; Svoboda, J; Walsh, KM | 1 |
| Buquicchio, C; Capalbo, S; Cascavilla, N; Curci, P; Di Renzo, N; Ditonno, P; Falcone, A; Guarini, A; Iannitto, E; Mazza, P; Mele, G; Melpignano, A; Minoia, C; Palazzo, G; Palumbo, G; Pavone, V; Polimeno, G; Quarta, G; Reddiconto, G; Ria, R; Rizzi, R; Rossini, B; Specchia, G; Tarantini, G; Vacca, A | 1 |
| Adusumilli, M; Andritsos, LA; Blum, KA; Byrd, JC; Cardone, MH; Doykin, C; Flynn, J; Grever, MR; Jiang, Y; Johnson, AJ; Jones, JA; Maddocks, K; Phelps, MA; Pierceall, WE; Rozewski, D; Wei, L; Zhao, Y | 1 |
| Kardaun, SH; Kuiper, EM | 1 |
| Avery, S; Fleming, S; Govindaraj, C; McManus, J; Patil, S; Perruzza, S; Plebanski, M; Spencer, A; Stevenson, W; Tan, P; Wei, A | 1 |
| Liu, G; Sheng, Z | 1 |
| Foster, MC; Lim, MY; Raval, JS; Richards, KL; Zeidner, JF | 1 |
| Colson, K | 1 |
| Holstein, SA; Laubach, JP; McCarthy, PL; Richardson, PG | 1 |
| Asvadi, P; Cuddihy, A; Dunn, RD; Jiang, V; Jones, DR; Khong, T; Spencer, A; Wong, MX | 1 |
| Fowler, NH | 1 |
| Sun, C; Wiestner, A | 1 |
| Klimek, V | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Cahn, JY; Carras, S; Gervasoni, J; Gressin, R; Molina, L; Peoc'h, M; Regny, C | 1 |
| Shen, Q; Zhuang, Y | 1 |
| Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Bashir, Q; Champlin, RE; Cornelison, A; Fox, PS; Hosing, CM; Kebriaei, P; Lin, P; Nieto, Y; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ; Thall, PF | 1 |
| Collet, P; Kong, S; Marotte, H; Thomas, T | 1 |
| Casanova, M; García-Sanz, R; Labrador, J; Pastor, M; Provencio, M; Quero-Blanco, C; Rueda, A; Salar, A | 1 |
| Coyle, M; Evens, AM; Kritharis, A; Sharma, J | 1 |
| Foster, MC; Zeidner, JF | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Ikeda, T; Kimura, F; Okamura, I; Sato, K | 1 |
| Blin, N; Brissot, E; Clavert, A; Dubruille, V; Gastinne, T; Gaugler, B; Guillaume, T; Le Gouill, S; Mahe, B; Mohty, M; Moreau, P; Roland, V | 1 |
| Cheson, BD; Crawford, J | 1 |
| Ai, H; Cai, Z; Chen, F; Chen, N; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Caffrey, MK | 1 |
| Cohen, EE; de Souza, J; Goloubeva, O; Jain, A; Kronsberg, S; Nagilla, M; Saloura, V; Seiwert, T; Silpino, L; Taylor, RJ; Villaflor, V; Vokes, E; Wong, S | 1 |
| Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C | 1 |
| Heaney, ML | 1 |
| Arikian, SR; Binder, G; Corvino, FA; Gibson, CJ; Hu, XH; Hussein, M; Milentijevic, D; Nagarwala, Y; Surinach, A; Usmani, SZ | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK | 1 |
| Hoskote, SS; Onigkeit, JA; Reddy, DR | 1 |
| Gandhi, V; He, J; Orlowski, RZ; Shentu, S; Stellrecht, CM; Yang, J; Zaman, S | 1 |
| Bellotti, D; Boiocchi, L; Borlenghi, E; Cerqui, E; Imberti, L; Lamorgese, C; Pagani, C; Pelizzari, A; Rossi, G; Schieppati, F; Sottini, A | 1 |
| Oza, A; Rajkumar, SV | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Kim, Y; Schmidt-Wolf, IG | 1 |
| Cejalvo, MJ; de la Rubia, J | 1 |
| Bay, JO | 1 |
| Laubach, JP; Richardson, PG | 1 |
| Beličková, M; Čermák, J; Dostálová Merkerová, M; Hruštincová, A; Jonášová, A; Kléma, J; Krejčík, Z; Michalová, K; Zemanová, Z | 1 |
| Boccadoro, M; Bringhen, S; Cavo, M; Conticello, C; Cuomo, C; D'Arena, G; Gay, F; Grossi, A; Guariglia, R; Larocca, A; Milone, G; Morabito, F; Musto, C; Musto, P; Offidani, M; Palumbo, A; Petrucci, MT; Pietrantuono, G; Simeon, V; Tacchetti, P; Villani, O; Zamagni, E | 1 |
| Blommestein, HM; de Groot, S; Huijgens, PC; Sonneveld, P; Uyl-de Groot, CA; Verelst, SG | 1 |
| Patnaik, MM; Tefferi, A | 1 |
| Alonso, S; Ganguly, S; Ghiaur, G; Jones, JW; Jones, RJ; Kane, MA; Su, M | 1 |
| Rosen, ST; Siddiqi, T | 1 |
| Avivi, I; Cicero, S; Drach, J; Fu, T; Goy, A; Herbrecht, R; Kalayoglu Besisik, S; Ramchandren, R; Robertson, MJ; Rowe, JM; Van Hoof, A; Witzig, T; Zhang, L | 1 |
| McCormack, PL | 1 |
| Printz, C | 1 |
| Areethamsirikul, N; Reece, DE | 1 |
| Kobayashi, T; Kuroda, J; Taniwaki, M | 1 |
| Guo, XN; Qiao, SK; Ren, HY; Ren, JH | 1 |
| Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Mancini, M; Montagna, C; Oliva, E; Roberto, A; Romano, A; Volpicelli, P; Vozella, F | 1 |
| Goy, AH; Skarbnik, AP | 1 |
| Barcellini, W; Cortelezzi, A; Fattizzo, B; Nesa, F; Sciumbata, VM; Zanella, A; Zaninoni, A | 1 |
| Anderson, S; Mante, M; Masliah, E; Rockenstein, E; Valera, E | 1 |
| Bladé, J; Cibeira, MT; de la Rubia, J; Fernández de Larrea, C; Granell, M; Hernández, MT; Lahuerta, JJ; Mateos, MV; Oriol, A; San Miguel, JF | 1 |
| Braggio, E; Bruins, L; Jedlowski, P; Kortüm, KM; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT | 1 |
| Anderson, JE; Anderson, KC; Avet-Loiseau, H; Bianchi, G; Cowens, KB; Dorfman, DM; Görgün, G; Harada, T; Hideshima, T; Kikuchi, S; Laubach, JP; Magrangeas, F; Minvielle, S; Munshi, NC; Ohguchi, H; Paula, S; Raje, N; Richardson, PG; Samur, MK; Singh, A; Suzuki, R; Tai, YT; White, RE | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Champlin, RE; Pingali, SR | 1 |
| Song, DK; Xing, DL; Zhang, LR | 1 |
| Andre, P; Benson, DM; Caligiuri, MA; Cohen, AD; Efebera, YA; Hofmeister, CC; Jagannath, S; Munshi, NC; Spitzer, G; Zerbib, R | 1 |
| Cheah, CY; Forbes, SG; Fowler, NH; Nastoupil, LJ; Neelapu, SS; Oki, Y | 1 |
| Barančik, M; Breier, A; Gibalová, L; Jonášová, A; Messingerová, L; Poleková, L; Šereš, M; Sulová, Z | 1 |
| Breier, A; Coculova, M; Imrichova, D; Kavcova, H; Messingerova, L; Pavlikova, L; Seres, M; Sulova, Z | 1 |
| Carisey, A; Chopra, R; Davis, DM; Lagrue, K; Morgan, DJ | 1 |
| Amantangelo, MD; Barnes, L; Bjorklund, C; Breider, M; Cai, T; Chiu, H; Chopra, R; Couto, S; Daniel, TO; Fontanillo, C; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Khambatta, G; Klippel, A; Kosek, J; Lopez-Girona, A; Lu, G; Man, HW; Narla, RK; Pourdehnad, M; Raymon, H; Rychak, E; Schafer, PH; Thakurta, A; Trotter, M; Waldman, M; Wang, M | 1 |
| Alrajeh, A; Hanbali, A; Rasheed, W | 1 |
| Aleman, A; Anand, P; Batra, V; Bednarz, U; Bilotti, E; Guerrero, L; Ivanovski, K; Mato, A; McBride, L; McNeill, A; Raucci, L; Richter, JR; Siegel, DS; Sims, T; Smith, J; Vesole, DH | 1 |
| Chen, N; Knight, R; Palmisano, M; Weiss, D; Zhou, S | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W | 1 |
| Anderson, KC; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, M; Einsele, H; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Palumbo, A; Poulart, V; Reece, D; Richardson, P; Röllig, C; San-Miguel, J; Singhal, A; Spencer, A; Spicka, I; Taniwaki, M; Walter-Croneck, A; White, D; Wu, KL | 1 |
| Cheah, CY; Manasanch, EE; Oo, TH; Orlowski, RZ | 1 |
| Gong, J; Mita, M; Rimel, B; Sachdev, E | 1 |
| Carter, C; Cook, G; Parrish, C; Scott, GB; Wood, PM | 1 |
| Benson, DM; Bowers, MA; Devine, S; Efebera, Y; Hofmeister, CC; Huang, Y; Humphries, K; Sborov, DW; Williams, N | 1 |
| Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y | 1 |
| An, N; Chen, S; Hu, Y; Huang, Z; Li, X; Shen, M; Sun, W; Zhan, X; Zhang, J; Zhong, Y | 1 |
| Borthakur, G; Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wang, X; Zhou, L | 1 |
| Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF | 1 |
| Chaudhary, PM; Gopalakrishnan, R; Matta, H; Tolani, B; Triche, T | 1 |
| Ali, A; Itzykson, R; Loiseau, C | 1 |
| Bullinger, L; Carr, SA; Cathers, BE; Chamberlain, PP; Chopra, R; Ebert, BL; Fink, EC; Gandhi, AK; Griffiths, E; Hollenbach, PW; Hurst, SN; Järås, M; Krönke, J; MacBeth, KJ; Man, HW; Mani, DR; McConkey, M; Schneider, RK; Svinkina, T; Udeshi, ND; Wetzler, M | 1 |
| Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Bieniaszewska, M; Butrym, A; Kumiega, B; Lech-Maranda, E; Madry, K; Mazur, G; Mital, A; Patkowska, E; Rybka, J; Torosian, T; Warzocha, K; Wichary, R | 1 |
| Endo, K; Fujii, H; Izumi, K; Kimura, S; Minami, H; Morita, TO; Saito, S; Yamaguchi, A | 1 |
| Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E; Zagouri, F | 1 |
| Alsina, M; Horna, P; Kharfan-Dabaja, MA; Nishihori, T; Salem, KZ | 1 |
| Giagounidis, A | 2 |
| Arnulf, B; Bridoux, F; Caulier, A; Chevret, S; Cohen, C; El Karoui, K; Fermand, JP; Jaccard, A; Javaugue, V; Knebelmann, B; Royer, B; Szalat, R; Touchard, G | 1 |
| Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M | 1 |
| Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S | 1 |
| Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D | 1 |
| Sofronescu, AG; Wedel, W | 1 |
| Fowler, N; Gribben, JG; Morschhauser, F | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Borrello, I; Consoli, ML; Conticello, C; Corso, A; Di Raimondo, F; Forte, S; Marchionni, L; Milone, G; Parrinello, NL; Pompa, A; Romano, A | 1 |
| Fong, R; Lo, M; Tan, M; Young, R | 1 |
| Chen-Kiang, S; He, X; Huang, X; Jaffrey, SR; Jiang, X; Liu, Y; Xu, G; Zhou, Y | 1 |
| Bazargan, A; Giv, MJ; Yoosuff, A | 1 |
| Cheah, CY; Fayad, LE; Fowler, NH; Hagemeister, FB; LeBlanc, D; Nastoupil, LJ; Neelapu, SS; Samaniego, F | 1 |
| Ailawadhi, S; Bartlett, B; Durie, B; Fredette, S; Hoering, A; Lipe, B; Orlowski, RZ; Rosenzweig, M; Sexton, R; Shah, JJ; Usmani, SZ; Valent, J; Zonder, JA | 1 |
| Dong, LF; Jiang, Q; Shan, K; Wang, XQ; Yan, B; Yang, H; Yao, J | 1 |
| Abe, Y; Ikeda, M; Meshitsuka, S; Miyazaki, K; Shingaki, S; Suzuki, K; Tsukada, N; Yoshiki, Y | 1 |
| Abruzzese, MP; Cecere, F; Cippitelli, M; Fionda, C; Molfetta, R; Paolini, R; Peruzzi, G; Petrucci, MT; Ricciardi, MR; Santoni, A; Soriani, A; Vulpis, E; Zingoni, A | 1 |
| Buadi, FK; Cheng, WY; Dea, K; Dispenzieri, A; Duh, MS; Engebretson, AE; Kumar, SK; Lacy, MQ; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Patt, D; Quick, M; Rajkumar, SV; Rembert, D | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Celik, H; Chigurapati, S; Chigurupati, S; Das, S; Eitan, E; Fishbein, KW; Ghosh, P; Ghosh, S; Greig, NH; Hutchison, ER; Mattson, MP; Raymick, J; Sarkar, S; Sasaki, CY; Seal, S; Spencer, RG; Tweedie, D | 1 |
| Braulke, F; Ganster, C; Haase, D; Platzbecker, U; Salinas-Riester, G; Schanz, J; Shirneshan, K | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O | 1 |
| Degen, L; Juskevicius, D; Läubli, H; Rochlitz, C; Stenner-Liewen, F; Tzankov, A | 1 |
| Kurtin, SE; Ridgeway, JA; Tinsley, SM | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G | 1 |
| Aylı, M; Cengiz Seval, G; Özcan, M | 1 |
| Fujii, S; Fujita, M; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Sakamoto, H; Sato, T; Shimoyama, S; Usami, M; Yamada, M; Yoshida, M | 1 |
| Choi, NR; Hoang, MD; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Lee, YK; Nguyen-Pham, TN; Thanh-Tran, HT; Vo, MC | 1 |
| Birgin, A; Buadi, FK; Duarte, L; Fiala, M; Gertz, MA; Krishnan, A; Kumar, SK; LaPlant, B; Laumann, K; Levy, J; Maharaj, M; Roy, V; Stockerl Goldstein, K; Vij, R; Zimmerman, T | 1 |
| Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H | 1 |
| Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
| Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L | 1 |
| Bacci, F; Di Bartolomeo, P; Morelli, AM; Pulini, S; Torti, L | 1 |
| Robak, T; Smolewski, P; Witkowska, M | 1 |
| Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J | 1 |
| Berube, C; Cardone, MH; Coutre, S; Doykan, C; Garcia, JS; Gotlib, J; Greenberg, P; Hewitt, R; Liedtke, M; McMillan, A; Medeiros, BC; Narayan, R; Percival, ME; Regan, K; Williamson, C | 1 |
| Alati, C; Aloe Spiriti, MA; Balleari, E; Cortelezzi, A; D'Errigo, MG; Germing, U; Kündgen, A; Latagliata, R; Lauseker, M; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Ronco, F; Sanpaolo, G; Santacaterina, I; Volpe, A | 1 |
| Kusec, R; Livun, A; Manshouri, T; Newberry, KJ; Verstovsek, S | 1 |
| Ar, MC; Salihoglu, A; Soysal, T | 1 |
| Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R | 1 |
| Hazlehurst, L; Lynch, CC; Shay, G | 1 |
| Byrd, JC; Canella, A; Cascione, L; Caserta, E; Consiglio, J; Cordero Nieves, H; Efebera, YA; Hofmeister, CC; Kaur, B; Mo, X; Pichiorri, F; Radomska, HS; Rizzotto, L; Sborov, DW; Smith, E; Stefano, V; Stiff, A; Zanesi, N | 1 |
| Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M | 1 |
| Anttila, P; Bazia, P; Heiskanen, J; Jantunen, E; Kakko, S; Kananen, K; Kuittinen, T; Kutila, A; Launonen, K; Lundan, T; Ollikainen, H; Putkonen, M; Räsänen, A; Remes, K; Säily, M; Selander, T; Siitonen, TM; Sikiö, A; Silvennoinen, R; Suominen, M; Terävä, V | 1 |
| Ebert, BL; Fink, EC | 1 |
| Al Ali, NH; Komrokji, RS; Lancet, J; List, A; Padron, E; Zeidan, AM | 1 |
| Bi, E; Hong, S; Qian, J; Wang, M; Yi, Q; Zhang, L; Zheng, C | 1 |
| Kato, A; Kondo, G; Kuramitsu, S; Kurimoto, M; Motomura, K; Natsume, A; Ohka, F; Ohno, M; Senga, T; Shiina, S; Tanahashi, K; Wakabayashi, T; Yamamichi, A | 1 |
| Colaci, E; Fiorcari, S; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Potenza, L | 1 |
| Ichikawa, K; Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Burgstaller, S; Stauder, R; Wiesinger, P | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, YL; Kapoor, P; Kaufman, GP; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, S | 1 |
| Cong, Z; Song, X; Wilson, K | 1 |
| Buadi, F; Dispenzieri, A; Gertz, MA; Gonsalves, W; Kumar, S; Lacy, MQ; Rajkumar, SV; Vu, T | 1 |
| Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Assal, A; Elman, J; Janakiram, M; Mohammadi, F; Rubinstein, M; Scherba, M; Strakhan, M; Verma, A; White, R | 1 |
| Ebert, BL; Guirguis, AA | 1 |
| Breier, F; Feldmann, R; Loader, D; Rehberger, A; Steiner, A; Wruhs, M | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Bogunia-Kubik, K; Butrym, A; Frontkiewicz, D; Gębura, K; Mazur, G; Rybka, J; Łacina, P | 1 |
| Christos, P; Coleman, M; Furman, RR; Katz, O; Leonard, JP; Lewis, J; Martin, P; Rodriguez, A; Ruan, J; Schuster, SJ; Shah, B; Smith, SM; Svoboda, J | 1 |
| Cai, XY; Guo, XF; Guo, XL; Guo, XN; Ren, JH; Yang, DY; Zhang, JN | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kastritis, E; Liacos, CI; Matsouka, C; Migkou, M; Mparmparousi, D; Tasidou, A; Terpos, E | 1 |
| Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A | 1 |
| Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W | 1 |
| Holstein, SA; McCarthy, PL | 2 |
| Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A | 1 |
| Dolak, W; Kiesewetter, B; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I; Troch, M | 1 |
| Campus, C; Ringuette, B; Robey, RC; Shumate, M | 1 |
| Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A | 1 |
| Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA | 1 |
| Facon, T | 1 |
| DeZern, AE | 1 |
| Duvic, M | 1 |
| Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Binder, G; Grigorian, M; Lee, C; Nolan, R; Rice, G | 1 |
| Cohen, A; Iakobishvili, Z; Itchaki, G; Kornowski, R; Magen, H; Muchtar, E; Raanani, P; Rosenfeld, R; Shochat, T | 1 |
| Alemayehu, WG; Bos, GM; Broijl, A; Cornelisse, PB; de Weerdt, O; Kersten, MJ; Levin, MD; Lokhorst, H; Meijer, E; Sonneveld, P; Stevens-Kroef, M; Tanis, BC; Vellenga, E; Wijermans, PW; Wittebol, S | 1 |
| Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R | 1 |
| Airoldi, I; Amiot, M; Aversa, F; Bolzoni, M; Campanini, N; Donofrio, G; Ferri, V; Fiorini, E; Giuliani, N; Guasco, D; Maiga, S; Mancini, C; Marchica, V; Martella, E; Storti, P; Toscani, D | 1 |
| Bacher, U; Braulke, F; Bug, G; Büsche, G; Ganser, A; Gattermann, N; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Wulfert, M | 1 |
| Bargay, J; Bladé, J; Corchete, LA; de Arriba, F; de la Rubia, J; Esteves, G; Giraldo, P; Hernández, J; Hernandez, MT; Lahuerta, JJ; López-Corral, L; Mateos, MV; Oriol, A; Paiva, B; Perez-Simon, JA; Prosper, F; Puig, N; Rosiñol, L; San Miguel, JF; Sanchez-Abarca, LI; Teruel, AI; Vidriales, MB | 1 |
| Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U | 1 |
| Cao, L; Fang, Q; Lu, T; Ma, D; Wang, J; Wang, P; Wu, W; Zhao, J | 1 |
| Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T | 1 |
| Buckstein, R; Rezmovitz, J; Wells, RA | 1 |
| Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Ciccone, G; Conticello, C; De Paoli, L; Falcone, AP; Gentili, S; Giuliani, N; Guglielmelli, T; Hajek, R; Ledda, A; Liberati, AM; Magarotto, V; Maisnar, V; Mina, R; Montefusco, V; Musolino, C; Offidani, M; Palumbo, A; Patriarca, F; Pietrantuono, G; Pulini, S; Ruggeri, M; Zambello, R | 1 |
| Burger, JA; Calin, G; Faderl, S; Falchi, L; Ferrajoli, A; Gao, H; Keating, MJ; O'Brien, S; Reuben, JM; Rezvani, K; Shaim, H; Ten Hacken, E; Van Roosbroeck, K; Vitale, C; Wang, X; Wierda, WG | 1 |
| Bouchnita, A; Eymard, N; Koury, MJ; Moyo, TK; Volpert, V | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Cheah, CY; Fowler, NH; Konoplev, S; Mistry, HE | 1 |
| Buhler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Stilgenbauer, S; Wendtner, CM; Zhang, J | 1 |
| Arai, N; Fujiwara, S; Homma, M; Kabasawa, N; Kawaguchi, Y; Kobayashi, K; Nakamaki, T; Okino, K; Shiozawa, E; Takimoto, M; Tate, G; Tazawa, S; Yamochi, T | 1 |
| Abonour, R; Durie, BG; Gasparetto, C; Hardin, JW; Kenvin, L; Knight, R; Lu, JJ; Mehta, J; Nagarwala, Y; Narang, M; Rifkin, RM; Shah, JJ; Srinivasan, S; Terebelo, H; Toomey, K | 1 |
| Adesunloye, BA; Arlen, PM; Beedie, SL; Chen, C; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Harold, N; Huang, X; Karzai, FH; Lee, MJ; Lee, S; Madan, RA; McLeod, DG; Ning, YM; Rosner, I; Sissung, T; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB | 1 |
| Badros, A; Berdeja, J; Bleickardt, E; Gupta, M; Jagannath, S; Kaufman, JL; Lynch, M; Manges, R; Paliwal, P; Tendolkar, A; Vij, R; Zonder, J | 1 |
| Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Hajek, R; Jelinek, T; Kufova, Z | 1 |
| Beličková, M; Bělohlávková, P; Čermák, J; Černá, O; Červinek, L; Hochová, I; Janoušová, E; Jonášová, A; Kačmářová, K; Rohoň, P; Šišková, M | 1 |
| Goto, C; Goto, H; Ichihashi, A; Kasahara, S; Nagaya, K; Osawa, T; Tachi, T; Takahashi, T; Teramachi, H; Umeda, M; Yasuda, M | 1 |
| Kobayashi, H; Komori, H; Nakamura, Y; Namba, K; Oi, N; Sato, H; Taniguchi, Y; Yahata, H | 1 |
| Cappel, M; Dholaria, BR; Roy, V | 1 |
| Cai, Z; Chen, F; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Chen, CY; Chen, HY; Chen, MJ; Hsu, PH; Huang, SY; Hung, KH; Lin, FR; Lin, KI; Su, ST; Tsai, MD; Wu, PC; Wu, WJ | 1 |
| Qian, W; Wang, B; Xu, G; Yang, M | 1 |
| Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y | 1 |
| Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A | 1 |
| Baldini, L; Bari, A; Buda, G; Carella, AM; Cesaretti, M; Chiapella, A; Di Raimondo, F; Ferrari, A; Guardigni, L; Marcheselli, L; Marcheselli, R; Molinari, AL; Musto, P; Pozzi, S; Ronconi, S; Sacchi, S; Santoro, A; Silvestris, F; Specchia, G; Vallisa, D | 1 |
| Dubey, P; Gemechu, Y; Kishimoto, T; Millrine, D; Miyata, H; Nakahama, T; Nyati, K; Ripley, B; Tei, M | 1 |
| Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM | 1 |
| Davis, MD; Kindle, SA; Pittelkow, MR; Sciallis, GF; Wetter, DA | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Kramm, CM; Kühnöl, CD; Staege, MS | 1 |
| Afanasyev, B; Alexeeva, J; Arcaini, L; Belada, D; Biyukov, T; Bravo, MC; Giza, A; Jurczak, W; Kaplanov, K; Kuliczkowski, K; Kuzmin, A; Lamy, T; Marks, R; Mayer, J; Milpied, N; Morschhauser, F; Patturajan, M; Radford, J; Rule, S; Stelitano, C; Thyss, A; Trněný, M; Trümper, L; Voloshin, S; Walewski, J | 1 |
| Galanina, N; Nabhan, C; Petrich, A | 1 |
| Fischer, ES; Petzold, G; Thomä, NH | 1 |
| Blank, J; Chang, JE; Eickhoff, J; Go, RS; Havighurst, T; Kahl, BS; Kim, K; Kirby-Slimp, R; Traynor, AM; Volk, LM; Weiss, M; Werndli, J | 1 |
| Chou, T; Ervin-Haynes, A; Hirata, H; Houck, V; Iida, S; Ikeda, T; Ishizawa, K; Matsue, K; Matsumoto, M; Matsumura, I; Midorikawa, S; Ogaki, Y; Ogawa, Y; Otsuka, M; Shimizu, T; Shinagawa, A; Suzuki, K; Takezako, N; Taniwaki, M; Terui, Y; Uchida, T | 1 |
| Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Beguin, Y; Caers, J; Decaux, O; Dimopoulos, M; Engelhardt, M; Fernández de Larrea, C; Heusschen, R; Jurczyszyn, A; Kastritis, E; Leleu, X; Ludwig, H; Mateos, MV; Minnema, M; Palumbo, A; Wäsch, R; Zojer, N | 1 |
| Izzedine, H; Kheder El-Fekih, R | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Li, KD; Salama, ME | 1 |
| Agarwal, S; Barley, K; Chari, A; He, W; Jagannath, S | 1 |
| Brady, WE; Dickey, NM; Ford, LA; Griffiths, EA; L Bashaw, H; Sperrazza, J; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A | 1 |
| Li, Y; Wang, X; Yan, X | 1 |
| Climente-Martí, M; Guglieri-López, B; Martinez-Gómez, MA; Merino-Sanjuán, M; Pérez-Pitarch, A; Porta-Oltra, B | 1 |
| Biernacka, M; Borycka, IS; Bujko, M; Błachnio, K; Grygorowicz, MA; Markowicz, S; Nowak, E; Paszkiewicz-Kozik, E; Rymkiewicz, G; Walewski, J | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Aurran-Schleinitz, T; Bühler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gregory, SA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Rassenti, L; Stilgenbauer, S; Trentin, L; Wendtner, CM; Zhang, J | 1 |
| Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R | 1 |
| Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV | 1 |
| Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K | 1 |
| Freedman, AS; Jacobson, CA | 1 |
| Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Childs, R; Costello, R; Korde, N; Kwok, M; Landgren, O; Loeliger, K; Maric, I; Mo, C; Noel, P; Poon, A; Silver, S; Simakova, O; Sloand, E; Young, N; Zhang, Y; Zingone, A | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Jin, Z; Li, J; Li, X; Liu, Z; Ouyang, Y; Qing, K; Wang, W; Xu, Z | 1 |
| Jurczyszyn, A; Olszewska-Szopa, M; Skotnicki, AB | 1 |
| Berardi Vilei, S; Cairoli, A; Caspar, CB; Eckhardt, K; Enoiu, M; Fischer, N; Hitz, F; Krasniqi, F; Mach, N; Mey, U; Pabst, T; Rondeau, S; Rothermundt, C; Samaras, P; Schmidt, A; Zucca, E | 1 |
| Adami, F; Angelini, A; Cacciavillani, L; Cianci, A; De Lazzari, M; Fedrigo, M; Giorgi, B; Iliceto, S; Migliore, F; Perazzolo Marra, M; Tarantini, G; Thiene, G; Valente, M | 1 |
| Martin, P; Ruan, J; Schuster, SJ; Shah, B | 1 |
| Cartron, G; Ceballos, P; Chopra, R; Cren, M; Duperray, C; Jourdan, M; Klein, B; Moreaux, J; Robert, N; Rossi, JF; Schafer, P; Vincent, L | 1 |
| Leebeek, FW | 1 |
| Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M | 1 |
| Gertz, M; Muchtar, E | 1 |
| Afifi, S; Lesokhin, A; Michael, A | 1 |
| Falchook, G; Fu, S; Hong, DS; Janku, F; Kakadiaris, E; Kurzrock, R; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Chiappella, A; Flament, J; Gascoyne, RD; Nowakowski, GS; Repici, J; Spina, M; Vitolo, U; Witzig, TE; Zhang, L | 1 |
| Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q | 1 |
| Cai, QQ; Guan, YZ; Li, J; Su, W; Wang, C; Zhou, DB | 1 |
| Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P | 1 |
| Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB | 1 |
| Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H | 1 |
| Cashen, AF; Cherian, MA; DiPersio, JF; Fiala, M; Fletcher, T; Gao, F; Jacoby, MA; Stockerl-Goldstein, K; Tibes, R; Uy, GL; Vij, R; Westervelt, P | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Chen, M; Dong, B; Dong, T; Guan, P; Li, J; Liu, T; Ma, H; Niu, T; Pan, L; Shuai, X; Valencia, CA; Wang, F; Wu, Y; Xiang, B; Xie, L; Zhang, L; Zhu, H; Zou, X | 1 |
| Braulke, F; Bug, G; Büsche, G; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, T; Hofmann, WK; Jann, JC; Lauinger-Lörsch, E; Letsch, A; Lübbert, M; Metzgeroth, G; Mossner, M; Müller, N; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Platzbecker, U; Pressler, J; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Weiß, C | 1 |
| Chang, XB; Erickson, P; Hou, YX; Langlais, P; Luo, M; Mandarino, LJ; Shi, CX; Stewart, K; Xu, Q; Xu, Y; Zhu, J; Zhu, Y | 1 |
| Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L | 1 |
| Chinen, Y; Fushiki, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Maegawa, S; Mizutani, S; Nagoshi, H; Sasaki, N; Shimura, Y; Tando, S; Taniwaki, M; Tatekawa, S; Tsukamoto, T | 1 |
| An, N; Huang, ZX; Jiang, XX; Li, X; Shen, M; Zhang, JJ | 1 |
| Chen, LM; Liu, HB | 1 |
| Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C | 1 |
| Assoumou, L; Balabanian, K; Boué, F; Carlotti, A; Deback, C; Desnoyer, A; Dupin, N; Gaudin, F; Marcelin, AG; Peytavin, G; Pourcher, V | 1 |
| Chasset, F; Cordel, N; Fennira, F; Francès, C; Petit, A; Soubrier, M | 1 |
| Basiorka, AA; Caceres, G; Clark, JA; De Ceuninck, L; Griner, LN; Komrokji, RS; List, AF; McGraw, KL; Reuther, GW; Sokol, L; Tavernier, J; Wei, S; Zhang, L | 1 |
| Chalayer, E; Chapelle, C; Elalamy, I; Laporte, S; Leleu, X; Tardy, B | 1 |
| Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E | 1 |
| Chen, L; de Miranda, NF; Dlugosz-Danecka, M; Galazka, K; Jurczak, W; Machaczka, M; Mansouri, L; Morin, RD; Pan-Hammarström, Q; Peng, R; Rosenquist, R; Sander, B; Wasik, AM; Wu, C; Zhang, H | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC | 1 |
| Bagacean, C; Bocsan, C; Ianotto, JC; Salaun, PY; Tempescul, A; Zdrenghea, M | 1 |
| Argnani, L; Broccoli, A; Pellegrini, C; Zinzani, PL | 1 |
| Adam, Z; Čermáková, Z; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Michalková, E; Penka, I; Petrášová, H; Pour, L; Pourová, E; Řehák, Z; Sandecká, V; Ševčíková, S; Sokol, F; Szturz, P; Volfová, P | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Vitolo, U; Zaja, F; Zinzani, PL | 1 |
| Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ | 1 |
| Hagihara, M; Hua, J; Inoue, M; Uchida, T | 1 |
| Montefusco, V; Musto, P | 1 |
| Gino-Moor, S; Khateeb, A; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Chavez, JC; Dalia, S; Kharfan-Dabaja, MA; Komrokji, R; Lancet, J; Locke, FL; Nodzon, L; Pinilla-Ibarz, J; Piris-Villaespesa, M; Powers, J; Sokol, L; Sotomayor, EM; Turba, E | 1 |
| Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E | 1 |
| Browning, RL; Byrd, JC; Byrd, WH; Gupta, N; Hertlein, E; Jones, J; Mo, X; Muthusamy, N; Yu, L | 1 |
| Barker, B; Bolanos, L; Cortelezzi, A; Cuzzola, M; Fang, J; Fontanillo, C; Grimes, HL; Komurov, K; Liu, X; MacBeth, K; Oliva, EN; Rigolino, C; Starczynowski, DT | 1 |
| Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| Bostrom, B; Vundamati, D | 1 |
| Bettelli, S; Luminari, S; Maiorana, A; Salati, M; Tarantino, V | 1 |
| Cai, Q; Cao, X; Huang, X; Li, J; Wang, C; Yang, H; Zhou, D | 1 |
| Nahmias, Z; Nambudiri, VE; Vleugels, RA | 1 |
| Jain, N; Malhotra, P; Prakash, G; Sahu, KK; Saikia, U; Yanamandra, U | 1 |
| Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K | 1 |
| Hu, X; Liang, L; Liu, H; Yang, LP; Zhao, M; Zhu, YC | 1 |
| Chen, W; Gao, S; Huang, L; Shu, C; Xia, T; Zeng, T; Zhang, F | 1 |
| Hollmann, S; LeBlanc, R; Tay, J | 1 |
| Ma, LM; Ruan, LH; Yang, XW; Zhao, XQ | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH | 1 |
| Chen, N; Palmisano, M; Zhou, S | 1 |
| Almeida, A; Beach, CL; Buckstein, R; Del Cañizo, C; Fenaux, P; Gattermann, N; Giagounidis, A; Gröpper, S; Hoenekopp, A; Jonasova, A; MacBeth, KJ; Mittelman, M; Mufti, GJ; Ozawa, K; Platzbecker, U; Ram, R; Risueño, A; Santini, V; Séguy, F; Shpilberg, O; Vey, N; Zhong, J | 1 |
| Cuzzocrea, S; Ferrero, S; Ghione, P; Marabese, A; Mian, M; Mondello, P; Pitini, V; Steiner, N; Willenbacher, W | 1 |
| Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM | 1 |
| Arguiñano, JM; Bargay, J; Bladé, J; Corral, LL; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López, J; Mateos, MV; Miguel, JS; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L | 1 |
| Assoumou, L; Boué, F; Cardon, F; Chennebault, JM; Costagliola, D; Curjol, A; Desnoyer, A; Gibowski, S; Lebbe, C; Marcelin, AG; Peytavin, G; Poizot-Martin, I; Pourcher, V; Salmon, D | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Bouabdallah, R; Coso, D; Garciaz, S; Schiano de Colella, JM | 1 |
| Chihara, D; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Maeng, H; Masarova, L; Newberry, KJ; Ravandi, F; Verstovsek, S | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Alsina, M; Baz, R; Dalton, W; Fisher, K; Fulp, W; Hampras, S; Kenvin, L; Knight, R; Komrokji, R; Lee, JH; Nishihori, T; Olesnyckyj, M; Rollison, DE; Shain, KH; Sullivan, D; Xu, Q | 1 |
| Avet-Loiseau, H; Ben-Yehuda, D; Bensinger, W; Dimopoulos, MA; Fonseca, R; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Kukreti, V; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, G; Minarik, J; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rosiñol, L; Siegel, D; Špička, I; Stewart, AK; Wang, M | 1 |
| Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I | 1 |
| Kimura, M; Kokuryou, T; Matsuoka, T; Mitani, Y; Nakao, T; Okada, K; Usami, E; Yamakawa, M; Yoshimura, T | 1 |
| Bertino, EM; Carson, WE; Davis, M; Grever, M; McMichael, EL; Mo, X; Otterson, GA; Paul, B; Trikha, P | 1 |
| Callander, NS; Dreosti, LM; Fonseca, R; Jacobus, SJ; Lacy, MQ; Rajkumar, SV; Stadtmauer, EA; Stewart, AK; Weiss, M | 1 |
| Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M | 1 |
| Chan, TS; Khong, PL; Kwong, YL | 1 |
| Krönke, J; Lindner, S | 1 |
| Balaian, E; Bornhäuser, M; Ehninger, G; Germing, U; Haase, D; Mohr, B; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Schönefeldt, C; Schuster, C; Tuve, S; von Bonin, M; Wermke, M | 1 |
| Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU | 1 |
| Lonial, S; Nooka, AK | 1 |
| Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ | 1 |
| Goto, T; Iida, K; Kasamatsu, Y; Shimizu, S; Shirano, M | 1 |
| Ahmadi, T; Arkenau, HT; Basse, L; Clemens, PL; de Boer, C; Gimsing, P; Guckert, ME; Khokhar, NZ; Krejcik, J; Lassen, U; Laubach, JP; Lemech, C; Lisby, S; Lokhorst, HM; Minnema, MC; Palumbo, A; Plesner, T; Richardson, PG; Sasser, AK; Wang, J; Yeh, H | 1 |
| Kaufman, J; Laubach, J; Lonial, S; Mateos, MV; Reece, D; Richardson, P | 1 |
| Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R | 1 |
| Fung, MA; Jagdeo, J; Mayo, K; Petukhova, TA; Tartar, DM; Tuscano, J | 1 |
| Braester, A; Ellis, M; Filanovsky, K; Goldschmidt, N; Herishanu, Y; Kirgner, I; Mittelman, M; Ofran, Y; Oster, HS; Perri, C; Raanani, P; Rosenbaum, H | 1 |
| Buadi, FK; Chakraborty, R; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Hogan, WJ; Kapoor, P; Kumar, S; Lacy, MQ; Leung, N; Muchtar, E | 1 |
| Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G | 1 |
| Cooper, A; Gimbel, J; Levinsky, DM; Manning, DC; Rauck, R; Wertz, R; Zeldis, JB | 1 |
| Bakane, A; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R | 1 |
| Cai, E; Connors, JM; Dutz, JP; Loree, JM; Savage, KJ; Sehn, LH; Sheffield, BS; Shepherd, LE; Villa, D | 1 |
| Adema, V; Clemente, MJ; Hirsch, C; Hosono, N; List, AF; Maciejewski, JP; Makishima, H; McGraw, KL; Nazha, A; Negoro, E; Polprasert, C; Przychodzen, B; Radivoyevitch, T; Santini, V; Sekeres, MA; Sole, F | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Abonour, R; Biran, N; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, MS; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME | 1 |
| Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N | 1 |
| Gemechu, Y; Kishimoto, T; Millrine, D; Tei, M | 1 |
| Lee, HS; Min, CK | 1 |
| Abe, Y; Fujiwara, H; Imaizumi, Y; Ishida, T; Ishizawa, K; Ito, S; Jo, T; Midorikawa, S; Moriuchi, Y; Nosaka, K; Ogura, M; Ohtsu, T; Otsuka, M; Ruiz, W; Taira, N; Tobinai, K; Tsukasaki, K; Yoshimitsu, M | 1 |
| Cornell, RF; Gailani, D; Garcia, D; Laubach, J; Li, W; Maglio, ME; Moslehi, J; Richardson, PG | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 2 |
| Bensinger, WI; Berdeja, JG; Birrer, NE; Burke, JN; Jones, SS; Libby, EN; Markelewicz, RJ; Raje, NS; Richardson, PG; Supko, JG; Tamang, DL; Voorhees, PM; Wallace, EE; Wheeler, CA; Yang, M; Yee, AJ | 1 |
| Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S | 1 |
| Ball, B; Gore, SD; Prebet, T; Zeidan, A | 1 |
| Chen, H; Greer, JP; Morgan, DS; Park, SI; Reddy, NM; Richards, KL | 1 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Aghemo, E; Corvatta, L; Gay, F; Gentili, S; Maracci, L; Offidani, M; Palumbo, A | 1 |
| Chen, Y; Chen, Z; He, Z; Shi, Y; Wang, C; Yu, L; Zhang, L | 1 |
| Bashir, Q; Champlin, RE; Kebriaei, P; Manasanch, EE; Mian, I; Milton, DR; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ | 1 |
| Bargou, RC; Bauer, S; Beilhack, A; Brandl, A; Brünnert, D; Chatterjee, M; Kreßmann, S; Mottok, A; Müller, E; Rosenwald, A; Scholz, CJ; Schraud, H; Steinbrunn, T; Stühmer, T | 1 |
| Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS | 1 |
| Elkon, J; Haroun, F; Mener, A; Tabbara, I | 1 |
| Fujimi, A; Hashimoto, A; Hirayama, Y; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Konuma, Y; Kuroda, H; Miyanishi, K; Murase, K; Nagamachi, Y; Ono, K; Sato, T; Takada, K; Tatekoshi, A; Yoshida, M | 1 |
| Ding, Y; Jiang, C; Qu, Z; Wu, J | 1 |
| Cartia, CS; Cazzola, M; Cocito, F; Corso, A; Ferretti, V; Klersy, C; Mangiacavalli, S; Pompa, A; Varettoni, M | 1 |
| Lipe, B; Mikhael, J; Vukas, R | 1 |
| Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH | 1 |
| Ban, SA; Banerjee, PP; Bennett, KL; Bilic, I; Boztug, K; Cagdas, D; Dupré, L; Garncarz, W; Gribben, JG; Hons, M; Hsu, HT; Huppa, JB; Jäger, U; Mace, EM; McClanahan, F; Mukherjee, M; Orange, JS; Petronczki, ÖY; Pfajfer, L; Pickl, WF; Platzer, R; Salzer, E; Sanal, Ö; Sinha, P; Sixt, M; Stockinger, H; Supper, V; Tezcan, I; Willmann, KL; Zlabinger, GJ | 1 |
| Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E | 1 |
| Carraway, HE; DeZern, A; Gojo, I; Gore, SD; Smith, BD; Zeidan, AM | 1 |
| Laubach, JP; Longo, DL; Paba Prada, CE; Richardson, PG | 1 |
| Asante, D; Buadi, FK; Herrmann, J; Lerman, A; Reneau, JC; Sangaralingham, LR; van Houten, H | 1 |
| Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH | 1 |
| Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY | 1 |
| Kwong, YL | 1 |
| Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K | 1 |
| Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M | 1 |
| Bourmaud, A; Cahn, JY; Cornillon, J; Guyotat, D; Molucon-Chabrot, C; Tavernier-Tardy, E; Thomas, X; Tinquaut, F | 1 |
| Abbasi, T; Bejar, R; Chang, M; Cogle, CR; Drusbosky, L; Hawkins, KE; Kumar, A; Lamba, JK; Mallo, M; Martuscello, R; Medina, C; Sekeres, MA; Singh, NK; Sole, F; Vali, S | 1 |
| Chao, NJ; Gasparetto, C; Green, MM; Horwitz, ME; Kang, Y; Li, Z; Long, GD; Lopez, RD; Rizzieri, DA; Sarantopoulos, S; Sivaraj, D; Sullivan, KM; Sung, AD | 1 |
| Anand, P; Bilotti, E; Biran, N; Ivanovski, K; McBride, L; Richter, JR; Sanchez, L; Siegel, DS; Vesole, DH | 1 |
| Aberer, E; Bata-Csörgő, Z; Caproni, M; Dreher, A; Frances, C; Gläser, R; Klötgen, HW; Kuhn, A; Landmann, A; Marinovic, B; Nyberg, F; Olteanu, R; Ranki, A; Szepietowski, JC; Volc-Platzer, B | 1 |
| Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Goliadze, E; Guruli, G; Manjili, MH; Petrossian, AA; Robinson, SP; Sulek, JE; Toor, A; Zhou, S | 1 |
| Horwitz, SM; Mehta-Shah, N | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Landon, J; Luo, J | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kamezaki, K; Kamimura, T; Kato, K; Kikushige, Y; Miyamoto, T; Mori, Y; Shima, T; Takenaka, K; Tochigi, T; Yamauchi, T; Yoshimoto, G | 1 |
| Egle, A; Greil, R; Kiesewetter, B; Mayerhoefer, ME; Melchardt, T; Neumeister, P; Raderer, M; Simonitsch-Klupp, I; Voskova, D; Willenbacher, E; Willenbacher, W | 1 |
| Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F | 1 |
| Atenafu, EG; Bahmanyar, M; Chang, H; Hou, J; Pourabdollah, M; Reece, D | 1 |
| Boultwood, J; Dimitriou, M; Douagi, I; Giai, V; Grandien, A; Hellström-Lindberg, E; Jacobsen, SE; Jädersten, M; Jansson, M; Karimi, M; LeBlanc, K; Neuberg, DS; Pellagatti, A; Saft, L; Scharenberg, C; Woll, PS | 1 |
| Anh-NguyenThi, T; Jaya Lakshmi, T; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Nguyen-Pham, TN; Vo, MC | 1 |
| Arjona-Aguilera, C; Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L; Rodríguez-Mateos, ME | 1 |
| Boccadoro, M; Bringhen, S; Corvatta, L; Gay, F; Gentili, S; Larocca, A; Leoni, P; Maracci, L; Offidani, M; Troia, R | 1 |
| Cavo, M; Mancuso, K; Pantani, L; Pezzi, A; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Lonial, S; Ribeiro, M; Scott, S; Xia, C | 1 |
| Carraway, HE | 1 |
| Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J | 2 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Cai, H; Cai, QQ; Cao, XX; Dai, RP; Huang, XF; Li, J; Zhang, X; Zhou, DB | 1 |
| Boyd, KD; Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Henderson, R; Jackson, GH; Jenner, M; Jones, JR; Kaiser, MF; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Pratt, G; Russell, NH; Sigsworth, R; Striha, A; Williams, C | 1 |
| Cabrera César, E; Fernández Aguirre, MC; González Fernández, A | 1 |
| Cherai, M; Garderet, L; Nguyen-Quoc, S; Norol, F; Rosenzwajg, M; Tanguy, ML; Trébéden-Negre, H; Vieillard, V | 1 |
| Agarwal, A; Bhutani, M; Chow, E; Friend, R; Usmani, SZ; Voorhees, PM | 1 |
| Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R | 1 |
| Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Boccadoro, M; Cafro, AM; Campbell, P; Caravita, T; Carella, AM; Catalano, L; Conticello, C; Evangelista, A; Falcone, AP; Gay, F; Hajek, R; Liberati, AM; Malfitano, A; Montefusco, V; Musto, P; Nagler, A; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Salvini, M; Spada, S; Spencer, A; Troia, R | 1 |
| Birkmann, J; Kalisch, A; Pretscher, D; Wilhelm, M | 1 |
| Chen, CC; Chen, TY; DeMarco, D; Dunn, P; Hua, Y; Huang, SY; Jacques, C; Kao, WY; Lin, HY; Lin, SF; Lin, TH; Puccio-Pick, M; Wang, MC; Yeh, SP; Yu, YB | 1 |
| Bargou, R; Bassermann, F; Bullinger, L; Bunjes, D; Döhner, H; Einsele, H; Engelhardt, M; Greiner, A; Knop, S; Kolmus, S; Köpff, S; Krönke, J; Kuchenbauer, F; Kull, M; Langer, C; Mügge, LO; Schreder, M; Straka, C; Teleanu, V | 1 |
| Ahmann, GJ; Bergsagel, PL; Braggio, E; Chesi, M; Fonseca, R; Panchabhai, SC; Sebastian, S; Shi, CX; Stewart, AK; Van Wier, SA; Zhu, YX | 1 |
| Climente-Martí, M; Guchelaar, HJ; Guglieri-López, B; Merino-Sanjuán, M; Moes, DJ; Pérez-Pitarch, A; Porta-Oltra, B | 1 |
| Bolomsky, A; Fritz, V; Heintel, D; Hübl, W; Ludwig, H; Müldür, E; Palumbo, A; Rocci, A; Schlangen, K; Spada, S; Weißmann, A; Willheim, M; Zojer, N | 1 |
| Frederiksen, H; Marcher, CW; Mortensen, TB; Preiss, B | 1 |
| Adame, A; Desplats, P; Fields, JA; Mante, M; Masliah, E; Rockenstein, E; Spencer, B; Trinh, I; Valera, E | 1 |
| Angelergues, A; Mejean, A; Michel, C; Oudard, S; Tartour, E; Thibault, C; Timsit, MO; Vano, Y | 1 |
| Rajan, AM; Rajkumar, SV | 1 |
| Landgren, O | 1 |
| Manasanch, EE | 1 |
| Bello, A; Dodge, R; Gibiansky, L; Gupta, M; Mora, J; Passey, C; Roy, A; Sheng, J | 1 |
| Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W | 1 |
| Brandenburg, NA; Bwire, R; Freeman, J; Houn, F; Sheehan, P; Zeldis, JB | 1 |
| Bernöster, K; Häder, T; Pinkas, J; Schönfeld, K; Uherek, C; Zuber, C | 1 |
| Arcari, A; Botto, B; Carmichael, J; Ceccarelli, M; Cellini, C; Drandi, D; Fanin, R; Ferranti, A; Ferrari, A; Ferrero, S; Ladetto, M; Liberati, AM; Minotto, C; Montechiarello, E; Musuraca, G; Patti, C; Pileri, SA; Salvi, F; Spina, M; Stelitano, C; Volpetti, S; Zaja, F | 1 |
| Cai, Z; Cang, Y; Gao, S; Geng, C; Lin, X; Liu, J; Song, T | 1 |
| Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C | 1 |
| DeLaune, J; Grosbach, A; Norkin, M; Schmit, JM | 1 |
| Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R | 1 |
| Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ | 1 |
| Barilà, G; Bonaldi, L; Cabrelle, A; Carrino, M; Costacurta, M; Gianesin, K; Macaccaro, P; Manni, S; Manzoni, M; Martines, A; Neri, A; Nunes, SC; Piazza, F; Semenzato, G; Taiana, E; Trentin, L; Tubi, LQ; Zambello, R | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Boudreault, JS; Moreau, P; Touzeau, C | 1 |
| Álvarez Rivas, MÁ; Chic Acevedo, C; García Torres, E | 1 |
| Blonski, JZ; Chanan-Khan, A; Desjardins, P; Dolan, S; Echeveste, MA; Egyed, M; Golany, N; Gribben, JG; Martinelli de Oliveira, FA; Mei, J; Robak, T; Zhang, J | 1 |
| Criado, G; Delgado, M; Diaz de la Guardia, R; García-Herrero, CM; Gonzalez-Rey, E; Lavoie, JR; Lopez-Millan, B; Menendez, P; O'Valle, F; Roca-Ho, H; Rosu-Myles, M | 1 |
| Al Ali, N; Cluzeau, T; Fenaux, P; Gore, SD; Komrokji, R; Park, S; Prebet, T; Sekeres, MA; Sugrue, MM; Toma, A; Vey, N | 1 |
| Bunnapradist, S; Danovitch, G; Huang, E; Lum, EL; Pham, T | 1 |
| Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S | 1 |
| Stahl, M; Zeidan, AM | 1 |
| Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C | 1 |
| Berchem, G; Giuliani, M; Janji, B | 1 |
| Lentzsch, S; Raza, S; Safyan, RA | 1 |
| Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A | 1 |
| Badarinath, S; Berenson, J; Cartmell, A; Harb, W; Lyons, R; Manges, R; McIntyre, K; Mohamed, H; Nourbakhsh, A; Rifkin, R | 1 |
| Arcari, A; Bertoldero, G; Calimeri, T; Cecchetti, C; Chiozzotto, M; Couto, S; Fabbri, A; Ferreri, AJ; Frezzato, M; Govi, S; Nonis, A; Ponzoni, M; Re, A; Ren, Y; Rocco, AD; Rusconi, C; Sassone, M; Scarfò, L; Spina, M; Stelitano, C; Zaja, F; Zambello, R | 1 |
| Ko, C; Leventhal, J; Much, M; Stahl, M; Weed, J; Witt, D; Zeidan, AM | 1 |
| Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R | 1 |
| Coleman, M; Ely, S; Forsberg, P; Gergis, U; Greenberg, J; Guarneri, D; Jayabalan, D; Mark, TM; Mayer, S; Niesvizky, R; Pearse, R; Pekle, K; Perry, A; Rossi, A; Sherbenou, D; Shore, T; Tegnestam, L; Van Besien, K | 1 |
| Li, B; Li, G; Liu, Y; Sheng, Z; Wang, L | 1 |
| Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I | 1 |
| Banerjee, D; Bhattacharyya, M; Kalantri, SA; Nath, UK | 1 |
| Garderet, L; Malard, F; Mohty, M; Savani, BN; Sengsayadeth, S | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Becker, PS; Bensinger, W; Holmberg, LA | 1 |
| Dai, K; Huang, Y; Wang, C; Wang, Y; Xu, J; Zhang, X | 1 |
| Carrasco, V; Cases, E; Gómez Gonzalez, C; Lázaro Sierra, J | 1 |
| Jin, J; Liu, H; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, G; Yang, M; Zhou, X | 1 |
| Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM | 1 |
| Bacher, U; Braulke, F; Brümmendorf, TH; Bug, G; Büsche, G; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Hofmann, WK; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schuler, E; Schulz, X; Shirneshan, K; Trümper, L | 1 |
| Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA | 1 |
| Brown, JR; Itchaki, G | 1 |
| Gupta, NK; Mannis, GN; Rubenstein, JL; Wang, CC; Yu, JJ | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Abe, N; Bohgaki, M; Kasahara, H; Koike, T; Tomita, T | 1 |
| Sun, H; Ying, L; YinHui, T; Yunliang, Z | 1 |
| Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A | 1 |
| Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S | 1 |
| Blijlevens, NMA; Cermak, J; Chiba, K; da Silva-Coelho, P; de Graaf, AO; de Witte, T; Dugas, M; Huls, G; Jansen, JH; Knops, R; Koorenhof-Scheele, TN; Kroeze, LI; Massop, M; Miyano, S; Muus, P; Ogawa, S; Sandmann, S; Shiraishi, Y; Stevens-Kroef, MJ; Tanaka, H; van de Locht, LT; van der Reijden, BA; Yoshida, K | 1 |
| Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A | 1 |
| Bargou, RC; Bassermann, F; Biersack, H; Einsele, H; Engelhardt, M; Günther, A; Held, S; Hertenstein, B; Junghanss, C; Knop, S; Kunitz, A; Langer, C; Liebert, A; Mügge, LO; Ostermann, H; Reichle, A; Ringhoffer, M; Röllig, C; Rösler, W; Schäfer-Eckart, K; Schreder, M | 1 |
| Jaya Lakshmi, T; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Nguyen-Pham, TN; Vo, MC; Yang, S | 1 |
| Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S | 1 |
| Faber, LM; Kootte, RS | 1 |
| Chung, DJ; Devlin, SM; Dogan, A; Gao, Q; Giralt, SA; Hassoun, H; Korde, N; Landau, H; Landgren, CO; Lendvai, N; Lesokhin, AM; Mailankody, S; Nguyen, J; Roshal, M; Sabari, J | 1 |
| Baz, R; Benson, DM; Campana, F; Charpentier, E; Lendvai, N; Lesokhin, AM; Martin, T; Munster, P; Vij, R; Wack, C; Wolf, J | 1 |
| Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
| Appelbaum, FR; Atallah, E; Attar, EC; Bloomfield, CD; Buckstein, R; Cook, EK; Cull, AH; Erba, HP; Fang, M; Gaur, R; Gore, SD; List, AF; Litzow, MR; Moseley, A; Nazha, A; Odenike, O; Othus, M; Rauh, MJ; Roulston, D; Sekeres, MA; Stone, RM; Velasco, MR; Zhang, Y | 1 |
| Figg, WD; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Peer, CJ; Sissung, TM; Venzon, DJ | 1 |
| Ahmed, S; Alousi, AM; Bassett, RL; Bueso-Ramos, CE; Ciurea, SO; Gulbis, AM; Jabbour, EJ; Khouri, IF; Khouri, MR; Korbling, M; Ledesma, C; Marin, D; Patel, KK; Popat, UR; Samuels, BI; Turturro, F | 1 |
| Chang, S; Maharaj, S; Seegobin, K; Serrano-Santiago, I; Zuberi, L | 1 |
| Becker, N; Beimler, J; Benner, A; Bochtler, T; Freiberger, A; Gawlik, M; Goldschmidt, H; Hegenbart, U; Ho, AD; Hose, D; Hund, E; Jauch, A; Kimmich, C; Kristen, AV; Schönland, SO; Zorn, M | 1 |
| Bai, W; Chen, Y; Cui, X; Ma, J; Wu, K; Xie, Y | 1 |
| Davidoff, AJ; Dusetzina, SB; Eaton, CB; Olszewski, AJ; Trivedi, AN | 1 |
| Bamdad, T; Borhani, K; Hashempour, T | 2 |
| de Wit, E; Moreau, P | 1 |
| Efebera, Y; Stino, AM | 1 |
| Hollingworth, SA; McKavanagh, D; Mollee, P; Sharkey, MM; Walpole, E | 1 |
| Banos, A; Béné, MC; Bernard, M; Bonmati, C; Bouscary, D; Carré, M; Choufi, B; Couturier, MA; Daguindau, E; Delaunay, J; Dreyfus, F; Fornecker, LM; Hamel, JF; Himberlin, C; Hunault-Berger, M; Ifrah, N; Lissandre, S; Luquet, I; Maillard, N; Marolleau, JP; Ojeda-Uribe, M; Orsini-Piocelle, F; Pigneux, A; Puyade, M; Recher, C; Rouillé, V; Saad, A; Sanhes, L; Schmidt-Tanguy, A; Sutton, L; Tavernier, E | 1 |
| Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L | 1 |
| Bouscary, D; Chavarot, N; Karras, A; Lebbe, C; Thervet, E | 1 |
| Bug, G; Fabarius, A; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, C; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Mossner, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Platzbecker, U; Pressler, J; Schlenk, R; Xanthopoulos, C | 1 |
| Bartlett, NL; Blum, KA; Christian, BA; Devine, SM; Fehniger, TA; Jaglowski, SM; Maly, JJ; Phelps, MA; Sexton, JL; Wagner-Johnston, ND; Wei, L; Zhu, X | 1 |
| Guruli, G; Matchavariani, K; Mchedlishvili, K; Mitskevich, N; Tsertsvadze, T | 1 |
| Cook, M; Denman, J; Manavi, K | 1 |
| Abuomar, W; Al Sughaiyer, H; Al-Mayoof, O; Khan, M | 1 |
| Benatti, S; Bulgarelli, J; Cuneo, A; Debbia, G; Fiorcari, S; Forconi, F; Gaidano, G; Laurenti, L; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Palumbo, GA; Rigolin, GM; Rizzotto, L; Rossi, D; Santachiara, R; Vallisa, D | 1 |
| Delforge, M; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Song, K; Vogl, DT | 1 |
| Anderson, K; Avigan, D; Gali, R; Hideshima, T; Kufe, D; Tagde, A; Tai, YT; Yin, L | 1 |
| Braga, WMT; Colleoni, GWB; Davies, FE; de Carvalho, MF; de Oliveira, MB; Eugenio, AIP; Fernando, RC; Fook-Alves, VL; Sanson, LFG | 1 |
| Beyne-Rauzy, O; Deeg, HJ; Del Cañizo, C; Fenaux, P; Giagounidis, A; Greenberg, PL; Guerci-Bresler, A; Hellström-Lindberg, E; List, AF; Mittelman, M; Muus, P; Nimer, SD; Powell, BL; Sekeres, MA; Selleslag, D; Shammo, JM; Skikne, B; Yu, X | 1 |
| Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D | 1 |
| Jantunen, E; Mäntymaa, P; Partanen, A; Pelkonen, J; Putkonen, M; Ropponen, A; Sankelo, M; Siitonen, T; Silvennoinen, R; Valtola, J; Varmavuo, V | 1 |
| Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D | 1 |
| Chen, WM; Fu, ZZ; Hu, Y; Huang, XJ; Huang, ZX; Jin, FY; Li, XL; Liao, AJ; Liu, H; Lu, J; Meng, FY; Wang, GM; Wang, XM; Yang, GZ; Zhang, X; Zhong, YP; Zhou, JF | 1 |
| Casadebaig Bravo, ML; Drach, J; Fu, T; Goy, A; Habermann, TM; Kalayoglu Besisik, S; Luigi Zinzani, P; Ramchandren, R; Takeshita, K; Tuscano, JM; Witzig, TE; Zhang, L | 1 |
| Boon, L; Gabrysiak, M; Golab, J; Kilarski, WW; Klaus, TJ; Muchowicz, A; Pilch, Z; Stachura, J; Tonecka, K; Wachowska, M; Wołosz, D | 1 |
| Falcon, CP; Matsui, T; Minagawa, K | 1 |
| Azuma, Y; Fujita, S; Hotta, M; Ishii, K; Ito, T; Nakanishi, T; Nakaya, A; Nomura, S; Satake, A; Tsubokura, Y; Yoshimura, H | 1 |
| Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z | 1 |
| Bladé, J; Calderón, M; de Larrea, CF; Díaz, T; Lozano, E; Martínez, A; Mena, MP; Pérez-Galán, P; Rodríguez, V; Rosiñol, L; Roué, G; Tovar, N | 1 |
| Hu, S; Li, Z; Yan, H; Yuan, L | 1 |
| Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M | 1 |
| Chung, YJ; Jung, SH; Kim, SH; Kim, TW; Lee, M; Lee, SE; Min, CK; Yim, SH | 1 |
| Chan, W; Chen, Y; Du, XL; Lairson, DR | 1 |
| Syed, YY | 1 |
| Ayyalu, TK; Issa, M | 1 |
| Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ | 1 |
| Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR | 1 |
| Anderson, KC; Bashey, A; Boyd, M; Callander, NS; Devine, SM; Gentile, TG; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Holstein, SA; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Jung, SH; Landau, H; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Qazilbash, MH; Richardson, PG; Rodriguez, C; Schlossman, RL; Schultz, C; Shea, TC; Smith, SE; Stadtmauer, EA; van Besien, K; Vij, R; Weisdorf, DJ; Wilson, M | 1 |
| Cairns, D; Cook, G; Davies, FE; Drayson, M; Gregory, WM; Houlston, RS; Jackson, G; Johnson, DC; Jones, JR; Kaiser, MF; Lenive, O; Mitchell, J; Morgan, GJ; Owen, R; Pawlyn, C; Walker, BA; Wardell, C | 1 |
| Andrea, M; Beck, J; Becker, C; Bill, M; Edelmann, T; Gläser, D; Heyn, S; Hoffmann, FA; Jentzsch, M; Kragl, B; Kreibich, U; Lange, T; Mohren, M; Mügge, LO; Niederwieser, D; Pönisch, W; Schliwa, T; Schwarzer, A; Schwind, S; Uhlig, J; Winkelmann, C; Zehrfeld, T | 1 |
| Dolak, W; Kiesewetter, B; Kornauth, C; Lukas, J; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I | 1 |
| Collado-Borrell, R; Escudero-Vilaplana, V; González-Arias, E; Osorio-Prendes, S; Sanjurjo-Sáez, M | 1 |
| Cho, H; Do, YR; Eom, HS; Jo, JC; Kang, HJ; Kim, JS; Kim, K; Kim, SY; Lee, HS; Lee, JB; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Moon, JH; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yoon, DH | 1 |
| Mikhael, JR | 1 |
| Beà, S; Campo, E; Colomer, D; Giné, E; Lee, E; Lopez-Guerra, M; López-Guillermo, A; Matas-Cespedes, A; Navarro, A; Pérez-Galán, P; Rivas-Delgado, A; Rodriguez, V; Roué, G; Vidal-Crespo, A | 1 |
| Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M | 1 |
| Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G | 1 |
| Batista, CR; DeKoter, RP; Solomon, LA | 1 |
| Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S | 1 |
| Autore, F; Bacigalupo, A; Chiusolo, P; Innocenti, I; Laurenti, L; Luigetti, M; Piccirillo, N; Sica, S; Sora, F | 1 |
| Al-Sawaf, O; Aldaoud, A; Bahlo, J; Bosch, F; Böttcher, S; Döhner, H; Dörfel, S; Eichhorst, B; Fink, AM; Fischer, K; Ghia, P; Hallek, M; Hebart, H; Jentsch-Ullrich, K; Kater, AP; Kneba, M; Kreuzer, KA; Nösslinger, T; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Condoluci, A; Rossi, D | 1 |
| Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K | 1 |
| Nutan, F; Ortega-Loayza, AG | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Hsi, ED; Jung, SH; Leonard, JP; Martin, P; Pitcher, B; Ruan, J; Shea, T; Smith, SE | 1 |
| List, A; Sallman, D; Talati, C | 1 |
| Chang, JE | 1 |
| Chanan-Khan, AA; Egyed, M; Foà, R; Kassis, J; Purse, B; Schuh, A; Semochkin, S; Simpson, D; Vokurka, S; Zaritskey, A; Zhang, J | 1 |
| Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Thakral, B; Wang, SA | 1 |
| Heightman, TD; Lebraud, H | 1 |
| Ades, L; Auberger, P; Basiorka, AA; Cluzeau, T; Fenaux, P; Irvine, B; List, A; Maciejewski, J; Masala, E; McGraw, KL; Santini, V; Wei, S | 1 |
| Di Raimondo, F; Ferrara, F; Fuligni, F; Isidori, A; Loscocco, F; Paolini, S; Piccaluga, PP; Rocchi, M; Spina, E; Visani, A; Visani, G; Zammit, V | 1 |
| Akiyama, H; Hara, D; Hasegawa, Y; Hoshikawa, M; Nukui, S; Shimizu, T | 1 |
| Bloem, AC; Broekmans, MEC; Chiu, C; Frerichs, KA; Groen, RWJ; Krejcik, J; Lokhorst, HM; Musters, RJP; Mutis, T; Nijhof, IS; Plesner, T; Poddighe, PJ; Sasser, AK; van de Donk, NWCJ; van Kessel, B; van Meerloo, J; van Velzen, JF; Zweegman, S | 1 |
| Adami, F; Briani, C; Gallia, F; Giordano, L; Merlini, G; Nobile-Orazio, E; Nozza, A; Santoro, A; Terenghi, F | 1 |
| Chong, H; Mahendran, P; Natkunarajah, J; Wee, J | 1 |
| Cheng, B; Guo, Y; Li, X; Ma, D; Tang, S; Wang, J; Wu, W; Xu, J; Zhe, N | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L | 1 |
| Au-Yeung, R; Hwang, YY; Kwong, YL; Lau, HP | 1 |
| Binder, G; DeZern, AE; McGuire, M; Ni, Q; Smith, BD | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Boulard, C; Courville, P; Gremain, V; Langlois, V; Litrowski, N; Marguet, F; Zarnitsky, C | 1 |
| Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M | 1 |
| Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F | 1 |
| Advani, P; Ailawadhi, S; Chanan-Khan, AA; Colibaseanu, DT; Colon-Otero, G; Frank, RD; Hashmi, SK; Hodge, DO; Kakar, TS; Khera, N; Meghji, Z; Menghani, R; Paulus, A; Paulus, S; Roy, V; Sharma, M; Swaika, A; Temkit, M; Vizzini, MR | 1 |
| Ciulli, A; Hughes, SJ | 1 |
| Blair, HA | 1 |
| Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A | 1 |
| Jaccard, A | 1 |
| Guo, H; Sun, X; Wang, B; Xu, W | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Migkou, M; Ntanasis-Stathopoulos, I; Roussou, M; Terpos, E; Ziogas, DC | 1 |
| Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL | 1 |
| Das, M | 1 |
| Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M | 1 |
| Alexeeva, J; Arcaini, L; Belada, D; Biyukov, T; Cabeçadas, J; Campo, E; Casadebaig Bravo, ML; Jurczak, W; Lamy, T; Mayer, J; Morschhauser, F; Patturajan, M; Pileri, SA; Radford, J; Rule, S; Trnĕný, M; Walewski, J | 1 |
| Foroughbakhshfasaei, M; Gál, R; Horváth, P; Komjáti, B; Noszál, B; Szabó, ZI; Tóth, G | 1 |
| Thieblemont, C | 1 |
| Boccadoro, M; Giudice, D; Larocca, A; Pautasso, C; Salvini, M; Troia, R | 1 |
| Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Schmidt, C | 1 |
| Cameron, H; Drennan, AC; Kellicut, A; Kelm, A; Kimpara, S; Li, Y; Lu, L; Rui, L; Rumball, I; Selzer, C; Waldmann, TA; Wang, F; Zhang, M; Zhu, F | 1 |
| Bacher, U; Betticher, D; Egger, T; Gössi, U; Jeker, B; Mansouri Taleghani, B; Novak, U; Pabst, T; Zander, T | 1 |
| Hellström-Lindberg, E; Jansson, M; Saft, L; Scharenberg, C | 1 |
| Mima, A; Nagahara, D; Tansho, K | 1 |
| Hashida, H; Hatano, K; Irie, K; Matsumoto, H; Mitsutake, A; Tsukada, N | 1 |
| Dahl, C; Eskelund, CW; Geisler, CH; Grønbæk, K; Hutchings, M; Jerkeman, M; Kolstad, A; Kuitunen, H; Laurell, A; Niemann, CU; Pedersen, LB; Räty, R; Toldbod, H; Wader, KF | 1 |
| Abumiya, M; Kanno, S; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L | 1 |
| Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS | 1 |
| Akuffo, AA; Alontaga, AY; Ayaz, M; Beatty, MS; Becker, A; Daniel, K; Epling-Burnette, PK; Goodheart, WE; Guida, W; Gunawan, S; Hesterberg, RS; Karim, MR; Lawrence, HR; Lawrence, NJ; McDaniel, JM; Metcalf, R; Orobello, ME; Rajadhyaksha, AM; Schönbrunn, E; Yang, Y; Yoder, JA | 1 |
| Chosidow, O; Drahy, F; Grootenboer-Mignot, S; Ingen-Housz-Oro, S; Wolkenstein, P | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S | 1 |
| Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y | 1 |
| Admojo, L; Darcy, PK; Davenport, AJ; Fairlie, DP; Gherardin, NA; Godfrey, DI; Harrison, SJ; Jenkins, MR; Kedzierska, K; Loh, L; McCluskey, J; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Rogers, A; Uldrich, AP | 1 |
| Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A | 1 |
| Arcioni, F; Covezzoli, A; Cundari, S; Di Battista, V; Mecucci, C; Roncadori, A; Tura, S | 1 |
| Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Deng, J; Ding, W; Ge, W; Lei, H; Liao, F; Tao, W; Xiao, Y; Zeng, T | 1 |
| Bao, C; Chen, W; Lawton, M; Li, Z; Saw, D; Shaligram, S; Shen, F; Su, H; Wang, L; Wang, S; Winkler, E; Zhan, L; Zhang, M; Zhu, W; Zou, D | 1 |
| Lai, B; Mu, Q; Ouyang, G; Sheng, L; Wang, Y; Xu, K; Zhang, Y; Zhu, H | 1 |
| Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U | 1 |
| Adey, DB; Jen, KY; Laszik, ZG; Walavalkar, V | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Wu, T | 1 |
| Foà, R; Mauro, FR | 1 |
| Guo, HM; Liu, XJ; Luo, JM; Nie, ZY; Sun, L; Yang, L | 1 |
| van de Donk, NWCJ | 2 |
| Dai, K; Mei, J; Qiao, H; Qu, X; Yu, Z; Zhai, Z | 1 |
| Adamopoulos, I; Aktypi, A; Anagnostopoulos, A; Briasoulis, E; Delimpasi, S; Douka, V; Fotiou, D; Giannakoulas, N; Giannopoulou, E; Gogos, D; Hatzimichael, E; Katodritou, E; Kioumi, A; Kokoviadou, K; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Megalakaki, A; Nikolaou, E; Papadaki, E; Pappa, V; Repousis, P; Spanoudakis, E; Symeonidis, A; Terpos, E; Timotheatou, D; Vasilopoulos, G; Zikos, P | 1 |
| Ben Amara, A; Benyamine, A; Castanier, C; Castellano, R; Collette, Y; Fauriat, C; Fournié, JJ; Goubard, A; Granjeaud, S; Le Roy, A; Mege, JL; Olive, D; Orlanducci, F; Pont, F; Prébet, T; Riccardi, F; Vey, N | 1 |
| Johnson, PRE; Mathur, A; Roddie, PH; Storrar, NPF | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Migkou, M; Terpos, E | 1 |
| Bouwmeester, W; Campioni, M; DeCosta, L; Fraňková, H; Gonzalez-McQuire, S; Gregora, E; Hájek, R; Jarkovsky, J; Kessler, P; Maisnar, V; Minařík, J; Pour, L; Špička, I; Sýkora, M; Treur, M | 1 |
| He, W; Min, X; Yang, X | 1 |
| Dusetzina, SB; Keating, NL; Rotenstein, LS | 1 |
| Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Burslem, GM; Crews, CM; Cromm, PM; Jaime-Figueroa, S; Morgan, A; Ottis, P; Toure, M | 1 |
| Guengerich, FP; Kamiya, Y; Kusama, T; Mitsui, M; Murayama, N; Shimizu, M; Suemizu, H; Uehara, S; Yamazaki, H | 1 |
| Gottwein, E; Manzano, M; Patil, A | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Abadi, U; Bekadja, MA; Beksac, M; Berthou, C; Boccadoro, M; Borbényi, Z; Cavo, M; Černelč, P; Corso, A; Couturier, C; De Stefano, V; Dimopoulos, M; Durán, MS; Feys, C; Kochkareva, Y; Laane, E; Legiec, W; Lejniece, S; Louw, V; Masliak, Z; Mateos, MV; Mohty, M; Nemet, D; Pečeliūnas, V; Pedersen, RS; Potamianou, A; Salwender, H; Silva, J; Stankovic, S; Terpos, E; Thoret-Bauchet, F; Willenbacher, W | 1 |
| Bohn, JP; Oberacher, H; Peschel, I; Steurer, M; Willenbacher, W | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y | 1 |
| Gilbert, L; Ordway, S; Wanko, S | 1 |
| Abonour, R; Durie, BGM; Gasparetto, CJ; Gibson, CJ; Hardin, JW; Jagannath, S; Kitali, A; Narang, M; Rifkin, RM; Srinivasan, S; Swern, AS; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Adams, DN; Carr, SA; Chen, M; Ebert, BL; Fink, EC; Guirguis, AA; Haldar, SD; Kennedy, JA; Liddicoat, B; Mani, DR; McConkey, M; Nguyen, AT; Svinkina, T; Udeshi, ND | 1 |
| Tomlinson, R | 1 |
| Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F | 1 |
| Chatterjee, S; Kumar, P; Sundaresan, L | 1 |
| Gordon, LI | 1 |
| Becker, S; Bouabdallah, R; Cabeçadas, J; Casasnovas, O; Feugier, P; Gabarre, J; Gouill, SL; Haioun, C; Jardin, F; Lamy, T; Molina, TJ; Morschhauser, F; Mounier, N; Salles, G; Tilly, H; Tournilhac, O | 1 |
| Cella, D; Davis, C; Kudlac, A; McKendrick, J; Oukessou, A; Palumbo, A; Vij, R; Zyczynski, T | 1 |
| Ando, K; André, M; Bartlett, NL; Bouabdallah, K; Bouabdallah, R; Brice, P; Cartron, G; Casasnovas, RO; Daguindau, N; Feugier, P; Flinn, IW; Fowler, NH; Fruchart, C; Gomes da Silva, M; Haioun, C; Larouche, JF; Le Gouill, S; Libby, EN; Liu, D; López-Guillermo, A; Maisonneuve, H; Martin Garcia-Sancho, A; Morschhauser, F; Palomba, ML; Pica, GM; Ribrag, V; Salles, GA; Sehn, LH; Tilly, H; Tobinai, K; Wang, J; Xerri, L; Ysebaert, L; Zachée, P | 1 |
| Aitini, E; Andriani, A; Angelucci, E; Annibali, O; Baraldi, A; Bernardini, A; Boccadoro, M; Bringhen, S; Centurioni, R; De Stefano, V; Di Renzo, N; Evangelista, A; Ferrando, P; Grammatico, S; Larocca, A; Marcatti, M; Meneghini, V; Musto, P; Offidani, M; Palmas, A; Palmieri, S; Palumbo, A; Pisani, F; Rizzi, R; Rocco, S; Siniscalchi, A; Spada, S; Storti, S; Vallone, R | 1 |
| Neri, P | 1 |
| Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L | 1 |
| D'Sa, S; Keddie, S; Lunn, MP | 1 |
| Abdulrahman, W; Bunker, RD; Ebert, BL; Liddicoat, BJ; Mikkelsen, T; Petzold, G; Renneville, A; Sievers, QL; Słabicki, M; Thomä, NH | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Bailly, S; Croizier, C | 1 |
| Bai, H; Chen, JW; Fan, WJ; Wu, T | 1 |
| Breitkreutz, I; Goldschmidt, H; Raab, M | 1 |
| de la Calle, VG; Mateos, MV | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Holstein, SA; McCarthy, PL; Suman, VJ | 1 |
| Gertz, M; Vaxman, I | 1 |
| Ashby, C; Begum, DB; Cairns, DA; Cook, G; Davies, FE; Drayson, MT; Ellis, S; Greaves, M; Gregory, WM; Jackson, GH; Johnson, D; Jones, JR; Kaiser, MF; Melchor, L; Morgan, GJ; Owen, RG; Pawlyn, C; Rasche, L; Sherborne, AL; Walker, BA; Wardell, C; Weinhold, N | 1 |
| Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A | 1 |
| Barosi, G; Gale, RP | 1 |
| Caballero García, A; Córdova Martínez, A; Fernández-Lázaro, CI; Fernández-Lázaro, D | 1 |
| Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C | 1 |
| Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S | 1 |
| Adachi, Y; Akashi, K; Choi, I; Fuchida, SI; Fujishima, N; Harada, M; Kiguchi, T; Kuroda, Y; Maeda, A; Matsumoto, M; Miyamoto, T; Nagafuji, K; Nakazato, T; Omoto, E; Sunami, K; Suzumiya, J; Takamatsu, H; Takamatsu, Y; Yamamura, R; Yujiri, T | 1 |
| Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Gay, F; Mina, R | 1 |
| Cao, Y; Jiang, J; Liang, Z; Lin, T; Wan, N; Wang, S; Xie, J; Zhang, T | 1 |
| Buadi, F; Kansagra, A; Kourelis, T; Milone, M; Naddaf, E | 1 |
| Chen, W; Lu, J | 1 |
| Alfaro, V; Banh, RH; Cannell, P; Carella, AM; D'Rozario, JM; Dimopoulos, MA; Extremera, S; Greil, R; Hájek, R; Huang, SY; Kahatt, C; Ludwig, H; Martínez, S; Mateos, MV; Meuleman, N; Min, CK; Oakervee, HE; Ocio, EM; Sonneveld, P; Spicka, I; Symeonidis, A | 1 |
| Kim, GW; Kwon, SH; Lee, DH; Ryu, HW; Won, HR; Yeon, SK | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Furukawa, Y; Hagiwara, S; Hori, M; Iha, H; Izumi, T; Kikuchi, J; Koyama, D; Kuroda, Y; Suzuki, A; Toyama-Sorimachi, N; Yasui, H | 1 |
| Leahy, J; Walsh, C | 1 |
| Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E | 1 |
| Alexanian, R; Feng, L; Johnson, RJ; Lee, HC; Morphey, A; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, ML; Weber, DM; Wesson, ET | 1 |
| Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| An, Z; Guo, X; Li, F; Li, H; Mei, J; Shao, J; Song, P; Wang, X; Zhai, Y; Zhao, Q; Zhou, X | 1 |
| Falcetta, FS; Manica, D; Morais, VD; Pithan, CDF; Ribeiro, MR; Ribeiro, RA; Salazar, AP; Sekine, L; Sosnoski, M; Ziegelmann, PK | 1 |
| Mo, CC; Richardson, PG | 1 |
| Paumgartten, FJR | 1 |
| Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Aikawa, NE; Bonfa, E; Heise, CO; Pasoto, SG; Romiti, R; Silva, CA; Yuki, EFN | 1 |
| Buchanan, V; D'Souza, VK; Dhanasiri, S; Ramasamy, K; Robinson, S; Thom, H; Weisel, K | 1 |
| Amatangelo, M; Bjorklund, CC; Chiu, H; Couto, S; Flynt, JE; Kang, J; Katz, M; Ortiz, M; Pierceall, W; Polonskaia, A; Ren, Y; Thakurta, A; Towfic, F; Wang, M | 1 |
| Kimball, A; Klippel, Z; Tekle, C | 1 |
| Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S | 1 |
| Djebbari, F; Fourali, S; Kothari, J; Lynes, JA; McLain-Smith, S; Ramasamy, K; Sharpley, FA | 1 |
| Garcia, DA; Li, A; Li, S; Libby, EN; Lyman, GH; Warnick, G; Wu, Q | 1 |
| Aboulafia, DM; Hwang, DG; Peterson, JF; Sinit, RB; Vishnu, P | 1 |
| Chen, P; Wang, T; Wu, Z; Zhang, F; Zhang, H; Zhang, J; Zhou, J | 1 |
| Delimpasi, S; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Migkou, M; Mparmparousi, D; Ntanasis-Stathopoulos, I; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Tsirigotis, P; Xirokosta, A; Ziogas, DC | 1 |
| Cahn, JY; Courby, S; Deteix, C; Larabi, A; Meunier, M; Schacherer, M | 1 |
| Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Anderson Tvedt, TH; Bruserud, Ø; Ersvær, E; Rundgren, IM; Ryningen, A | 1 |
| de Vassoigne, F; Gaugler, B; Malard, F; Marjanovic, Z; Mohty, M; Ricard, L; Stocker, N | 1 |
| Bahlis, NJ; Benboubker, L; Chiu, C; Cook, G; Dimopoulos, MA; Ho, PJ; Kaufman, JL; Kim, K; Krevvata, M; Leiba, M; Moreau, P; Okonkwo, L; Qi, M; Qin, X; San-Miguel, J; Takezako, N; Trivedi, S; Ukropec, J; White, DJ | 1 |
| Amino, H; Iwai, Y; Katayama, K; Kuwabara, S; Misawa, S; Nagashima, K; Nakamura, K; Sato, Y; Sekiguchi, Y; Shibuya, K; Suichi, T; Suzuki, YI; Tsuneyama, A | 1 |
| Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Giesen, N; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengass, J; Hoffmann, M; Hose, D; Hügle-Dörr, B; Huhn, S; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Munder, M; Raab, MS; Rabold, B; Salwender, HJ; Scheid, C; Seckinger, A; Tichy, D; Weisel, KC | 1 |
| Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Santini, V; Skikne, B; Tu, N; Weaver, J | 1 |
| Belair, DG; Collins, ND; Gustin, JA; Kolaja, KL; Lu, G; Waller, LE | 1 |
| Djebbari, F; Eyre, TA; Kothari, J; McLain-Smith, S; Moore, S; Ramasamy, K; Sharpley, FA; Vallance, G | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I | 1 |
| Dew, A; Hill, E; Kazandjian, D | 1 |
| Lu, SX | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A | 1 |
| Fernández, GI; Ribera, JM; Sabater, LA | 1 |
| Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M | 1 |
| Daguenet, E; Fouillet, L; Guyotat, D; Laurent, B; Le Jeune, C; Sapet, M | 1 |
| Cavion, F; Decorti, G; Fazzi, EM; Ferraro, RM; Genova, E; Giliani, S; Lanzi, G; Lucafò, M; Masneri, S; Orcesi, S; Pelin, M; Stocco, G; Tommasini, A | 1 |
| Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F | 1 |
| Hagiwara, S; Hirai, R; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Almodovar-Rivera, CM; Nie, X; Tang, W; Wang, B; Wu, H; Xie, H; Yang, K; Zhao, Y | 1 |
| Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C | 1 |
| Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Jeon, YH; Kim, GW; Kwon, SH; Lee, DH; Lee, SW; Won, HR; Yeon, SK; Yoo, J | 1 |
| Chen, Y; Cutter, D; Loh, Y; Master, Z; Mikhaeel, G; Nagarajan, C; Thitsar, SM; Tin, KM; Yeoh, KW | 1 |
| Chinen, Y; Fujibayashi, Y; Gütschow, M; Horiike, S; Isa, R; Kobayashi, T; Kuroda, J; Kuwahara-Ota, S; Matsumura-Kimoto, Y; Mizuno, Y; Nishiyama, D; Shimura, Y; Steinebach, C; Takimoto-Shimomura, T; Taniwaki, M; Tsukamoto, T; Yamaguchi, J | 1 |
| Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Taylor, C; Waterhouse, A; Williams, CD; Wilson, J | 1 |
| Bittrich, M; Danhof, S; Einsele, H; Gisslinger, B; Gisslinger, H; Hefner, J; Hose, D; Knop, S; Krauth, MT; Schoder, R; Schreder, M; Strifler, S | 1 |
| Bergeret, B; Bessis, D; Dandurand, M; Dereure, O; Du-Thanh, A; Lipsker, D; Reymann, V; Terrail, N | 1 |
| Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH | 1 |
| Al Ali, N; Castillo-Tokumori, F; Komrokji, R; Kuykendall, AT; Lancet, J; Padron, E; Sallman, D; Sweet, K; Talati, C; Yun, S | 1 |
| Hou, HA; Liu, Y; Qiu, H; Tang, CH | 1 |
| Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T | 1 |
| Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M | 1 |
| Asatsuma-Okumura, T; Handa, H; Ito, T; Kishi, T; Kizaki, M; Mizutome, H; Momose, S; Murase, Y; Shimizu, N; Suwa, T; Tateno, S; Yamaguchi, Y; Yamamoto, J | 1 |
| Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K | 1 |
| Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D | 1 |
| Ahmed, Z; Anwer, F; Ashraf, A; Ehsan, H; Faisal, MS; Khakwani, M; Khan, A; Mushtaq, K; Rafae, A; Rehan, T; Shah, Z; Wahab, A | 1 |
| Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM | 1 |
| Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| Korst, CLBM; van de Donk, NWCJ | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Jiang, X; Kan, W; Li, J; Li, Y; Mi, T; Wang, Y; Xu, G; Zhou, Y | 1 |
| Baker, B; Chan, H; Chien, N; Goodman, H; Romeril, K | 1 |
| Beverloo, HB; Broijl, A; Dumee, B; Hansson, M; Koenders, J; Kuiper, R; Levin, MD; Sonneveld, P; Stevens-Kroef, M; van Beers, EH; van der Holt, B; van der Velden, AWG; van Duin, M; van Vliet, MH; Vermeulen, M; Visser-Wisselaar, H; Waage, A; Zweegman, S | 1 |
| Avilés, A; Candelaria, M; Fabian-Morales, E; Gutierrez, O; Palacios-Campos, A | 1 |
| Hou, HA; Liu, Y; Qiu, H; Siggins, S; Tang, CH | 1 |
| Ansari-Pour, N; Bahlis, N; Chamberlain, PP; Dhiman, P; Flynt, E; Gooding, S; Hirst, M; Neri, P; Ortiz Estévez, M; Ramasamy, K; Rozelle, D; Thakurta, A; Towfic, F; Tsai, KT; Vyas, P | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Cippitelli, M; Fionda, C; Gismondi, A; Kosta, A; Petillo, S; Santoni, A; Stabile, H | 1 |
| Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Grant, S | 1 |
| Bernabei, L; Cohen, AD; Garfall, AL; Gonzalez, VE; June, CH; Lacey, SF; Levine, BL; Melenhorst, JJ; Milone, MC; Plesa, G; Stadtmauer, EA; Tian, L; Vogl, DT; Waxman, A; Young, RM | 1 |
| Blevins, F; Hughes, D; Lerner, A; Milrod, CJ; Sanchorawala, V; Sarosiek, S; Sloan, JM | 1 |
| Delforge, M; Kint, N; Vlayen, S | 1 |
| Bewersdorf, JP; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhang, C | 1 |
| Carr, SA; Cayuela, JM; Chamberlain, PP; Clayton, T; Cotteret, S; De Botton, S; Ebert, BL; Gasser, JA; Grinshpun, DE; Guirguis, AA; Jean Beltran, PM; Kiladjian, JJ; Marzac, C; Matyskiela, ME; McConkey, M; Renneville, A; Rolfe, M; Saada, V; Sellar, RS; Tepper, A; Udeshi, ND; Viswanathan, K | 1 |
| Cheng, CN; Huang, ST; Huang, SY; Lien, PW; Lin, FJ | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD | 1 |
| Ciotkowska, A; Gratzke, C; Hennenberg, M; Huang, R; Li, B; Rutz, B; Sauckel, C; Stief, CG; Tamalunas, A; Wang, R | 1 |
| Chen, J; Ding, X; Elvassore, N; Jiang, B; Kong, Y; Liu, H; Liu, L; Mi, Q; Qiu, X; Ren, C; Shao, Y; Yang, X; Yin, Q; Zhao, Q | 1 |
| Lewis, DJ; Mueller, M | 1 |
| Prince, HM | 1 |
| Hasegawa, A; Ishizawa, M; Kannagi, M; Katagiri, K; Kondo, N; Masuda, T; Nagano, Y; Yoneda, T | 1 |
| Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Chen, D; Feng, P; Gao, T; Liu, X; Luo, Z; Miao, J; Shen, Q; Xiang, J; Zheng, L | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| D'Rozario, J; Estell, J; Ho, PJ; Kalff, A; Kemp, R; Kennedy, N; Khong, T; Mitchell, AJ; Mollee, P; Norton, S; Quach, H; Ramachandran, M; Reynolds, J; Spencer, A; Taylor, K | 1 |
| Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC | 1 |
| Bassermann, F; Bertsch, U; Eichner, R; Emde-Rajaratnam, M; Goldschmidt, H; Heider, M; Hose, D; Keller, U; Rudelius, M; Salwender, H; Scheid, C; Schick, M; Seckinger, A; Slawska, J; Stroh, J; Weisel, K | 1 |
| Adelman, K; Amaka, S; de Leval, L; Donaldson, NL; Donovan, KA; Duffy, J; Fischer, ES; Gaulard, P; Hagner, PR; Heavican-Foral, TB; Iqbal, J; Jain, S; Jones, MK; Koch, R; Liu, H; Nelson, GM; Ng, SY; Nirmal, AJ; Nowak, RP; Powers, F; Stevenson, KE; Thakurta, A; Trevisani, C; Weinstock, DM; Wu, G; Wu, W; Xu, R; Yang, L | 1 |
| Baljevic, M; Callander, NS; Castillo, JJ; Hillengass, J; Kumar, SK; Lim, MY; Martin, T; Sborov, DW; Streiff, MB | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Ali, NA; Chan, O; Komrokji, R; Lancet, J; Padron, E; Sallman, D | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Cheng, S; Fan, W; Ge, Y; Huang, L; Jiang, S; Liang, D; Zhu, X | 1 |
| Certan, M; Garcia Garrido, HM; Goorhuis, A; Grobusch, MP; Heijmans, J; Wong, G | 1 |
| Goede, JS; Wilk, CM | 1 |
| Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Aul, C; Bock, O; Buesche, G; Ebert, BL; Ganser, A; Germing, U; Giagounidis, A; Göhring, G; Kreipe, H; Ribezzo, F; Schlegelberger, B; Schneider, RK; Teoman, H | 1 |
| Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K | 1 |
| Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A | 1 |
| Buonomo, M; El Jurdi, N; Giubellino, A; Kabbur, G; Schultz, B | 1 |
| Daver, N; DiNardo, CD; Ebert, BL; Furudate, K; Futreal, PA; Garcia-Manero, G; Guerra, VA; Gumbs, C; Hsu, JI; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Kennedy, JA; Little, L; McConkey, ME; Miller, PG; Nguyen, AT; Quevedo Barrios, VA; Ravandi, F; Sperling, AS; Takahashi, K; Wang, F; Yan, Y; Zhang, J; Zhang, L | 1 |
| Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C | 1 |
| Antonioli, E; Ballanti, S; Belotti, A; Boccadoro, M; Bonalumi, A; Botta, C; Bringhen, S; Brunori, M; Bruzzese, A; Califano, C; Cascavilla, N; Cavo, M; Cerchione, C; Consoli, U; Conticello, C; Criscuolo, C; Cupelli, L; Curci, P; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Farina, G; Frigeri, F; Gagliardi, A; Galli, M; Gamberi, B; Gangemi, D; Gentile, M; Giuliani, N; Iaccino, E; Lombardo, A; Mangiacavalli, S; Marcacci, G; Martino, EA; Martino, M; Mele, G; Mendicino, F; Mimmi, S; Morabito, F; Musto, P; Neri, A; Offidani, M; Palmieri, S; Palumbo, G; Patriarca, F; Petrucci, MT; Pietrantuono, G; Pompa, A; Ria, R; Rocco, S; Rossi, E; Sgherza, N; Stocchi, R; Tripepi, G; Uccello, G; Vigna, E; Vincelli, D; Zamagni, E; Zambello, R | 1 |
| Patrick, H; Ramasamy, K; Rashid, S | 1 |
| Beach, CL; Fenaux, P; Franco-Villalobos, C; Giagounidis, A; Hu, A; Morison, J; Pelligra, CG; Platzbecker, U; Santini, V; Tang, D | 1 |
| Arai, A; Miura, I; Sakai, H | 1 |
| Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H | 1 |
| Alwafi, H; Awawdeh, SA; Liew, D; Naser, AY; Ofori-Asenso, R; Qadus, S | 1 |
| Costa, BA; Mouhieddine, TH; Richter, J | 1 |
| Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG | 1 |
| Ito, T | 1 |
| Atta, M; Deplano, S; Innes, A; McVinnie, K; Nadal-Melsio, E | 1 |
| Afari, J; Berenson, JR; Bessudo, A; Cohen, A; Eades, BM; Eshaghian, S; Gabrail, N; Jhangiani, H; Kim, C; Kim, S; Kubba, S; Neidhart, JD; Spektor, TM; Swift, RA; Turner, C; Vescio, R | 1 |
| Abdelmagid, M; Al-Kali, A; Badar, T; Begna, K; Elliott, MA; Fleti, F; Foran, JM; Gangat, N; Ketterling, RP; Khera, N; Pardanani, A; Reichard, KK; Singh, A; Tefferi, A | 1 |
| Cardis, MA; Kirkorian, AY; Sherman, MA; Srinivasalu, H | 1 |
| Bonanni, F; Breccia, M; Buccisano, F; Cicconi, L; Criscuolo, M; Di Veroli, A; Fenu, S; Fianchi, L; Gumenyuk, S; Gurnari, C; Latagliata, R; Maciejewski, JP; Maiorana, G; Maurillo, L; Niscola, P; Piccioni, AL; Piciocchi, A; Piedimonte, M; Salutari, P; Santopietro, M; Sarlo, C; Scalzulli, E; Soddu, S; Tafuri, A; Voso, MT | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Chiba, A; Honda, A; Ikemura, M; Kurokawa, M; Maki, H; Masamoto, Y; Oyama, T; Taoka, K | 1 |
| Dubin, DP; Gulati, N; Han, J; Jagannath, S; Owji, S; Parekh, S; Tan, K; Yassky, D | 1 |
| Flaxman, HA; Ichikawa, S; Lloyd, HC; Pratt, MR; Shen, D; Vallavoju, N; Wang, B; Woo, CM; Xu, W | 1 |
| Chakraborty, S; Park, CY | 1 |
| Bæch-Laursen, C; Eskelund, CW; Favero, F; Grønbæk, K; Husby, S; Hutchings, M; Jerkeman, M; Jespersen, JS; Kolstad, A; Larsen, TS; Niemann, CU; Pedersen, LB; Räty, R; Weischenfeldt, J | 1 |
| Fuchs, A; Hui, JY; Kumar, G | 1 |
| Lin, Z; Shen, D; Woo, CM; Yang, B | 1 |
| Borsi, E; Bratosin, F; Cerbu, B; Costachescu, D; Negrean, RA; Potre, C; Potre, O; Samfireag, M; Secosan, C | 1 |
| Dhamija, P; Handu, S; Kumar, V; Nath, UK; Prakash, A; Sahu, PL; Vardhan, G | 1 |
| Jiang, B; Kong, Y; Liu, H; Liu, L; Qiu, X; Ren, C; Sun, R; Yang, X; Zhou, Y | 1 |
| Beksac, M; Gurman, G; Ilhan, O; Koyun, D; Seval, GC; Topcuoglu, P; Yuksel, MK | 1 |
| Corvatta, L; Manieri, MV; Morè, S; Offidani, M; Olivieri, A | 1 |
| Bergsagel, PL; Meermeier, EW | 1 |
| Alaibac, M; Gnesotto, L; Mioso, G; Piaserico, S; Russo, I | 1 |
| Costa, L; Kapur, R; Mohyuddin, GR | 1 |
| Li, M; Wang, Q; Wang, X; Zeng, X | 1 |
| González-Calle, V; Mateos, MV | 1 |
| Anagnostopoulos, A; Arcese, W; Beksac, M; Bolaman, AZ; Bulabois, CE; Bunjes, D; Deconinck, E; Delforge, M; Eikema, DJ; Fenk, R; Gagelmann, N; Hayden, PJ; Itälä-Remes, M; Koster, L; Labussière-Wallet, H; Lund, J; McDonald, A; Nabil, Y; Netelenbos, T; Reményi, P; Schönland, S; Stoppa, AM; Thurner, L; van Gorkom, G; Yakoub-Agha, I | 1 |
| Brazauskas, R; D'Souza, A; Dong, J; Dwinell, MB; Giralt, S; Janz, S; Krishnan, A; Landau, H; Mohan, M; Pasquini, MC; Stadtmauer, E; Teng, BQ; Yun, G | 1 |
| Donarska, B; Mizerska-Kowalska, M; Płaziński, W; Sławińska-Brych, A; Zdzisińska, B; Łączkowski, KZ | 1 |
| Bardin, C; Hulin, C; Madelaine, I; Moreau, P; Rioufol, C; Slimano, F; Tournamille, JF | 1 |
| Katayama, S; Ota, M; Yamaga, M | 1 |
| Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF | 1 |
| Arévalo, CE; Arnan, M; Arribas, I; Baca, C; Bosch, A; Carro, I; Gamundi, E; Granada, I; Maluquer, C; Montané, C; Pomares, H; Ribes-Amorós, J; Sureda, A; Zamora, L | 1 |
| Aoki, Y; Minehata, K; Motegi, Y; Uno, S | 1 |
| Filanovsky, K; Shvidel, L; Stanevsky, A; Temper, N | 1 |
| Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K | 1 |
| Anderson, LD; Bumma, N; Chari, A; Cortoos, A; Costa, LJ; Costello, C; Cowan, AJ; Dinner, S; Efebera, YA; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Nathwani, N; Orlowski, RZ; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Usmani, SZ; Voorhees, PM; Wildes, TM | 1 |
| Akdeniz, A; Aslan, C; Aslaner Ak, M; Bağcı, M; Çeneli, Ö; Dağlı, M; Dal, MS; Demircioğlu, S; Doğan, A; Erol, HA; Ertop, Ş; Gedük, A; Gürsoy, V; Keklik Karadağ, F; Merter, M; Oruç Uysal, A; Özkalemkaş, F; Saydam, G; Seçilmiş, S; Tekinalp, A; Terzi Demirsoy, E; Ural, C | 1 |
596 review(s) available for thalidomide and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2002 |
Potential new therapeutics for Waldenstrom's macroglobulinemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lenalidomide; Ligases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Thalidomide; Ubiquitin-Protein Ligases; Waldenstrom Macroglobulinemia | 2003 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
The role of immunomodulatory drugs in multiple myeloma.
Topics: Adjuvants, Immunologic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Screening Assays, Antitumor; Female; Humans; Immunotherapy; Lenalidomide; Male; Mice; Mice, Mutant Strains; Mice, Nude; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2003 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities | 2003 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
CC-5013 (Celgene).
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drugs, Investigational; Humans; Lenalidomide; Neoplasms; Thalidomide | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia | 2005 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Topics: Aged; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Female; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2005 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
Topics: Chromosome Aberrations; Erythroid Cells; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Properties of thalidomide and its analogues: implications for anticancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Screening Assays, Antitumor; Endothelium, Vascular; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; T-Lymphocyte Subsets; Thalidomide | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Immunomodulatory drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neovascularization, Physiologic; Thalidomide | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Lenalidomide: patient management strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2005 |
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide | 2005 |
Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Female; Hematopoiesis; Humans; Lenalidomide; Male; Myeloproliferative Disorders; Prognosis; Thalidomide | 2006 |
Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; MEDLINE; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2006 |
Current therapeutic uses of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Lenalidomide: an immunomodulatory drug.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Thalidomide | 2005 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2006 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
Immunomodulating drugs for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Down-Regulation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Thalidomide | 2006 |
Thalidomide and lenalidomide in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
MDS: navigating the complex course.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Medical History Taking; Myelodysplastic Syndromes; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oncology Nursing; Physical Examination; Thalidomide | 2006 |
Lenalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Safety; Stem Cell Transplantation; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Advances in oral therapy in the treatment of multiple myeloma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Drug Monitoring; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Quality of Life; Thalidomide; Treatment Outcome | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Thalidomide and lenalidomide in multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Remission Induction; Thalidomide | 2006 |
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.
Topics: Drug Delivery Systems; Drug Design; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2006 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Treatment of the 5q- syndrome.
Topics: Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2006 |
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide; Thromboembolism | 2006 |
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
Topics: Chromosome Aberrations; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Thalidomide | 2007 |
Risk of thrombosis with lenalidomide and its prevention with aspirin.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2007 |
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
Topics: Algorithms; Anemia; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Thalidomide | 2006 |
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
Topics: Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Thalidomide | 2007 |
The evolving role of lenalidomide in the treatment of hematologic malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Hematologic Neoplasms; Humans; Lenalidomide; Leukemia; Myelodysplastic Syndromes; Thalidomide | 2007 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Azacitidine; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Differentiation; Endothelial Cells; Enzyme Inhibitors; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Monocytes; Myelodysplastic Syndromes; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
Myelodysplasia: the good, the fair and the ugly.
Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide | 2007 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Thalidomide; Treatment Outcome | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2007 |
Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma; Polyethylene Glycols; Recurrence; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Lenalidomide in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide | 2007 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2007 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure | 2007 |
Lenalidomide in the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Approval; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Patient Education as Topic; Thalidomide; United States | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Management of novel therapeutics' side effects: a nurse-centric model.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nursing; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Advocacy; Patient Education as Topic; Pyrazines; Thalidomide | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Topics: Antineoplastic Agents; Drug Monitoring; Early Diagnosis; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Primary Prevention; Risk Factors; Thalidomide; Thromboembolism | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2007 |
[Action mechanism of thalidomide in treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; DNA; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leprostatic Agents; NF-kappa B; Pregnancy; Teratogens; Thalidomide | 2007 |
[Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Design; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
Lenalidomide in multiple myeloma.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2008 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
Evaluating new treatment options for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2007 |
The role of lenalidomide in the management of myelodysplasia with del 5q.
Topics: Anemia, Refractory; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2008 |
Lenalidomide: a new therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Thalidomide | 2008 |
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Thalidomide | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
[Myelodysplastic syndrome].
Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization | 2008 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Humans; Immune System; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Lenalidomide in the treatment of multiple myeloma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Targeted therapies in Waldenström macroglobulinemia.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Proteasome Inhibitors; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2008 |
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Platelet Activation; Risk Assessment; Thalidomide; Thrombin; Thrombophilia; Thrombosis; Treatment Outcome; von Willebrand Factor | 2008 |
[Lenalidomide. Treatment of multiple myeloma].
Topics: Antineoplastic Agents; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Lenalidomide and its role in the management of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide | 2008 |
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Van-den Berghe's 5q- syndrome in 2008.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 5; Cytogenetics; Gene Deletion; Genes, Tumor Suppressor; Humans; Lenalidomide; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide | 2009 |
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom | 2009 |
Are new agents really making a difference in MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Waldenstrom Macroglobulinemia | 2009 |
Management of myelodysplastic syndromes: 2008 update.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Multiple myeloma: epidemiology and therapeutic options.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Medical Oncology; Multiple Myeloma; Patient Care Management; Prognosis; Thalidomide | 2008 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2008 |
Myelodysplastic syndromes: biology and treatment.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropoietin; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Sequence Deletion; Thalidomide; World Health Organization | 2009 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
Lenalidomide: a novel anticancer drug with multiple modalities.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Molecular Structure; Neoplasms; Thalidomide | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2009 |
Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.
Topics: Crohn Disease; Humans; Immunosuppressive Agents; Lenalidomide; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Tumor Necrosis Factor-alpha | 2009 |
Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.
Topics: Crohn Disease; Humans; Immunosuppressive Agents; Lenalidomide; Remission Induction; Thalidomide; Tumor Necrosis Factor-alpha | 2009 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Mechanism of action of lenalidomide in hematological malignancies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Hematologic Neoplasms; Humans; Immunomodulation; Lenalidomide; Models, Biological; Neovascularization, Pathologic; Signal Transduction; Thalidomide | 2009 |
Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Male; Prostatic Neoplasms; Thalidomide; Treatment Outcome | 2009 |
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
Topics: Antineoplastic Agents; Chronic Disease; Humans; Immunologic Factors; Lenalidomide; Leukemia, T-Cell; Thalidomide | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2009 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome | 2009 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2009 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Costs; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2010 |
Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Topics: Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Lenalidomide-induced acute liver failure.
Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lenalidomide; Liver Failure, Acute; Male; Myelodysplastic Syndromes; Organophosphonates; Thalidomide | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; T-Lymphocytes; Thalidomide; Treatment Outcome | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.
Topics: Antineoplastic Agents; Benzoates; Enzyme Inhibitors; Humans; Hydrazines; Lenalidomide; Methyltransferases; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide in multiple myeloma: current role and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Thalidomide | 2010 |
Pharmacological properties of thalidomide and its analogues.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Patents as Topic; Thalidomide | 2010 |
Novel agents in development for peripheral T-cell lymphoma.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide | 2010 |
Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Japan; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Multicenter Studies as Topic; Purine Nucleosides; Pyrimidinones; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Topics: Aged; Anemia; Animals; Apoptosis; Blood Transfusion; Bone Marrow; cdc25 Phosphatases; Cell Nucleus; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Erythropoiesis; Forecasting; G2 Phase; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Rats; Receptors, Erythropoietin; Thalidomide | 2010 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2010 |
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Thalidomide | 2010 |
[Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Humans; Immunoglobulin lambda-Chains; Lenalidomide; Melphalan; Paraneoplastic Syndromes, Nervous System; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2010 |
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?
Topics: Blood Transfusion; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Immunologic Factors; Lenalidomide; Multicenter Studies as Topic; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2006 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Disease Progression; Erythropoiesis; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk; Survival Analysis; Thalidomide | 2010 |
New agents in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; Flavonoids; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thalidomide | 2010 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine | 2010 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
[The use of lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Cost-effectiveness of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Thalidomide | 2010 |
The lower risk MDS patient at risk of rapid progression.
Topics: Age Factors; alpha Catenin; Antigens, Differentiation; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Caspase 3; Chromosome Aberrations; Cyclin-Dependent Kinase Inhibitor p15; Cytokines; DNA Methylation; Erythrocyte Transfusion; Female; Ferritins; Fibrosis; Gene Expression Regulation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Lenalidomide; Leukocyte Count; Lipoproteins, LDL; Lymphoid Enhancer-Binding Factor 1; Male; Microtubule-Associated Proteins; Mutation; Myelodysplastic Syndromes; Platelet Count; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Survivin; Thalidomide | 2010 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape | 2010 |
Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Topics: Antineoplastic Agents; Drug Administration Schedule; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
Thalidomide and lenalidomide in primary myelofibrosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Hematopoiesis; Humans; Janus Kinase 2; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
Lenalidomide: a synthetic compound with an evolving role in cancer management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Treatment Outcome | 2010 |
Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Thromboembolism; Warfarin | 2011 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide | 2010 |
The potential of immunomodulatory drugs in the treatment of solid tumors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Neoplasms; Thalidomide | 2010 |
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Pregnancy; Radiotherapy; Salvage Therapy; Thalidomide; Urinary Bladder; Urinary Bladder Neoplasms | 2010 |
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Genes; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Hodgkin's lymphoma: current treatment strategies and novel approaches.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Thalidomide; Transplantation, Homologous | 2008 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective.
Topics: Abnormalities, Drug-Induced; Contraception; Contraindications; Drug Industry; Female; Humans; Lenalidomide; Pregnancy; Risk Management; Thalidomide | 2011 |
Lenalidomide mode of action: linking bench and clinical findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Secondary Prevention; Thalidomide | 2010 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Humans; Immune System Diseases; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Microenvironment | 2011 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Thrombosis in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism | 2010 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Biology and treatment of the 5q- syndrome.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Deletion; Humans; Lenalidomide; Thalidomide | 2011 |
Maintenance therapy for B-chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Catechin; Curcumin; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thalidomide | 2011 |
Novel agents for the treatment of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Immunoglobulin G; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Thalidomide | 2010 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
Lenalidomide - current understanding of mechanistic properties.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Communication; Cell Proliferation; Cytokines; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Mice; Multiple Myeloma; Rats; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
Topics: Drug Discovery; History, 20th Century; History, 21st Century; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Neoplasms; Thalidomide; Treatment Outcome | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Management of lower-risk myelodysplastic syndromes: the art and evidence.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2011 |
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Multiple Myeloma; Prednisolone; Stevens-Johnson Syndrome; Thalidomide | 2012 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2012 |
[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Genes, p53; Haploidy; Humans; Lenalidomide; MicroRNAs; Molecular Targeted Therapy; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide | 2011 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2011 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Cytogenetic and molecular abnormalities in myelodysplastic syndrome.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chromosome Aberrations; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide | 2011 |
Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Immunomodulation; Lenalidomide; Neoplasms; Patents as Topic; Thalidomide | 2011 |
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2010 |
Continuous treatment in multiple myeloma - ready for prime time?
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Secondary Prevention; Thalidomide | 2011 |
Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Norway; Scotland; Sweden; Thalidomide | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2011 |
Treatment of higher-risk myelodysplastic syndrome.
Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide | 2011 |
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Haploinsufficiency; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
[Treatment of multiple myeloma by immunomodulatory drugs].
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2011 |
[Novel therapeutics for myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Antiangiogenesis in myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2011 |
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hyperthyroidism; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Iodine Radioisotopes; Ipilimumab; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Radioimmunotherapy; Recombinant Fusion Proteins; Recombinant Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Thyroiditis, Autoimmune | 2011 |
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Renal Insufficiency; Thalidomide; Time Factors | 2012 |
Lenalidomide in multiple myeloma: current experimental and clinical data.
Topics: Animals; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Humans; Immune System; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Osteoclasts; Thalidomide; Treatment Outcome | 2012 |
Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Treatment Outcome | 2011 |
Immunomodulating drugs in myelodysplastic syndromes.
Topics: Chromosome Deletion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2011 |
Clinical experience with thalidomide and lenalidomide in multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytokines; Down-Regulation; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2012 |
Immune reconstitution in chronic lymphocytic leukemia.
Topics: Adoptive Transfer; Antineoplastic Agents; CD40 Ligand; Genetic Therapy; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Thalidomide | 2012 |
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Thalidomide | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Risk Assessment; Thalidomide | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide | 2012 |
[MDS].
Topics: Azacitidine; Benzoates; Clinical Trials as Topic; Cytokines; Deferasirox; Drug Therapy, Combination; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Thrombopoietin; Treatment Outcome; Triazoles | 2012 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
[Lenalidomide in hematological malignancies---review].
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2012 |
Drug profiles.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Drug Approval; Drug Costs; Humans; Ipilimumab; Lenalidomide; Medical Oncology; Neoplasms; Paclitaxel; Thalidomide | 2012 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide | 2012 |
Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Prognosis; Pyrazines; Thalidomide | 2012 |
New developments in the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Vincristine; Vindesine | 2012 |
Thrombosis in multiple myeloma (MM).
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Thalidomide; Thrombosis | 2012 |
Lenalidomide for treatment of myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Drug-induced interstitial pneumonitis due to low-dose lenalidomide.
Topics: Aged; Antineoplastic Agents; Humans; Lenalidomide; Lung Diseases, Interstitial; Male; Thalidomide | 2012 |
Lenalidomide in solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Neoplasms; Thalidomide | 2012 |
The role of IMiDs alone or in combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Thalidomide | 2012 |
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Renal Insufficiency; Retrospective Studies; Thalidomide | 2012 |
Lenalidomide in multiple myeloma: Current status and future potential.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytokines; Disease Management; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; T-Lymphocytes; Thalidomide; Treatment Outcome | 2012 |
Autologous transplantation and management of younger patients with mantle cell lymphoma.
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Remission Induction; Rituximab; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Novel agents in Hodgkin lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide | 2012 |
Myelodysplastic syndromes: a challenging disease for patients and physicians.
Topics: Antineoplastic Agents; Blood Transfusion; Cytogenetics; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Stem Cell Transplantation; Thalidomide | 2012 |
[New tools and treatments in myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2013 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Novel lenalidomide-based combinations for treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Lenalidomide maintenance for multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2012 |
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thalidomide; Venous Thromboembolism | 2012 |
Waldenström macroglobulinemia: my way.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Pyrazines; Rituximab; Survival Analysis; Thalidomide; Waldenstrom Macroglobulinemia | 2013 |
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon-alpha; Lenalidomide; Lymphoma, Follicular; Pyrazines; Rituximab; Thalidomide; Tumor Microenvironment | 2012 |
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Karyotype; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Thalidomide | 2013 |
Novel agents in acute myeloid leukemia.
Topics: Antineoplastic Agents; Aurora Kinases; DNA Modification Methylases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Research Design; Thalidomide; Ubiquitin-Activating Enzymes | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
[Action mechanism of lenalidomide in hematological malignancies - review].
Topics: Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Thalidomide | 2012 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
Advances in the management of follicular lymphoma.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Management; Humans; Lenalidomide; Lymphoma, Follicular; Molecular Targeted Therapy; Rituximab; Standard of Care; Thalidomide | 2012 |
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Lenalidomide-associated hepatotoxicity--a case report and literature review.
Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Lenalidomide; Male; Thalidomide | 2012 |
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Light-chain amyloidosis: SCT, novel agents and beyond.
Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide | 2013 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Novel therapeutic strategies: hypomethylating agents and beyond.
Topics: Aged; Aged, 80 and over; Algorithms; Cell Transformation, Neoplastic; Comorbidity; Cytogenetics; DNA Methylation; Erythropoiesis; Hematology; Humans; Immunosuppressive Agents; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Remission Induction; Thalidomide; Treatment Outcome | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Thalidomide | 2012 |
[Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Novel immunomodulatory compounds in multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Molecular Structure; Multiple Myeloma; Thalidomide | 2013 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: a follow-up case report and overview of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Female; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
Lenalidomide as a novel treatment of acute myeloid leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide | 2013 |
Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Thalidomide | 2013 |
Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Proportional Hazards Models; Thalidomide; Treatment Outcome | 2013 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
[Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Topics: Amyloidosis; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Lenalidomide; Pyrazines; Thalidomide | 2013 |
Lenalidomide and thalidomide in the treatment of chronic pain.
Topics: Anti-Inflammatory Agents; Chronic Pain; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Lenalidomide; Thalidomide | 2013 |
Current approaches for the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide; Transplantation, Autologous | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Therapies for mantle cell lymphoma: current challenges and a brighter future.
Topics: Antibodies; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cyclin D1; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Thalidomide; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome | 2013 |
How we treat lower-risk myelodysplastic syndromes.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2013 |
Novel agents for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Thalidomide | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Pyrazines; Remission Induction; Thalidomide | 2013 |
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hypothyroidism; Interferon-alpha; Interleukin-2; Lenalidomide; Neoplasms; Recombinant Fusion Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Diseases; Thyroid Gland; Thyroid Hormones; Thyroxine | 2013 |
Tumor-induced host immunosuppression: special focus on CLL.
Topics: Antineoplastic Agents; Gene Expression Regulation; HLA-G Antigens; Humans; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
[Lenalidomide maintenance therapy in patients with multiple myeloma].
Topics: Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2013 |
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Topics: Angiogenesis Inhibitors; Exanthema; Humans; Incidence; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis | 2014 |
TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
Topics: Animals; Antibodies, Blocking; Clinical Trials as Topic; Drug Resistance; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Interferons; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide | 2013 |
[Rapid improvement of fluid retention with lenalidomide plus low-dose dexamethasone for POEMS syndrome relapsed after autologous peripheral blood stem cell transplantation].
Topics: Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Secondary Prevention; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunomodulation; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Thalidomide; Tumor Microenvironment | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Disease Progression; Erythropoiesis; Gene Dosage; Genes, Tumor Suppressor; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Recent advances in the management of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Patient Selection; Phosphatidylinositol 3-Kinases; Prognosis; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
[Chemotherapy-free treatment of chronic lymphocytic leukemia?].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials as Topic; Drugs, Investigational; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.
Topics: Agammaglobulinaemia Tyrosine Kinase; Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Immune Tolerance; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Thalidomide | 2014 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide | 2013 |
Lenalidomide and chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thalidomide | 2013 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Middle Aged; POEMS Syndrome; Thalidomide; Treatment Outcome | 2014 |
Myelodysplastic syndromes: diagnosis, prognosis, and treatment.
Topics: Blood Transfusion; Combined Modality Therapy; Humans; Immunologic Factors; Incidence; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2013 |
Initial treatment of transplant-ineligible patients in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chromosome Aberrations; Glucocorticoids; Humans; Immunophenotyping; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Quality of Life; Remission Induction; Thalidomide | 2014 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning | 2013 |
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Prognosis; Recurrence; Retreatment; Thalidomide; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
Accelerated therapeutic progress in diffuse large B cell lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Randomized Controlled Trials as Topic; Rituximab; Thalidomide | 2014 |
Update on second primary malignancies in multiple myeloma: a focused review.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Risk; Thalidomide | 2014 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Deletion 5q MDS: molecular and therapeutic implications.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Haploinsufficiency; Humans; Lenalidomide; Megakaryocytes; MicroRNAs; Myelodysplastic Syndromes; Phenotype; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53 | 2013 |
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2014 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic | 2014 |
New treatment options for chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Receptors, Antigen, B-Cell; Signal Transduction; Thalidomide | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Expression; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Practice Guidelines as Topic; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53 | 2014 |
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Topics: Animals; Catalytic Domain; Drug Design; Drug Screening Assays, Antitumor; Fluorescence Resonance Energy Transfer; Humans; Lenalidomide; Ligands; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Thalidomide; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases | 2014 |
Emerging drugs for T-cell lymphoma.
Topics: Alemtuzumab; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Azepines; Brentuximab Vedotin; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Lenalidomide; Lymphoma, T-Cell; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thalidomide | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment | 2014 |
An update on emerging drugs for Hodgkin lymphoma.
Topics: Brentuximab Vedotin; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Janus Kinases; Lenalidomide; Thalidomide; TOR Serine-Threonine Kinases | 2014 |
Lenalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide | 2014 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
[Application of lenalidomide in chronic lymphocytic leukemia].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2014 |
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.
Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2014 |
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Cancer Vaccines; CD40 Ligand; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2014 |
Update on the pharmacotherapy for myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide | 2014 |
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Topics: B-Lymphocytes; Biomarkers, Tumor; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Quinazolinones; T-Lymphocytes; Thalidomide | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases | 2011 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Depsipeptides; Diphtheria Toxin; Doxorubicin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Interleukin-2; Lenalidomide; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peptides, Cyclic; Prednisolone; Recombinant Fusion Proteins; Stem Cell Transplantation; Thalidomide; Topoisomerase Inhibitors; Vincristine | 2014 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Maintenance therapy for multiple myeloma.
Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Radionuclide Imaging; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
Managing multiple myeloma in the over 70s: a review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Density Conservation Agents; Bortezomib; Comorbidity; Cyclophosphamide; Dexamethasone; Diphosphonates; Fractures, Compression; Geriatric Assessment; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Palliative Care; Stem Cell Transplantation; Thalidomide; Vertebroplasty | 2015 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Management of relapsed multiple myeloma after autologous stem cell transplant.
Topics: Autografts; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Stem Cell Transplantation; Thalidomide | 2015 |
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Humans; Integrin alpha4; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Smith-Magenis Syndrome; Thalidomide; ZAP-70 Protein-Tyrosine Kinase | 2015 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2017 |
Waldenstrom macroglobulinemia: prognosis and management.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide | 2015 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide | 2015 |
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Overload; Janus Kinase 2; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Platelet Aggregation Inhibitors; Receptors, Thrombopoietin; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Thalidomide; Thrombocytosis | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
The risk of secondary primary malignancies after therapy for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Retreatment; Risk; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2015 |
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Topics: Biomarkers; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide; Tumor Microenvironment | 2015 |
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide for mantle cell lymphoma.
Topics: Angiogenesis Inhibitors; Animals; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Thalidomide | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Topics: Allografts; Bortezomib; Chemoradiotherapy; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Transplantation Conditioning | 2015 |
Treatment for patients with newly diagnosed multiple myeloma in 2015.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Precision Medicine; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2015 |
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical | 2015 |
An update on the use of lenalidomide for the treatment of multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2015 |
Where Does Lenalidomide Fit in Non-del(5q) MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Humans; Immunologic Factors; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Thalidomide; Treatment Outcome | 2015 |
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bortezomib; Cytokines; Dendritic Cells; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Hematopoiesis; Humans; Killer Cells, Natural; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Peptide Hydrolases; Rituximab; T-Lymphocytes; Thalidomide; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
Practical Management of Lenalidomide-Related Rash.
Topics: Exanthema; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Thalidomide | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Thalidomide | 2015 |
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Topics: Angiogenesis Inhibitors; B-Lymphocytes; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide | 2015 |
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Tumor Microenvironment | 2016 |
The novel mechanism of lenalidomide activity.
Topics: Animals; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Proteasome Endopeptidase Complex; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2015 |
Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Thalidomide | 2016 |
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literat
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Osteogenesis; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Thalidomide | 2015 |
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Topics: Angiogenesis Inhibitors; Animals; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Substrate Specificity; Thalidomide; Transcription, Genetic; Ubiquitination | 2015 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism | 2016 |
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Salvage Therapy; Thalidomide | 2016 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Postoperative Complications; Thalidomide; Venous Thromboembolism | 2016 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
Immunomodulatory drugs in AL amyloidosis.
Topics: Amyloidosis; Animals; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Salvage Therapy; Thalidomide | 2016 |
The evolving role of lenalidomide in non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide; Treatment Outcome | 2016 |
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Dexamethasone; Diphosphonates; Disease Progression; Europe; Humans; Immunoglobulin Light Chains; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Risk Factors; Thalidomide; Tumor Burden | 2016 |
[Lenalidomide nephrotoxicity].
Topics: Graft vs Host Disease; Humans; Immunologic Factors; Kidney; Kidney Tubules; Lenalidomide; Necrosis; Nephritis, Interstitial; Prevalence; Renal Insufficiency; Thalidomide | 2016 |
Therapy Effect: Impact on Bone Marrow Morphology.
Topics: Antineoplastic Agents; Atrophy; Bone Marrow; Cytokines; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myeloablative Agonists; Necrosis; Rituximab; Thalidomide | 2016 |
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
Topics: Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2016 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Risk; Thalidomide; Venous Thromboembolism | 2016 |
Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Combined Modality Therapy; Humans; Lenalidomide; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2015 |
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Receptors, Antigen, B-Cell; Thalidomide | 2016 |
Update of thrombosis in multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis; Warfarin | 2016 |
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2016 |
[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Castleman Disease; Drug Therapy, Combination; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Remission Induction; Rituximab; Thalidomide | 2016 |
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Outcome Assessment, Health Care; Recurrence; Rituximab; Thalidomide | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Hematologic Neoplasms; Humans; Kidney; Lenalidomide; Thalidomide | 2017 |
Lenalidomide for the treatment of B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Thalidomide | 2016 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Is Maintenance Therapy for Everyone?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Disease Management; Humans; Lenalidomide; Maintenance Chemotherapy; Molecular Targeted Therapy; Mortality; Multiple Myeloma; Proportional Hazards Models; Thalidomide; Treatment Outcome | 2016 |
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome | 2016 |
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Induction Chemotherapy; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2016 |
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Topics: Bortezomib; Consolidation Chemotherapy; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2016 |
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Risk Factors; Thalidomide; Thromboembolism; Thrombosis | 2017 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; DNA Methylation; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Thalidomide; Treatment Outcome | 2017 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Stem Cell Transplantation in Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
The role of maintenance therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2016 |
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Topics: Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2016 |
Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Complement System Proteins; Cytotoxicity, Immunologic; Humans; Lenalidomide; Multiple Myeloma; Phagocytosis; Thalidomide | 2016 |
Treatment of low-risk myelodysplastic syndromes.
Topics: Allografts; Blood Transfusion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2016 |
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.
Topics: Azacitidine; Drug Resistance; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Lenalidomide; Male; Plasmablastic Lymphoma; Prognosis; Thalidomide; Treatment Outcome | 2017 |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2017 |
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2017 |
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Topics: Alveolitis, Extrinsic Allergic; Angioedema; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Tomography, X-Ray Computed | 2016 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progression; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2017 |
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Topics: Animals; B7-H1 Antigen; Disease Progression; Humans; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Thalidomide | 2017 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism | 2017 |
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2017 |
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Molecular Targeted Therapy; Multiple Myeloma; Postoperative Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Two cases of permanent indwelling catheter for long-term administration of intrapleural chemotherapy.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Catheters, Indwelling; Dexamethasone; Drainage; Fatal Outcome; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Pleural Effusion, Malignant; Rituximab; Thalidomide; Thoracentesis | 2017 |
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thalidomide | 2017 |
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Incidence; Infections; Lenalidomide; Mortality; Multiple Myeloma; Publication Bias; Risk; Severity of Illness Index; Thalidomide | 2017 |
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2017 |
Daratumumab for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk; Risk Assessment; Thalidomide; Thromboembolism | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Topics: Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2017 |
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2017 |
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome.
Topics: Angiogenesis Inhibitors; Biomarkers; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Thalidomide | 2017 |
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Protein degradation: a validated therapeutic strategy with exciting prospects.
Topics: Adaptor Proteins, Signal Transducing; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Discovery; Humans; Lenalidomide; Ligands; Models, Molecular; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Binding; Protein Conformation; Proteins; Proteolysis; Small Molecule Libraries; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders.
Topics: Binding Sites; Crystallography, X-Ray; Drug Design; Drug Discovery; Humans; Lenalidomide; Ligands; Models, Molecular; Protein Binding; Protein Conformation; Protein Engineering; Proteins; Proteolysis; Small Molecule Libraries; Structure-Activity Relationship; Thalidomide | 2017 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
POEMS Syndrome: Therapeutic Options.
Topics: Allografts; Humans; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Radiotherapy; Thalidomide | 2018 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide | 2018 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Transplantation, Autologous; Vorinostat | 2017 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Current treatment algorithm for the management of lower-risk MDS.
Topics: Algorithms; Allografts; Erythrocyte Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transforming Growth Factor beta | 2017 |
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Boron Compounds; Dexamethasone; Glycine; Half-Life; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Salvage Therapy; Thalidomide; Tissue Distribution | 2018 |
Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
Topics: Adult; Aged; Bortezomib; Humans; Immunoglobulin Light-chain Amyloidosis; Intestinal Perforation; Lenalidomide; Male; Middle Aged; Thalidomide | 2018 |
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Factors; Immunosuppressive Agents; Incidence; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Opportunistic Infections; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2018 |
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Treatment Outcome | 2018 |
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Thalidomide | 2018 |
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; B7-H1 Antigen; Humans; Immunologic Factors; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Thalidomide | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2018 |
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
[Daratumumab for multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2018 |
[Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Topics: Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide | 2018 |
[First-line treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bortezomib; Germany; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2019 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Risk adapted post-transplant maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
[Immunomodulator drugs for the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2019 |
Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Combined Modality Therapy; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Quality-Adjusted Life Years; Stem Cell Transplantation; Thalidomide | 2019 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Retrospective Studies; Thalidomide | 2021 |
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Network Meta-Analysis; Thalidomide; Treatment Outcome | 2020 |
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide | 2019 |
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Marrow; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2019 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Second malignancies in multiple myeloma; emerging patterns and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous | 2020 |
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Risk Factors; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2020 |
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalidomide | 2020 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2020 |
Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Consensus; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; New Zealand; Practice Guidelines as Topic; Thalidomide | 2020 |
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Ikaros Transcription Factor; Immunity; Immunomodulation; Lenalidomide; Lymphocytes; Mice; Multiple Myeloma; Thalidomide | 2021 |
Implementation of a Pregnancy Prevention Programme (PPP) with a Controlled Distribution System (CDS) for the Generic Teratogenic Phthalimides Thalidomide, Lenalidomide and Pomalidomide.
Topics: Child; Female; Humans; Infant, Newborn; Lenalidomide; Phthalimides; Pregnancy; Teratogens; Thalidomide | 2021 |
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Pharmacovigilance; Prednisone; Rituximab; Thalidomide | 2022 |
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Topics: Anticoagulants; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboembolism | 2022 |
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.
Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Proteasome Endopeptidase Complex; Thalidomide; Ubiquitin | 2022 |
Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis.
Topics: Humans; Lenalidomide; Medication Adherence; Melphalan; Multiple Myeloma; Panobinostat; Pharmaceutical Preparations; Thalidomide | 2022 |
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Salvage Therapy; Thalidomide | 2022 |
[Development of novel cereblon modulators and their target molecules].
Topics: Adaptor Proteins, Signal Transducing; Female; Humans; Lenalidomide; Peptide Hydrolases; Pregnancy; Thalidomide; Ubiquitin-Protein Ligases | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
Topics: Humans; Lenalidomide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2023 |
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
479 trial(s) available for thalidomide and lenalidomide
| Article | Year |
|---|---|
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2002 |
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytokines; Female; Fibroblast Growth Factor 2; Humans; Immunization; Lenalidomide; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Safety; Skin Neoplasms; T-Lymphocytes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Topics: Administration, Oral; Humans; Lenalidomide; Male; Neoplasm Metastasis; Palliative Care; Prostatic Neoplasms; Research Design; Thalidomide | 2004 |
Efficacy of lenalidomide in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Angiogenesis Inhibitors; Bone Marrow; Female; Gene Deletion; Hematopoiesis; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2005 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2005 |
CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Dexamethasone; Double-Blind Method; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Patient Selection; Placebos; Salvage Therapy; Thalidomide | 2003 |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Topics: Administration, Oral; Adult; Aged; Anemia; Anemia, Myelophthisic; Female; Hemoglobins; Humans; Janus Kinase 2; Lenalidomide; Male; Neovascularization, Pathologic; Neutropenia; Platelet Count; Point Mutation; Primary Myelofibrosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Remission Induction; Sequence Deletion; Splenomegaly; Thalidomide; Thrombocytopenia; Time Factors | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Thalidomide; Venous Thrombosis | 2006 |
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Neoplasms; Thalidomide | 2006 |
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Thalidomide | 2006 |
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Predictive Value of Tests; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2006 |
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2006 |
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thalidomide; Thrombocytopenia | 2006 |
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Thalidomide | 2007 |
Phase I study of lenalidomide in solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Neoplasms; Thalidomide; Treatment Outcome | 2007 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Vincristine | 2007 |
A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Topics: Adolescent; Adult; Aged; Crohn Disease; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Placebos; Severity of Illness Index; Thalidomide; Treatment Outcome; Venous Thrombosis | 2007 |
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide | 2007 |
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome | 2008 |
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease Progression; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kidney; Kidney Failure, Chronic; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Severity of Illness Index; Stereoisomerism; Tandem Mass Spectrometry; Thalidomide | 2007 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Time Factors | 2008 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide | 2007 |
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide | 2007 |
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2008 |
Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
Topics: Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kidney Diseases; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cytokines; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; T-Lymphocytes; Thalidomide | 2008 |
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Lenalidomide; Male; Middle Aged; Pilot Projects; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide therapy for metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Fatigue; Female; Hematologic Diseases; Humans; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Survival Rate; Thalidomide | 2008 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cells; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide | 2008 |
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; Spectrometry, Mass, Electrospray Ionization; Thalidomide; Time Factors | 2008 |
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs.
Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Forkhead Transcription Factors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; T-Lymphocytes, Regulatory; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2009 |
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 13; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Remission Induction; Thalidomide; Trisomy | 2009 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Drug Approval; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Placebos; Thalidomide; United States; United States Food and Drug Administration | 2008 |
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Taxoids; Thalidomide; Treatment Outcome; Young Adult | 2009 |
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2008 |
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Lenalidomide; Male; Middle Aged; Neutropenia; Rituximab; Thalidomide; Thrombocytopenia; Waldenstrom Macroglobulinemia | 2009 |
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Treatment Outcome | 2009 |
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Disease-Free Survival; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Thalidomide | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Biological; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Chromosome Deletion; Chromosomes, Human, Pair 5; Chronic Disease; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Retreatment; Skin Neoplasms; Survival Analysis; Thalidomide | 2009 |
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; B7-1 Antigen; Cytokines; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Syndrome; Thalidomide; Time Factors; Up-Regulation | 2009 |
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Topics: Adult; Antineoplastic Agents; Cisplatin; Compassionate Use Trials; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Thalidomide; Treatment Outcome | 2010 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recurrence; Retreatment; Skin Neoplasms; Thalidomide | 2010 |
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Staging; Recurrence; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2010 |
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; B-Lymphocytes; BH3 Interacting Domain Death Agonist Protein; CD40 Ligand; Cells, Cultured; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunophenotyping; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; NFATC Transcription Factors; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Stability; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Tumor Protein p73; Tumor Suppressor Proteins | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytogenetics; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prognosis; Recurrence; Risk; Thalidomide; Treatment Outcome | 2010 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide | 2010 |
Distribution of lenalidomide into semen of healthy men after multiple oral doses.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Lenalidomide; Male; Middle Aged; Semen; Tandem Mass Spectrometry; Thalidomide; Young Adult | 2010 |
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Precancerous Conditions; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome; United States | 2010 |
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Ribosomal Proteins; Risk Factors; Thalidomide; Transcription, Genetic | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Thalidomide; Treatment Outcome | 2010 |
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Thalidomide | 2010 |
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Thalidomide | 2010 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clarithromycin; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide; Thrombocytopenia | 2010 |
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide | 2010 |
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Thalidomide | 2010 |
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Rate; Thalidomide | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Thalidomide | 2010 |
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Double-Blind Method; Humans; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Testosterone; Thalidomide | 2010 |
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2011 |
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Lenalidomide; Male; Middle Aged; Risk Factors; Thalidomide | 2011 |
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Recurrence; Thalidomide; Young Adult | 2011 |
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Immunity, Cellular; Infant; Lenalidomide; Maximum Tolerated Dose; Myelodysplastic Syndromes; Neoplasms; Recurrence; Salvage Therapy; Thalidomide; Young Adult | 2011 |
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; International Agencies; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Treatment Outcome; Young Adult | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2012 |
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Cross-Sectional Studies; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Spain; Survival Rate; Thalidomide | 2011 |
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neutropenia; Prospective Studies; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2011 |
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Female; Humans; Immunity, Cellular; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Thalidomide; Treatment Outcome | 2011 |
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Thalidomide; Topotecan | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide | 2011 |
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neutropenia; Patient Dropouts; Survival Analysis; Thalidomide | 2011 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oncogene Protein p21(ras); Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; WT1 Proteins | 2011 |
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Rituximab; Survival Rate; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Male; Neoadjuvant Therapy; Thalidomide | 2011 |
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Humans; Immunomodulation; Interleukin-8; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Thalidomide | 2012 |
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Double-Blind Method; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide | 2011 |
Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Blood Coagulation; Endothelium, Vascular; Female; Humans; Inflammation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Risk Factors; Thalidomide; Tumor Necrosis Factor-alpha; Up-Regulation; Venous Thrombosis | 2011 |
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Interactions; Humans; Lenalidomide; Maximum Tolerated Dose; Multiple Myeloma; Neoplasm Recurrence, Local; Sirolimus; Survival Rate; Thalidomide; Tissue Distribution; Treatment Outcome | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Enoxaparin; Female; Humans; Incidence; Israel; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation Inhibitors; Pulmonary Embolism; Risk Factors; Thalidomide; Venous Thromboembolism; Venous Thrombosis | 2012 |
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Rituximab; Thalidomide | 2011 |
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Dexamethasone; Female; Gene Expression Profiling; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Survival Analysis; Thalidomide | 2011 |
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL17; Chemokine CCL22; Disease-Free Survival; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Stem Cell Transplantation; Thalidomide | 2011 |
Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Topics: B7-1 Antigen; B7-2 Antigen; CD40 Ligand; Cytokines; Humans; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; MAP Kinase Signaling System; Thalidomide; Up-Regulation | 2011 |
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytokines; DNA Methylation; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Thalidomide; Treatment Outcome | 2012 |
Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
Topics: Absorption; Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Biological Availability; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Humans; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Thalidomide; Tissue Distribution; Young Adult | 2012 |
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neovascularization, Pathologic; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2012 |
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide; Young Adult | 2012 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Gossypol; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thalidomide; Tumor Cells, Cultured | 2012 |
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematinics; Humans; Karyotype; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Thalidomide; Treatment Failure; Treatment Outcome | 2012 |
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Cohort Studies; Female; Humans; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumococcal Vaccines; T-Lymphocytes; Thalidomide; Vaccines, Conjugate | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Quality of Life; Recurrence; Spain; Surveys and Questionnaires; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunotherapy, Adoptive; Lenalidomide; Living Donors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Heart Diseases; Humans; Immunoglobulin Light Chains; Kidney Diseases; Lenalidomide; Male; Middle Aged; Thalidomide; Time Factors; Treatment Outcome | 2012 |
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Hematologic Tests; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Thalidomide | 2012 |
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Female; Glutathione; Glutathione Transferase; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2012 |
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphatidylinositol 3-Kinase; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Thalidomide; Treatment Outcome | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypophosphatemia; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide | 2012 |
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Rituximab; Thalidomide | 2012 |
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells.
Topics: 5'-Nucleotidase; Adipogenesis; Adult; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Chemokine CXCL12; Female; GPI-Linked Proteins; Hematologic Neoplasms; Humans; Integrin beta1; Lenalidomide; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Osteogenesis; Thalidomide; Transplantation, Homologous | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Thalidomide; Young Adult | 2013 |
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Interleukin-10; Interleukin-12 Subunit p40; Lenalidomide; Leukocyte Count; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Sex Characteristics; Sex Factors; Survival Rate; Thalidomide; United Kingdom | 2012 |
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Thalidomide; Treatment Outcome | 2013 |
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; DNA Mutational Analysis; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Risk; Severity of Illness Index; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross-Over Studies; Dietary Fats; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Half-Life; Humans; Japan; Lenalidomide; Male; Stereoisomerism; Thalidomide; Time Factors; White People; Young Adult | 2012 |
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Thalidomide; Treatment Outcome | 2013 |
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Topics: Aged; Anemia, Macrocytic; Apoptosis; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Forkhead Transcription Factors; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation; Genetic Association Studies; Humans; Immunity, Innate; Lenalidomide; Male; MicroRNAs; Models, Genetic; Myelodysplastic Syndromes; Ribosomal Proteins; Signal Transduction; Thalidomide | 2013 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide | 2013 |
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thalidomide | 2012 |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Drug Synergism; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Middle Aged; Monocytes; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Thalidomide; Treatment Outcome | 2013 |
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin | 2012 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide | 2013 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Remission Induction; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Thalidomide; Treatment Outcome; Vomiting | 2012 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide | 2013 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Humans; Immunologic Factors; Infections; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Health Status; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Quality of Life; Risk; Severity of Illness Index; Thalidomide; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2013 |
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide; Treatment Outcome | 2013 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome | 2013 |
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Consolidation Chemotherapy; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoadjuvant Therapy; Recovery of Function; Retrospective Studies; T-Lymphocytes; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Apoptosis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 5; Disease-Free Survival; Erythroblasts; Female; Gene Expression Regulation; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Ribosomal Proteins; Survival Rate; Thalidomide | 2013 |
Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dendritic Cells; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Survival Analysis; T-Lymphocytes, Regulatory; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Rituximab; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2013 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Middle Aged; Remission Induction; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Germany; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Humans; Lenalidomide; Male; Middle Aged; Moxifloxacin; Quinolines; Thalidomide; Young Adult | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Thalidomide | 2013 |
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide | 2013 |
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Topics: Aged; Aged, 80 and over; Amyloidosis; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Heart Diseases; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Pilot Projects; Survival Rate; Thalidomide | 2013 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Thalidomide; Time Factors; Treatment Outcome | 2013 |
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sorafenib; Thalidomide; Young Adult | 2014 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Neoplasm, Residual; Remission Induction; T-Lymphocytes; Thalidomide; Time Factors | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Doxorubicin; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2013 |
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk; Survival Rate; Thalidomide | 2013 |
Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cohort Studies; Dexamethasone; Female; Flow Cytometry; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Sirolimus; Thalidomide; TOR Serine-Threonine Kinases; Young Adult | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide | 2013 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Polyethylene Glycols; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Topics: Cytokines; Female; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Count; Male; Multiple Myeloma; Natural Killer T-Cells; Thalidomide | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Combined Modality Therapy; Cost-Benefit Analysis; Data Collection; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Quality of Life; Thalidomide; Transplantation, Autologous; Young Adult | 2013 |
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Topics: Administration, Intravenous; Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Cell Survival; Endothelial Cells; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thalidomide | 2014 |
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2014 |
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide; Time Factors | 2013 |
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Humans; Lenalidomide; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide | 2013 |
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Remission Induction; Salvage Therapy; Thalidomide; Thrombosis; Treatment Outcome; Vincristine | 2014 |
Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mycosis Fungoides; Sezary Syndrome; Thalidomide; Treatment Outcome | 2014 |
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Thalidomide | 2014 |
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Thalidomide; Thrombocytopenia; Vorinostat | 2014 |
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Patient Safety; Prospective Studies; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymorphism, Genetic; Receptors, IgG; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Treatment Outcome | 2014 |
No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Healthy Volunteers; Humans; Lenalidomide; Male; Middle Aged; Thalidomide; Young Adult | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.
Topics: Administration, Oral; Aged; Amyloidosis; Angiogenesis Inhibitors; Dexamethasone; Dialysis; Drug Administration Schedule; Female; Humans; Kidney Diseases; Lenalidomide; Male; Middle Aged; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Receptors, Tumor Necrosis Factor, Type II; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2014 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Sirolimus; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Disease Progression; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A | 2014 |
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi- center phase II study of lenalidomide plus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Thalidomide | 2014 |
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib; Thalidomide; Treatment Outcome | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Phenotype; Prednisone; Prognosis; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Thalidomide; Treatment Outcome | 2015 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide | 2014 |
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Stem Cell Transplantation; Thalidomide | 2014 |
Lenalidomide for complex regional pain syndrome type 1: lack of efficacy in a phase II randomized study.
Topics: Aged; Analgesics, Non-Narcotic; Chronic Disease; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Reflex Sympathetic Dystrophy; Thalidomide; Treatment Outcome | 2014 |
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2015 |
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anemia; Dexamethasone; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Survival Analysis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hypothyroidism; Immunologic Factors; Interferon-gamma; Interleukin-12; Interleukin-15; Interleukin-6; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha | 2015 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Proteasome Inhibitors; Safety; Survival Rate; Thalidomide | 2014 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2015 |
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukocytes; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Grading; Receptors, IgG; Retreatment; Rituximab; T-Lymphocytes, Regulatory; Thalidomide; Treatment Outcome; Tumor Burden | 2015 |
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Recurrence; Thalidomide; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Nucleophosmin; Thalidomide; Treatment Outcome | 2015 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Thalidomide; Treatment Outcome; Valproic Acid | 2015 |
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine | 2015 |
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
Topics: Administration, Metronomic; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Early Termination of Clinical Trials; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Prospective Studies; Recurrence; Retreatment; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome; Young Adult | 2015 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; China; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Thalidomide | 2015 |
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Receptors, IgG; Squamous Cell Carcinoma of Head and Neck; Thalidomide; Treatment Outcome | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Cell Proliferation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Survival Rate; Thalidomide | 2015 |
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immune System; Immunoglobulin G; Immunotherapy; Killer Cells, Natural; Lenalidomide; Ligands; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, KIR; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Purines; Quinazolinones; Rituximab; Thalidomide | 2015 |
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Myelodysplastic Syndromes; Reproducibility of Results; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2015 |
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interferon Regulatory Factor-7; Interferons; Lenalidomide; Lentivirus; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Molecular Mimicry; Peptide Hydrolases; Piperidones; Proteolysis; Quinazolinones; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thalidomide; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Vorinostat | 2015 |
Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
Topics: Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Male; Middle Aged; Prothrombin Time; Thalidomide; Warfarin; Young Adult | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Receptors, Immunologic; Recurrence; Signaling Lymphocytic Activation Molecule Family; Thalidomide | 2015 |
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Thalidomide; Vorinostat | 2015 |
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide | 2015 |
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Female; Fibrin Fibrinogen Degradation Products; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maryland; Middle Aged; Multiple Myeloma; National Institutes of Health (U.S.); Neoplasm, Residual; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Risk Factors; Thalidomide; Time Factors; Treatment Outcome; United States | 2015 |
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drugs, Investigational; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Retrospective Studies; Risk Assessment; Thalidomide | 2015 |
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Prospective Studies; Rituximab; Thalidomide | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Progression; Disease-Free Survival; Female; Heparin; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Rituximab; Thalidomide; Thrombosis; Treatment Outcome | 2015 |
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Bone Marrow; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Thalidomide; Treatment Outcome | 2016 |
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Topics: Adult; Aged; Autografts; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide | 2016 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Quality of Life; Rituximab; Survival Analysis; Thalidomide | 2015 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2015 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome | 2016 |
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lenalidomide; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Thalidomide; Treatment Outcome | 2016 |
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Proliferation; Demography; Dexamethasone; Female; Humans; Immunophenotyping; Induction Chemotherapy; Killer Cells, Natural; Lenalidomide; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Risk Factors; T-Lymphocytes; Thalidomide | 2016 |
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2016 |
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Demography; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bevacizumab; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Thalidomide | 2016 |
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Female; Humans; Kidney Diseases; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retreatment; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment | 2016 |
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lenalidomide; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2016 |
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Survival Rate; Thalidomide | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.
Topics: Aged; Aged, 80 and over; Dexamethasone; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide | 2016 |
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide | 2016 |
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Peripheral; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Young Adult | 2016 |
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Thalidomide | 2016 |
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Response Evaluation Criteria in Solid Tumors; Thalidomide | 2016 |
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Thalidomide; Vincristine | 2016 |
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio
Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Exanthema; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Quality of Life; Thalidomide; Thrombocytopenia | 2016 |
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prevalence; Prospective Studies; Thalidomide; Tumor Suppressor Protein p53 | 2016 |
Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions.
Topics: Adult; Angiogenesis Inhibitors; Antigens, Viral; Biomarkers, Tumor; Case-Control Studies; Chemokine CXCL12; Female; Humans; Lenalidomide; Male; Nuclear Proteins; Receptors, CXCR; Receptors, CXCR4; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide; Vascular Endothelial Growth Factor A | 2016 |
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Rituximab; Salvage Therapy; Thalidomide | 2016 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide | 2016 |
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infections; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Salvage Therapy; Thalidomide | 2016 |
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Renal Insufficiency; Thalidomide | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide | 2016 |
[Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF].
Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Fibroblast Growth Factor 2; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Vascular Endothelial Growth Factor A | 2016 |
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Double-Blind Method; Drug Resistance; Erythrocyte Transfusion; Erythropoiesis; Female; Gene Expression; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide | 2016 |
Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
Topics: Angiogenesis Inhibitors; Bone Marrow; Consolidation Chemotherapy; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myelopoiesis; Thalidomide | 2016 |
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Risk Factors; Survival Rate; Thalidomide | 2016 |
Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lenalidomide; Male; Middle Aged; Sarcoma, Kaposi; Thalidomide; Treatment Outcome; Young Adult | 2017 |
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Remission Induction; Thalidomide; Treatment Outcome | 2016 |
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Risk Factors; Survival Rate; Thalidomide | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Cytokines; Female; Head and Neck Neoplasms; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Staging; Retreatment; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome | 2016 |
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2016 |
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Topics: Aged; Aged, 80 and over; Anemia, Macrocytic; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2016 |
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide | 2017 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2016 |
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease-Free Survival; DNA Methylation; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Risk; Thalidomide; Treatment Outcome | 2016 |
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Vincristine | 2017 |
A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Immunologic Factors; Lenalidomide; Lumbosacral Region; Male; Middle Aged; Neuralgia; Radiculopathy; Thalidomide | 2017 |
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2017 |
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Quality of Life; Recurrence; Thalidomide; Young Adult | 2016 |
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoint Determination; Female; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrimidines; Thalidomide | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Thalidomide; Treatment Outcome | 2016 |
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Risk Assessment; Rituximab; Survival Rate; Thalidomide; Young Adult | 2017 |
Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Thalidomide | 2017 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Thalidomide | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2016 |
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide; Treatment Outcome | 2016 |
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Salvage Therapy; Survival Rate; Thalidomide; Treatment Failure; Treatment Outcome | 2017 |
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Leukopenia; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome | 2017 |
A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality of Life; Survival Analysis; Thalidomide | 2017 |
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Vorinostat | 2017 |
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rituximab; Thalidomide | 2017 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Oligopeptides; Risk Factors; Thalidomide; Vorinostat | 2016 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia | 2017 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide | 2017 |
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Retreatment; Rituximab; Thalidomide; Treatment Outcome | 2017 |
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Pancreatic Neoplasms; Thalidomide | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
Topics: Aged; Antineoplastic Agents; Chlorambucil; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Analysis; Thalidomide | 2017 |
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Recurrence; Thalidomide | 2017 |
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide; Treatment Outcome | 2017 |
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Humans; Lenalidomide; Multiple Myeloma; Patient Safety; Premedication; Thalidomide | 2017 |
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quality of Life; Thalidomide; Treatment Outcome | 2017 |
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2017 |
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Germany; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Failure | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine | 2017 |
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Young Adult | 2017 |
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms; Thalidomide | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Vorinostat | 2017 |
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.
Topics: Acute Disease; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Thalidomide | 2017 |
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Remission Induction; Survival Analysis; Thalidomide | 2017 |
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Topics: Aged; Aged, 80 and over; Azacitidine; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Survival Rate; Thalidomide | 2017 |
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Panobinostat; Remission Induction; Thalidomide; Young Adult | 2017 |
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cytokines; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunomodulation; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Monocytes; Thalidomide | 2018 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome | 2017 |
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulins; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2017 |
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; China; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Placebo Effect; Thalidomide | 2017 |
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Count; Lymphoma, Mantle-Cell; Mutation; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome | 2017 |
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Placebos; Survival Analysis; Thalidomide; Transplantation, Autologous; Young Adult | 2017 |
Neutral tumor evolution in myeloma is associated with poor prognosis.
Topics: Exome; Female; Gene Frequency; Genetic Drift; Humans; Immunologic Factors; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Mutation; Prognosis; Thalidomide; Tumor Microenvironment | 2017 |
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Prospective Studies; Thalidomide | 2017 |
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; United States | 2017 |
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2017 |
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Thalidomide | 2017 |
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Treatment Outcome | 2017 |
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Transcriptome; Treatment Outcome | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Monocytes; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2017 |
Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Lenalidomide; Male; Middle Aged; Pilot Projects; POEMS Syndrome; Prospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide | 2017 |
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.
Topics: Female; Humans; Immunity, Cellular; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Male; Mucosal-Associated Invariant T Cells; Multiple Myeloma; Neoplasm Proteins; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2018 |
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; Italy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Registries; Remission Induction; Retrospective Studies; Thalidomide | 2018 |
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Apoptosis; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Disease Progression; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Tumor Cells, Cultured; Vaccination | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2018 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Quality of Life; Registries; Thalidomide; United States | 2018 |
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Tumor Burden; Vincristine | 2018 |
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Quality of Life; Survival Rate; Thalidomide | 2018 |
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Rituximab; Skin Diseases; Survival Rate; Thalidomide | 2018 |
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clonal Evolution; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Treatment Outcome | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism | 2019 |
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prognosis; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Depsipeptides; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peptides, Cyclic; Survival Rate; Thalidomide | 2019 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Salvage Therapy; Thalidomide | 2019 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide | 2020 |
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2020 |
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Registries; Retrospective Studies; Thalidomide; Thromboembolism | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2020 |
Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Topics: Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Prospective Studies; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2020 |
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Transplantation, Autologous | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2020 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine | 2020 |
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Immunomodulation; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2021 |
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Glycine; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States | 2020 |
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2020 |
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Receptors, Chimeric Antigen; Survival Rate; Thalidomide | 2021 |
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Physicians; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2022 |
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2022 |
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopenia; Multiple Myeloma; Prospective Studies; Thalidomide | 2022 |
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thrombocytopenia | 2023 |
1293 other study(ies) available for thalidomide and lenalidomide
| Article | Year |
|---|---|
Angiogenesis inhibitors derived from thalidomide.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Structure-Activity Relationship; Thalidomide; Umbilical Veins | 2005 |
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; Antineoplastic Agents; HEK293 Cells; Humans; Lenalidomide; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2012 |
Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Cell Proliferation; Half-Life; Humans; Interleukin-2; Lenalidomide; Leukocytes, Mononuclear; Rats; Structure-Activity Relationship; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Stem Cells; Thalidomide | 2016 |
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).
Topics: Cell Line; Humans; Indoles; Models, Molecular; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Protein Conformation; Proteolysis; Sulfonamides; Ubiquitination | 2019 |
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Drug Design; Humans; Hydrolysis; Ikaros Transcription Factor; Molecular Docking Simulation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2019 |
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Anilides; Animals; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Phenylenediamines; Proteolysis; RAW 264.7 Cells; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |
In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfides; Tumor Cells, Cultured | 2021 |
Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition.
Topics: | 2021 |
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.
Topics: Animals; Antitubercular Agents; Brain; Central Nervous System; Female; Immunosuppressive Agents; Lenalidomide; Male; Meninges; Mycobacterium bovis; Rabbits; Thalidomide; Tuberculosis, Meningeal; Tumor Necrosis Factor-alpha | 2002 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro.
Topics: Adjuvants, Immunologic; CD8-Positive T-Lymphocytes; Cell Division; Coculture Techniques; Cytokines; Cytomegalovirus Infections; Dendritic Cells; Dose-Response Relationship, Immunologic; Flow Cytometry; HIV Infections; Humans; Immunosorbent Techniques; Lenalidomide; Thalidomide | 2003 |
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Topics: Antigens, CD; Antigens, Differentiation; B7-1 Antigen; Blotting, Western; CD28 Antigens; CD3 Complex; CD4 Antigens; CD8 Antigens; Cell Division; CTLA-4 Antigen; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-gamma; Interleukin-4; Lenalidomide; Lymphocyte Activation; NF-kappa B; Phosphorylation; Precipitin Tests; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Thalidomide; Tyrosine; Up-Regulation | 2004 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Topics: Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Multiple Myeloma; Protein Kinases; Sirolimus; Stromal Cells; Thalidomide; TOR Serine-Threonine Kinases | 2004 |
Novel immunomodulatory therapies in the treatment of multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Lenalidomide; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity; Thalidomide | 2004 |
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.
Topics: Blotting, Northern; Blotting, Western; Cyclooxygenase 2; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Humans; Immunologic Factors; Interleukin-10; Isoenzymes; Lenalidomide; Leukocytes, Mononuclear; Lipopolysaccharides; Lymphocyte Activation; Lymphotoxin-alpha; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; RNA; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
Circulating endothelial progenitor cells in multiple myeloma: implications and significance.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cells, Cultured; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Stem Cells; Thalidomide; Umbilical Veins | 2005 |
The 5q- syndrome.
Topics: Age Factors; Antigens, CD; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythropoietin; Female; Gene Deletion; Genes, Tumor Suppressor; Humans; Immunosuppressive Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Sex Factors; Thalidomide | 2004 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Myelodysplastic syndromes--coping with ineffective hematopoiesis.
Topics: Angiogenesis Inhibitors; Hematopoiesis; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Area Under Curve; Cell Movement; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Kinetics; Lenalidomide; Male; Mesentery; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Thalidomide; Umbilical Veins | 2005 |
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate; Thalidomide | 2005 |
Treatment of myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
Treatment of myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antilymphocyte Serum; Blood Transfusion; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Mice; Mice, SCID; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Current treatment of myelofibrosis.
Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous | 2005 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
New drug induces long-term MDS remission.
Topics: Chromosomes, Human, Pair 5; Gene Deletion; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2005 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2003 |
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A | 2005 |
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
Topics: Angiogenesis Inhibitors; Antilymphocyte Serum; Antineoplastic Agents; Blood Transfusion; Cyclosporine; Granulocyte Colony-Stimulating Factor; Growth Substances; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide | 2005 |
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Signal Transduction; Thalidomide | 2005 |
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Apoptosis; CD40 Antigens; CD40 Ligand; CD56 Antigen; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Humans; Immunization, Passive; Interleukin-6; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Thalidomide | 2005 |
Combo drug therapy beneficial for new cases of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Biopsy; Diagnosis, Differential; Drug Eruptions; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Skin; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
New agents in the treatment of MDS.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome | 2005 |
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.
Topics: Adaptor Protein Complex 1; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; G1 Phase; Humans; Lenalidomide; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Erythropoietin; Resting Phase, Cell Cycle; Signal Transduction; Structure-Activity Relationship; Thalidomide | 2006 |
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Cell Count; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Fas Ligand Protein; Female; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Humans; Immunosuppressive Agents; Lenalidomide; Male; Membrane Glycoproteins; Mice; Mice, Transgenic; Middle Aged; Motor Activity; Neurons; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Survival; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Topics: Antigen Presentation; Cells, Cultured; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Ligands; Lymphocyte Activation; Multiple Myeloma; Thalidomide | 2006 |
Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
Topics: Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Contraindications; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Pregnancy; Pregnancy Complications; Thalidomide; Transfusion Reaction | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Multiple Myeloma; Multivariate Analysis; Thalidomide; Venous Thrombosis | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Venous Thrombosis | 2006 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thromboembolism; Thrombosis; Treatment Outcome | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |
Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide.
Topics: Aged; Diagnosis, Differential; Hand Dermatoses; Humans; Immunologic Factors; Lenalidomide; Male; Primary Myelofibrosis; Sweet Syndrome; Thalidomide | 2006 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Point Mutation; Thalidomide | 2006 |
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Topics: Amyloidosis; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Eruptions; Drug Therapy, Combination; Humans; Lenalidomide; Medical Records; Minnesota; Multiple Myeloma; Prevalence; Retrospective Studies; Severity of Illness Index; Thalidomide | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Anticoagulation regimens for thalidomide and lenalidomide.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Treatment Outcome; Venous Thrombosis | 2006 |
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Topics: Adult; Aged; Chromosome Deletion; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2007 |
Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Cytogenetic Analysis; DNA Probes; Early Growth Response Protein 1; Female; Gene Deletion; Hematologic Diseases; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Thalidomide | 2007 |
Lenalidomide-induced warm autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2006 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Lenalidomide; Male; Melena; Recurrence; Thalidomide; Treatment Outcome; von Willebrand Diseases | 2006 |
Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Hematopoietic Stem Cells; Humans; Lenalidomide; Lymphoma, B-Cell; Phosphorylation; Retinoblastoma Protein; Thalidomide; Up-Regulation | 2007 |
Lenalidomide: from bench to bedside (part 1).
Topics: Anemia; Antineoplastic Agents; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2006 |
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States | 2006 |
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Thalidomide | 2006 |
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Topics: Antineoplastic Agents; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lenalidomide; Models, Biological; Multiple Myeloma; Osteoclasts; Oxidative Stress; Plasma Cells; Proto-Oncogene Proteins c-jun; Signal Transduction; Thalidomide; Tumor Suppressor Protein p53 | 2007 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2007 |
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Point Mutation; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
Managing myelodysplastic syndromes.
Topics: Aged; Antineoplastic Agents; Bone Marrow Examination; Clinical Trials as Topic; Cytogenetic Analysis; Drug Monitoring; Erythrocyte Transfusion; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Oncology Nursing; Thalidomide | 2007 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dyspnea; Female; Fever; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Syndrome; Thalidomide | 2007 |
Evaluation of the developmental toxicity of lenalidomide in rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Embryonic Development; Female; Fetal Death; Fetus; Lenalidomide; Pregnancy; Rabbits; Teratogens; Thalidomide | 2007 |
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 5; Clone Cells; Erythroblasts; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Osteonectin; Thalidomide; Tumor Cells, Cultured | 2007 |
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Chromosomes, Human, Pair 5; Cytogenetics; Early Growth Response Protein 1; Gene Deletion; Humans; Lenalidomide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Homologous | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
Topics: Female; Humans; Kinetics; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Thalidomide; Treatment Outcome | 2007 |
Successful desensitization in a patient with lenalidomide hypersensitivity.
Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays | 2007 |
Lenalidomide therapy in a patient with POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Black or African American; Diagnosis, Differential; Humans; Interleukin-6; Lenalidomide; Male; POEMS Syndrome; Thalidomide; Time Factors; Vascular Endothelial Growth Factor A | 2007 |
Advances in MDS.
Topics: Antineoplastic Agents; Erythropoietin; Female; Granulocyte Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2007 |
Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Humans; Kidney Neoplasms; Lenalidomide; Male; Thalidomide; Thyroid Function Tests; Thyroiditis; Treatment Outcome | 2007 |
Thalidomide in Kaposi sarcoma: promising or disappointing?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide | 2007 |
Thalidomide in the treatment of Kaposi's sarcoma.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Sarcoma, Kaposi; Thalidomide | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Lenalidomide, a thalidomide derivative, shows promise in various applications.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Terminology as Topic; Thalidomide | 2007 |
Spinal epidural lipomatosis in myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Dexamethasone; Disease Progression; Humans; Lenalidomide; Lipomatosis; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Spinal Cord; Spinal Diseases; Thalidomide; Treatment Outcome | 2007 |
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
Topics: Aged; Humans; Lenalidomide; Male; Penis; Primary Myelofibrosis; Thalidomide; Thrombosis | 2008 |
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide | 2007 |
Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Lysis Syndrome | 2007 |
Lenalidomide in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Lenalidomide-induced severe hepatotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Resistance, Neoplasm; Humans; Lenalidomide; Liver; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2007 |
Successful treatment of Behçet's disease with lenalidomide.
Topics: Adult; Behcet Syndrome; Humans; Immunologic Factors; Lenalidomide; Male; Oral Ulcer; Thalidomide | 2008 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Interactions; Immunohistochemistry; Immunosuppressive Agents; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Rituximab; Thalidomide | 2008 |
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Lenalidomide--the phoenix rises.
Topics: Antineoplastic Agents; Drug Design; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2008 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Cells, Cultured; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Synergism; Erythroid Cells; Erythropoiesis; Fetal Hemoglobin; Humans; Hydroxyurea; Lenalidomide; Models, Biological; Thalidomide; Up-Regulation | 2008 |
How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Topics: Antineoplastic Agents; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2007 |
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Thrombosis | 2007 |
Lenalidomide-associated hypothyroidism.
Topics: Antineoplastic Agents; Female; Humans; Hypothyroidism; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Thalidomide | 2007 |
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recombinant Proteins; Thalidomide; Treatment Outcome | 2008 |
Concurrent radiation therapy and lenalidomide in myeloma patient.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2008 |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Endothelial Cells; Female; Fluorescent Antibody Technique; Humans; Indoles; Lenalidomide; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Rats; Sunitinib; Thalidomide; Xenograft Model Antitumor Assays | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Myelodysplastic syndromes: introduction.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2008 |
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Drug Resistance; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide | 2008 |
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials, Phase II as Topic; Erythroid Precursor Cells; Erythropoiesis; Gene Expression Profiling; Genetic Markers; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide | 2008 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis | 2008 |
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |
Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
Topics: Drug Resistance; Fatal Outcome; Female; Humans; Immunologic Factors; Kidney Transplantation; Lenalidomide; Lymphoproliferative Disorders; Middle Aged; T-Lymphocytes; Thalidomide | 2008 |
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Thalidomide; Tumor Cells, Cultured | 2008 |
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Leukemia, Plasma Cell; Male; Recurrence; Salvage Therapy; Thalidomide | 2008 |
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Skin; Skin Diseases, Bacterial; Thalidomide | 2008 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Paraproteins; Renal Dialysis; Thalidomide | 2008 |
Lenalidomide in myelodysplastic syndromes.
Topics: Clinical Trials as Topic; Gene Deletion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2008 |
Lessons from a Jehovah's Witness with 5q- syndrome: role of systemic immunosuppression and kinetics of recovery with lenalidomide from a life threatening anaemia.
Topics: Antineoplastic Agents; Female; Gene Deletion; Humans; Immunosuppression Therapy; Jehovah's Witnesses; Lenalidomide; Middle Aged; Neural Tube Defects; Thalidomide | 2008 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide | 2008 |
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Topics: Actins; Animals; Antigen Presentation; Antineoplastic Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Immunologic Factors; Interleukin-2; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Function-Associated Antigen-1; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Mice, Inbred Strains; Mice, Transgenic; Microfilament Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Antigen, T-Cell; Superantigens; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Thalidomide | 2008 |
Waldenstrom macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Humans; Lenalidomide; Prognosis; Proteasome Inhibitors; Rituximab; Signal Transduction; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Endpoint Determination; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Research Design; Thalidomide; Treatment Outcome; United States | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.
Topics: Adult; Blood Platelets; Chemistry, Pharmaceutical; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Myelodysplastic Syndromes; Stem Cells; Syndrome; Thalidomide | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2008 |
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lenalidomide; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Simvastatin; STAT3 Transcription Factor; Thalidomide | 2009 |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Flow Cytometry; Hematologic Neoplasms; Humans; Killer Cells, Natural; Lenalidomide; Monocytes; Rituximab; Thalidomide | 2008 |
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2009 |
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Risk Factors; Thalidomide; Thromboembolism | 2009 |
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Thalidomide | 2009 |
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.
Topics: Antineoplastic Agents; Cytoskeleton; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Models, Statistical; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Thalidomide; Time Factors; Treatment Outcome | 2008 |
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Female; Fetus; Humans; Lenalidomide; Male; Maternal Exposure; Paternal Exposure; Pregnancy; Risk Management; Teratogens; Thalidomide; United States | 2008 |
Aspirin as thromboprophylaxis in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytotoxicity, Immunologic; Down-Regulation; Drug Antagonism; Drug Delivery Systems; Endocytosis; Female; Genetic Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Male; Middle Aged; Rituximab; Thalidomide; Tumor Cells, Cultured | 2008 |
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.
Topics: Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Lysis Syndrome | 2008 |
Myeloma patient wins fight for drug not yet approved by NICE.
Topics: Antineoplastic Agents; Drug Approval; England; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Terminally Ill; Thalidomide | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Placebos; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; beta Catenin; Cadherins; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Lenalidomide; Lung Neoplasms; Melanoma, Experimental; Mice; Microcirculation; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy; Proto-Oncogene Proteins c-akt; Thalidomide; Umbilical Arteries | 2009 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Clarithromycin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Thalidomide | 2008 |
The current landscape of multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Patient Selection; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous | 2008 |
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
Topics: Antigens, CD1; Cell Line; Cytotoxicity, Immunologic; Humans; Immunotherapy; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
[Myelodysplastic syndromes: therapeutic advances and promising future].
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunosuppressive Agents; Interleukin-10; Lenalidomide; Mice; Mice, Inbred BALB C; Receptors, Nerve Growth Factor; Receptors, OX40; Receptors, Transforming Growth Factor beta; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2009 |
A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Topics: Anemia, Aplastic; Antineoplastic Agents; Biopsy; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2009 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Topics: Algorithms; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Spectral Karyotyping; Thalidomide | 2008 |
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Topics: Antineoplastic Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Hepatocytes; Humans; In Vitro Techniques; Isoenzymes; Lenalidomide; Microsomes, Liver; Recombinant Proteins; Substrate Specificity; Thalidomide | 2009 |
Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema Multiforme; Female; Humans; Lenalidomide; Male; Middle Aged; Stevens-Johnson Syndrome; Thalidomide | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide | 2009 |
50th ASH Annual Meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Nadroparin; Rituximab; Thalidomide; Thromboembolism; Uric Acid | 2009 |
Lenalidomide in renal insufficiency--balancing the risks and benefits.
Topics: Antineoplastic Agents; Area Under Curve; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remission Induction; Thalidomide | 2009 |
Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2009 |
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 13; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Trisomy | 2009 |
The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2009 |
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD40 Antigens; Cytotoxicity Tests, Immunologic; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Tumor Cells, Cultured | 2009 |
Health department sets up cost sharing deal for multiple myeloma drug.
Topics: Antineoplastic Agents; Cost Sharing; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
[Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2008 |
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Databases, Factual; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Pulmonary Embolism; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration; Venous Thromboembolism | 2009 |
Lenalidomide for the treatment of resistant discoid lupus erythematosus.
Topics: Adult; Female; Humans; Lenalidomide; Lupus Erythematosus, Discoid; Neutropenia; Thalidomide | 2009 |
Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Treatment Outcome | 2009 |
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Topics: Animals; Disease Models, Animal; Disease Progression; Gene Expression Profiling; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Proto-Oncogene Proteins; Signal Transduction; T-Lymphocytes; Thalidomide | 2009 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide | 2008 |
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Topics: Antineoplastic Agents; Dexamethasone; Drug Approval; Drug Therapy, Combination; France; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2008 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lenalidomide; Pancreatic Neoplasms; Thalidomide | 2010 |
Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Chronic Disease; Female; Gastrointestinal Hemorrhage; Humans; Lenalidomide; Telangiectasia, Hereditary Hemorrhagic; Thalidomide | 2009 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Chromosome Deletion; Chromosomes, Human, Pair 5; G2 Phase; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Phosphatase 2; Thalidomide; U937 Cells | 2009 |
Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report.
Topics: Adult; Antineoplastic Agents; Female; Graft vs Leukemia Effect; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Thalidomide; Treatment Outcome | 2009 |
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2009 |
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
Topics: Aged; Female; Follow-Up Studies; Gene Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2010 |
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blood Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Synergism; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; MAP Kinase Kinase 4; Mice; Mice, SCID; Neoplasms, Experimental; Phosphorylation; Rituximab; Thalidomide | 2009 |
Neutrophilic dermatosis complicating lenalidomide therapy.
Topics: Antineoplastic Agents; Biopsy; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Skin; Sweet Syndrome; Thalidomide | 2009 |
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomide; Leukopenia; Multiple Myeloma; Recurrence; Salvage Therapy; T-Lymphocytes; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide for the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Health Care Rationing; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Recurrence; Technology Assessment, Biomedical; Thalidomide; United Kingdom | 2009 |
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2009 |
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Thalidomide | 2010 |
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro.
Topics: Animals; Biomarkers; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Immunologic Factors; Lenalidomide; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Quality Control; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2010 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2009 |
Lifesaving myths.
Topics: Advisory Committees; Antineoplastic Agents; Hospices; Humans; Lenalidomide; Quality-Adjusted Life Years; Thalidomide; United Kingdom | 2009 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Immunoblotting; Immunohistochemistry; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2009 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured | 2010 |
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immunoglobulins; Lenalidomide; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Monosomy; Myelodysplastic Syndromes; Prognosis; Risk; Survival Analysis; Thalidomide | 2009 |
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Pulmonary Eosinophilia; Secondary Prevention; Thalidomide; Treatment Outcome | 2009 |
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide | 2009 |
Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART.
Topics: Anti-HIV Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; HIV Infections; Humans; Lenalidomide; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Thalidomide | 2010 |
[Lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2009 |
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasma Cells; Remission Induction; Thalidomide | 2009 |
Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Female; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2010 |
Clinical roundtable monograph. Combination therapies for MDS.
Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat | 2009 |
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight; Cell Survival; Cytokines; Disease Models, Animal; Humans; Immunologic Factors; Lameness, Animal; Lenalidomide; Mice; Mice, Transgenic; Motor Neurons; Nerve Degeneration; Spinal Cord; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |
Myeloma-associated polyneuropathy responding to lenalidomide.
Topics: Adult; Female; Humans; Lenalidomide; Multiple Myeloma; Paraneoplastic Polyneuropathy; Thalidomide | 2009 |
Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction.
Topics: Antineoplastic Agents; Female; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Middle Aged; POEMS Syndrome; Thalidomide | 2009 |
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Colony-Forming Units Assay; Cytokines; Female; Flow Cytometry; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2010 |
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.
Topics: Actins; Antineoplastic Agents; Cell Communication; Coculture Techniques; Fluorescent Antibody Technique; Humans; Image Processing, Computer-Assisted; Immune Tolerance; Immunological Synapses; Immunotherapy; Lenalidomide; Lymphoma, Follicular; Microscopy, Confocal; rab GTP-Binding Proteins; rab27 GTP-Binding Proteins; T-Lymphocytes; Thalidomide; Tissue Array Analysis; Tumor Escape | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Female; Gene Expression Profiling; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Tumor Suppressor Protein p53 | 2009 |
Lenalidomide, an antineoplastic drug, and its hemihydrate.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Hydrogen Bonding; Lenalidomide; Models, Molecular; Solubility; Thalidomide; Water | 2009 |
Towards a new standard of care for patients with myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Quality of Health Care; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythroid Cells; Female; Follow-Up Studies; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Hypothyroidism: a growing complication of cancer treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Hypothyroidism; Incidence; Iodide Peroxidase; Lenalidomide; Male; Neoplasms; Radioimmunotherapy; Radiotherapy; Thalidomide; United States | 2009 |
Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Female; Hemangioendothelioma, Epithelioid; Humans; Lenalidomide; Magnetic Resonance Imaging; Thalidomide; Tomography, X-Ray Computed | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2010 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Survival; Complement System Proteins; Cytotoxicity, Immunologic; Drug Synergism; Humans; Immunologic Factors; In Vitro Techniques; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Rituximab; Thalidomide | 2010 |
Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.
Topics: Antineoplastic Agents; Humans; Interleukin-17; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; In Vitro Techniques; Lactones; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrroles; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Young Adult | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Compassionate Use Trials; Hodgkin Disease; Humans; Inflammation; Lenalidomide; Male; Neoplasm Recurrence, Local; Thalidomide; Young Adult | 2010 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CD3 Complex; Cytokines; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Myelodysplastic Syndromes; Natural Killer T-Cells; Thalidomide | 2010 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide | 2010 |
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Topics: Adenosine Triphosphate; Apoptosis; Biomarkers, Tumor; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Immunomodulation; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Retinoblastoma Protein; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Neoplasm, Residual; Remission Induction; Thalidomide | 2010 |
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Cryoglobulinemia; HLA-B27 Antigen; Humans; Lenalidomide; Lumbar Vertebrae; Male; Multiple Myeloma; Sacroiliac Joint; Spondylarthropathies; Thalidomide | 2010 |
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Division; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokinesis; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tumor Cells, Cultured | 2010 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
[Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes].
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2010 |
Lenalidomide-induced interstitial lung disease.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Diagnosis, Differential; Dinoprostone; Female; Humans; Lenalidomide; Lung; Lung Diseases, Interstitial; Multiple Myeloma; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Kidney; Lenalidomide; Male; Methotrexate; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2010 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Erythropoietin; Humans; Hypertension, Pulmonary; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism; Pyridoxine; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thrombocytosis; Vitamin B Complex | 2010 |
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2010 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2009 |
Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Cytogenetic Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2010 |
Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Dexamethasone; Granuloma; Humans; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Necrobiotic Disorders; Thalidomide | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Erythroid Cells; Glutathione; Hemoglobins; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome | 2010 |
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Topics: Antigens, CD34; Antineoplastic Agents; Blood Component Removal; Cyclophosphamide; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Medical Records; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Myelodysplastic syndrome: An update on diagnosis and therapy.
Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide | 2009 |
Lenalidomide in myelodysplastic syndromes: where do we go from here?
Topics: Antineoplastic Agents; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2008 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide | 2008 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2008 |
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Topics: Antibodies, Monoclonal; Antigen-Antibody Complex; Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; B7-H1 Antigen; Cell Line, Tumor; Chemokine CXCL12; Cytotoxicity, Immunologic; Down-Regulation; Humans; In Vitro Techniques; Interferon-gamma; K562 Cells; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Receptors, CXCR4; Signal Transduction; Thalidomide | 2010 |
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome | 2010 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Topics: Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2011 |
Lenalidomide-induced hypersensitivity pneumonitis.
Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2010 |
A case of lenalidomide-induced hypersensitivity pneumonitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity; Humans; Lenalidomide; Lung; Male; Multiple Myeloma; Thalidomide; Tomography, X-Ray Computed | 2010 |
Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Lenalidomide; Neoplasm Recurrence, Local; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Topics: Bendamustine Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Thalidomide; TOR Serine-Threonine Kinases | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Down-Regulation; Humans; Immunomodulation; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Mice; Natural Cytotoxicity Triggering Receptor 1; Receptors, KIR; Thalidomide | 2010 |
Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Topics: Animals; Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2010 |
Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Salvage Therapy; Thalidomide | 2010 |
Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
Topics: Adult; Antineoplastic Agents; Chimerism; Chromosome Deletion; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Sequence Deletion; Thalidomide | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Signal Transduction; Stromal Cells; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes; Thalidomide | 2010 |
Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Kidney dysfunction during lenalidomide treatment for AL amyloidosis.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Female; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide-induced acute interstitial nephritis.
Topics: Acute Disease; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nephritis, Interstitial; Thalidomide | 2010 |
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide | 2010 |
Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.
Topics: Aged; Anemia; Antineoplastic Agents; Cell Survival; Drug Therapy, Combination; Female; Hematinics; Hemoglobins; Humans; Lenalidomide; Myelodysplastic Syndromes; Sequence Deletion; Thalidomide | 2010 |
Treatment considerations for primary myelofibrosis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Neovascularization, Pathologic; Primary Myelofibrosis; Prognosis; Risk Factors; Thalidomide | 2010 |
Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).
Topics: Adult; Aged; Antineoplastic Agents; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Protein Array Analysis; Proteome; Sequence Deletion; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide: Stevens-Johnson syndrome.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Stevens-Johnson Syndrome; Thalidomide | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Female; Gene Expression; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Phenotype; Remission Induction; Thalidomide; Thy-1 Antigens | 2010 |
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
Topics: Amyloidosis; Antineoplastic Agents; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulin Light Chains; Lenalidomide; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cetuximab; Cytotoxicity, Immunologic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Lenalidomide; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Virus; Sarcoma; Thalidomide; Trastuzumab | 2011 |
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Topics: Age Distribution; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Triazoles | 2010 |
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Patient Dropouts; Peptide Fragments; Stem Cell Transplantation; Thalidomide; Troponin T | 2010 |
Myocarditis during lenalidomide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Autopsy; Dexamethasone; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Organ Failure; Myocarditis; T-Lymphocytes; Thalidomide | 2010 |
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Female; Humans; Lenalidomide; Leukocytosis; Lymphoma, Mantle-Cell; Male; Splenomegaly; Thalidomide | 2010 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lenalidomide; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide; Tumor Cells, Cultured | 2011 |
Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cystoscopy; Dexamethasone; Humans; Lenalidomide; Male; Plasmacytoma; Radiation Tolerance; Radiotherapy; Remission Induction; Thalidomide; Treatment Failure; Urinary Bladder; Urinary Bladder Neoplasms | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Thalidomide; Thrombocytosis | 2010 |
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Dexamethasone; Female; Fluorodeoxyglucose F18; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Positron-Emission Tomography; Radiopharmaceuticals; Thalidomide | 2011 |
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Topics: Aged; Anti-Inflammatory Agents; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Blotting, Western; Case-Control Studies; Cell Proliferation; Clinical Trials, Phase II as Topic; Cytotoxicity, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flow Cytometry; Humans; Immunization; Interleukin-2; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily K; Prospective Studies; T-Lymphocytes; Thalidomide | 2011 |
Case 23-2010: Unusual paraprotein effects in MGUS--treat or not?
Topics: Antineoplastic Agents; Humans; Kidney Diseases; Lenalidomide; Lymphangiectasis; Lymphangioma, Cystic; Paraproteinemias; Polycythemia; Thalidomide | 2010 |
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Synergism; Humans; In Vitro Techniques; Lenalidomide; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Thalidomide | 2011 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate; Thalidomide | 2011 |
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Complement System Proteins; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2011 |
In vivo efficacy of griseofulvin against multiple myeloma.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Ciclopirox; Griseofulvin; Humans; Immunosuppressive Agents; Lenalidomide; Lymphoma; Mice; Mice, Inbred BALB C; Multiple Myeloma; Pyridones; Signal Transduction; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide | 2010 |
Lenalidomide: an update on evidence from clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2010 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Agents; Biomarkers; Clinical Trials as Topic; Female; Heart; Humans; Lenalidomide; Male; Middle Aged; Natriuretic Peptide, Brain; Retrospective Studies; Thalidomide | 2010 |
Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide.
Topics: Adult; Aged; Aging; bcl-X Protein; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL21; Chemotaxis; Cytokines; Female; Humans; Lenalidomide; Lymphocyte Activation; Male; Monocytes; T-Lymphocytes; Thalidomide; Young Adult | 2011 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5.
Topics: Aged; Chromosome Banding; Chromosome Mapping; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 5; Cytogenetics; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2010 |
Immunomodulatory drugs increase endothelial tissue factor expression in vitro.
Topics: Cell Line; Endothelial Cells; Humans; Immunologic Factors; Lenalidomide; RNA, Messenger; Thalidomide; Thromboplastin; Umbilical Veins; Up-Regulation | 2011 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Lenalidomide: myocardial infarction.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Myocardial Infarction; Thalidomide | 2010 |
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
Topics: Antineoplastic Agents; beta Catenin; Casein Kinase Ialpha; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Transcription, Genetic; Wnt Proteins; Wnt3 Protein; Wnt3A Protein | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Spectral Karyotyping; Thalidomide | 2011 |
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Inflammation Mediators; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2011 |
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Myeloproliferative Disorders; Neoplasms; Philadelphia Chromosome; Polycythemia Vera; Splenomegaly; Thalidomide | 2011 |
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2011 |
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cell Movement; Chemokine CCL2; Chemokine CXCL12; Chickens; Chorioallantoic Membrane; Culture Media, Conditioned; Endothelial Cells; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Male; Membrane Proteins; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteome; Proto-Oncogene Proteins; Selenoprotein W; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Coma; Fatal Outcome; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Stroke; Thalidomide; Thromboembolism; Tomography, X-Ray Computed | 2011 |
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; ATP-Binding Cassette Transporters; Bone Marrow Cells; Cell Division; Cell Fractionation; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Stromal Cells; Syndecan-1; Thalidomide | 2011 |
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interactions; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythroid Cells; Exanthema; Humans; Lenalidomide; Ribosomal Proteins; Thalidomide | 2011 |
Initial testing of lenalidomide by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Child; Female; Humans; Lenalidomide; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Enzyme Activation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; RNA, Small Interfering; Thalidomide | 2011 |
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Topics: Apoptosis; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; Cell Separation; Down-Regulation; Eukaryotic Initiation Factor-4E; Flow Cytometry; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Immunohistochemistry; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transfection | 2011 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Lenalidomide in treating AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; HIV-1; Humans; Lenalidomide; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide | 2011 |
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Pruritus; Thalidomide; Time Factors | 2011 |
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
[The 5q- syndrome].
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2010 |
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.
Topics: Erythema; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Sweet Syndrome; Thalidomide | 2011 |
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzimidazoles; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Male; Mice; Mice, SCID; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; STAT3 Transcription Factor; Thalidomide; Treatment Outcome; Urea; Xenograft Model Antitumor Assays | 2011 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bence Jones Protein; Calcium; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Monitoring, Physiologic; Multiple Myeloma; Patient Selection; Radiography; Thalidomide; Time; Treatment Outcome; Venous Thromboembolism | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
Type 1 cryoglobulinemia: response to thalidomide and lenalidomide.
Topics: Cryoglobulinemia; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Thalidomide; Treatment Outcome | 2011 |
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide; Male; Middle Aged; Patch Tests; Plasmacytoma; Skin Diseases, Papulosquamous; Thalidomide | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dexamethasone; Disease-Free Survival; Drug Evaluation; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Mitotic Index; Multiple Myeloma; Plasma Cells; Proportional Hazards Models; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide in CLL: what is the optimal dose?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide; Treatment Outcome | 2011 |
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-Johnson Syndrome; Thalidomide; Transplantation, Homologous | 2012 |
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Germinal Center; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prognosis; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Spontaneous huge hematoma in the abdominal wall after lenalidomide.
Topics: Abdomen, Acute; Abdominal Wall; Antineoplastic Agents; Female; Hematoma; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide; Tomography, X-Ray Computed | 2011 |
Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Ectromelia; Female; Humans; Lenalidomide; Leprosy; Multiple Myeloma; Nausea; Oxidative Stress; Pregnancy; Teratogens; Thalidomide; Treatment Outcome; United States | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.
Topics: Antineoplastic Agents; Eye Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Thalidomide | 2011 |
[Study to castrate-resistant prostate cancer: AUO study AP 60/10].
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure | 2011 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Thalidomide; Translocation, Genetic | 2011 |
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.
Topics: Anemia, Diamond-Blackfan; Coculture Techniques; Dexamethasone; Drug Therapy, Combination; Erythroid Precursor Cells; Erythropoiesis; Gene Expression Profiling; Humans; Lenalidomide; Myelodysplastic Syndromes; Ribosomal Proteins; Stromal Cells; Thalidomide | 2011 |
Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Health Services Accessibility; Humans; Lenalidomide; Multiple Myeloma; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Dexamethasone; Humans; Immunoglobulin Isotypes; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Homologous; Treatment Outcome | 2011 |
Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Thyroid Diseases; Thyroid Function Tests | 2011 |
Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Diffuse alveolar hemorrhage associated with lenalidomide.
Topics: Aged; Antineoplastic Agents; Hemorrhage; Humans; Lenalidomide; Male; Multiple Myeloma; Pulmonary Alveoli; Radiography; Thalidomide | 2011 |
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Topics: Aged; Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Middle Aged; Thalidomide; Transplantation Conditioning | 2011 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Sarcoma, Myeloid; Thalidomide | 2012 |
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Hematologic Tests; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2011 |
Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity.
Topics: Animals; Cell Line, Tumor; Drug Design; Lenalidomide; Mice; Phthalimides; Piperidines; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retreatment; Thalidomide | 2011 |
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cells, Cultured; Cytokines; Down-Regulation; Epitopes, T-Lymphocyte; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukocyte Common Antigens; Lymphocyte Activation; Middle Aged; Multiple Myeloma; Paraproteinemias; T-Lymphocyte Subsets; Thalidomide; Up-Regulation | 2011 |
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; T-Lymphocytes; Thalidomide | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Indoles; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2011 |
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, myc; Humans; Interferon Regulatory Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prognosis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Thalidomide; Thrombocytopenia; Transfusion Reaction; Treatment Outcome | 2011 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Reversible pulmonary toxicity due to lenalidomide.
Topics: Antineoplastic Agents; Cough; Dyspnea; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Regression Analysis; Survival Analysis; Thalidomide | 2011 |
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |
Lenalidomide in del 5q MDS: responses and side effects revisited.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Transfusion Reaction | 2011 |
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Topics: Amino Acid Substitution; Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Middle Aged; Mutation, Missense; Myelodysplastic Syndromes; Phenylalanine; Thalidomide; Treatment Outcome; Valine | 2011 |
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Telomere; Thalidomide | 2012 |
Anti-myelin associated glycoprotein neuropathy responding to lenalidomide.
Topics: Aged; Antineoplastic Agents; Demyelinating Diseases; Humans; Immunoglobulin M; Lenalidomide; Male; Myelin-Associated Glycoprotein; Paraproteinemias; Peripheral Nervous System Diseases; Thalidomide | 2011 |
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasmacytoma; Recurrence; Thalidomide | 2011 |
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
Topics: Aged; Animals; Female; Humans; Immunologic Factors; Lenalidomide; Male; Mice; Middle Aged; Paraproteinemias; Pneumonia; Thalidomide | 2011 |
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Topics: Adult; Female; Humans; Lenalidomide; Leukocytes; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Middle Aged; Risk Factors; Thalidomide | 2012 |
Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Drug Eruptions; Humans; Lenalidomide; Male; Purpura; Thalidomide | 2011 |
Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Gait Disorders, Neurologic; Glucocorticoids; Hand Deformities, Acquired; Humans; Lenalidomide; POEMS Syndrome; Prednisolone; Proteasome Inhibitors; Remission Induction; Thalidomide; Vascular Endothelial Growth Factors | 2011 |
Distinct clonal deletions of the long arm of chromosome 5 in a patient with myelodysplastic syndrome.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Chromosome Deletion; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 5; Clone Cells; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Thalidomide | 2012 |
Parvovirus B19-induced type II mixed cryoglobulinemia.
Topics: Acute Disease; Antibodies, Viral; Antineoplastic Agents; Cryoglobulinemia; Diagnosis, Differential; DNA, Viral; Glomerulonephritis, Membranoproliferative; Humans; Lenalidomide; Male; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Thalidomide; Viral Load; Virulence | 2011 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide | 2011 |
Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.
Topics: Animals; Antineoplastic Agents; Dendritic Cells; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Killer Cells, Natural; Lenalidomide; Lymphoma; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Thalidomide; Transplantation, Heterologous | 2011 |
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Clinical Trials as Topic; Cytokines; Female; Humans; Immunologic Factors; Immunophenotyping; Interleukin-2; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; T-Lymphocyte Subsets; Thalidomide | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide | 2011 |
Lenalidomide: a new treatment option for Castleman disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Humans; Lenalidomide; Lymph Nodes; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; Thalidomide | 2011 |
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Topics: Aged; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2012 |
The 5q- syndrome: biology and treatment.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Lenalidomide; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chromatography, Liquid; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Orbit; Tandem Mass Spectrometry; Thalidomide | 2011 |
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Disease Progression; Female; France; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Thalidomide | 2012 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigen-Antibody Complex; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; Drug Evaluation, Preclinical; Humans; Immunomodulation; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Ligands; Mice; Mice, Inbred C57BL; Multiple Myeloma; Receptors, KIR; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide | 2012 |
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Depression; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prognosis; Recurrence; Risk Factors; Thalidomide; Treatment Outcome; Tremor | 2012 |
POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.
Topics: Adult; Aged; Female; Humans; Lenalidomide; Male; Middle Aged; Nervous System Diseases; POEMS Syndrome; Recovery of Function; Thalidomide; Treatment Outcome | 2012 |
[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].
Topics: Adult; Bone Marrow; Brain; Cladribine; Erdheim-Chester Disease; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Remission Induction; Thalidomide; Tomography, X-Ray Computed | 2011 |
Lenalidomide proved effective in multisystem Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Agents; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Treatment Outcome | 2012 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Lenalidomide; Macaca mulatta; Male; Thalidomide | 2012 |
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Receptors, Calcitriol; Thalidomide; Tumor Suppressor Protein p53 | 2012 |
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lenalidomide; Nitriles; Pancreatic Neoplasms; Phosphorylation; Thalidomide; Tumor Cells, Cultured | 2011 |
[Myelodysplastic syndrome. What can be achieved with supportive therapy and new approaches].
Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; Erythrocyte Transfusion; Hematopoietic Stem Cell Transplantation; Hemochromatosis; Humans; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Thalidomide | 2011 |
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholestasis, Intrahepatic; Humans; Jaundice; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Myeloma and second primary cancers.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Female; HLA-A Antigens; HLA-B Antigens; HLA-C Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Severity of Illness Index; Thalidomide; White People | 2012 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Humans; Lenalidomide; Megakaryocytes; Myelodysplastic Syndromes; Thalidomide | 2012 |
Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Topics: Aged; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2012 |
Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Humans; Intracranial Thrombosis; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2011 |
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.
Topics: Antineoplastic Agents; Humans; Immune Tolerance; Lenalidomide; Myelodysplastic Syndromes; Prognosis; T-Lymphocytes; Thalidomide | 2012 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis | 2012 |
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
Topics: Antineoplastic Agents; Humans; Immunomodulation; Immunosuppressive Agents; Lenalidomide; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Radiography; Thalidomide | 2012 |
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Drug Administration Schedule; Humans; Lenalidomide; Lymphocyte Count; Middle Aged; Multiple Myeloma; T-Lymphocytes; T-Lymphocytes, Regulatory; Thalidomide; Treatment Outcome | 2012 |
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Dexamethasone; Humans; Immunoglobulin G; Immunoglobulin M; Interleukin-2; Interleukin-6; Lenalidomide; Leukocytes, Mononuclear; Multiple Myeloma; Pokeweed Mitogens; Thalidomide | 2012 |
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Antineoplastic Agents; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Female; GPI-Linked Proteins; Humans; Immunoglobulin Fc Fragments; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Depletion; Macaca fascicularis; Mice; Mice, SCID; Multiple Myeloma; Phagocytosis; Plasma Cells; Thalidomide; Xenograft Model Antitumor Assays | 2012 |
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Topics: Adult; Aged; Antigens, CD34; Blood Platelets; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutrophils; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Failure | 2012 |
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Cell Nucleus; Chromosomes, Human, Pair 17; Dexamethasone; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gene Deletion; Hemizygote; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Survival Rate; Thalidomide; Tumor Suppressor Protein p53 | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide | 2012 |
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Pulmonary zygomycosis in a non-neutropenic patient with myelodysplastic syndrome on lenalidomide.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Lenalidomide; Lung Diseases, Fungal; Male; Myelodysplastic Syndromes; Thalidomide; Zygomycosis | 2012 |
Effect of a patient support program on access to oral therapy for hematologic malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Industry; Female; Health Services Accessibility; Hematologic Neoplasms; Humans; Insurance Coverage; Lenalidomide; Male; Middle Aged; Thalidomide; Time Factors; United States | 2012 |
In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Topics: Animals; beta Catenin; Cell Line, Tumor; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Humans; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Thalidomide; Wnt Signaling Pathway | 2012 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; POEMS Syndrome; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A | 2012 |
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methyltransferase 3A; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polymorphism, Single Nucleotide; Prognosis; Thalidomide | 2012 |
Multiple myeloma and immunomodulation: regulating the regulatory cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP; Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Male; Models, Immunological; Multiple Myeloma; Signal Transduction; T-Lymphocytes; T-Lymphocytes, Regulatory; Thalidomide | 2012 |
Lenalidomide-induced elevated bilirubin.
Topics: Bilirubin; Humans; Lenalidomide; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Thalidomide | 2012 |
[Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Renal Insufficiency; Thalidomide | 2012 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neurotoxicity Syndromes; Off-Label Use; Pharmacovigilance; Thalidomide; Vascular Diseases | 2012 |
Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Plasma Exchange; Rituximab; Thalidomide | 2012 |
Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process!
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Cell Differentiation; Cell Movement; Cytokines; Hair Color; Hair Follicle; Humans; Lenalidomide; Male; Melanocytes; Multiple Myeloma; Thalidomide | 2013 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
[A case of POEMS syndrome associated with Waldenström's macroglobulinemia and treated with lenalidomide].
Topics: Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Thalidomide; Waldenstrom Macroglobulinemia | 2012 |
[Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide].
Topics: Adult; Angiogenesis Inhibitors; Angiomatosis; Biomarkers; Disseminated Intravascular Coagulation; Humans; Interferon-alpha; Lenalidomide; Magnetic Resonance Imaging; Male; Multimodal Imaging; Positron-Emission Tomography; Thalidomide; Tomography, X-Ray Computed | 2012 |
Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteogenesis; Radiography; Thalidomide | 2012 |
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Topics: Aged; Algorithms; Antigens, CD34; Benzylamines; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Thalidomide | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Humerus; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Prednisolone; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous | 2012 |
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Topics: Activins; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2012 |
Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease.
Topics: Aged; Amyloidosis; Biopsy; Cardiomyopathy, Restrictive; Fatal Outcome; Female; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Muscular Diseases; Myocardium; Thalidomide | 2013 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Topics: Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Female; Humans; Immunophenotyping; Lenalidomide; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2012 |
Short-term lenalidomide (Revlimid) administration ameliorates cardiomyocyte contractile dysfunction in ob/ob obese mice.
Topics: Absorptiometry, Photon; Animals; Blotting, Western; Caspases, Effector; Cells, Cultured; Endoplasmic Reticulum; Fas Ligand Protein; Interleukin-6; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Myocardial Contraction; Myocytes, Cardiac; Obesity; Signal Transduction; Thalidomide; Tumor Necrosis Factor-alpha | 2012 |
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.
Topics: Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mice; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-mdm2; Thalidomide; Tumor Suppressor Protein p53; Ubiquitination | 2013 |
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Topics: Actins; Antibodies, Neoplasm; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Agents; Down-Regulation; Enzyme Activation; Humans; Immune Evasion; Immunologic Factors; Immunological Synapses; Immunosuppression Therapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Ligands; Polymerization; Prognosis; rho GTP-Binding Proteins; Signal Transduction; T-Lymphocytes; Thalidomide; Up-Regulation | 2012 |
Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Eruptions; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Stevens-Johnson Syndrome; Thalidomide | 2012 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2012 |
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lenalidomide; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; State Medicine; Survival Analysis; Thalidomide; United Kingdom | 2013 |
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Gastrointestinal Tract; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Transplantation; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Topics: Actin-Related Protein 2-3 Complex; Aged; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Gene Expression; Humans; Interleukin-1beta; Lenalidomide; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins c-jun; Signal Transduction; Stem Cell Niche; Thalidomide; Transcriptome; Tumor Necrosis Factor-alpha; Up-Regulation | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Humans; Indoles; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2012 |
Relapse of liver amyloidosis 6 years after autologous stem cell transplantation.
Topics: Adult; Amyloidosis; Female; Humans; Lenalidomide; Liver Diseases; Magnetic Resonance Imaging; Peripheral Blood Stem Cell Transplantation; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.
Topics: Antineoplastic Agents; Disease Management; Hematologic Diseases; Humans; Lenalidomide; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide | 2012 |
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.
Topics: Cohort Studies; Humans; Infections; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Interferon-beta; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BCG Vaccine; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fas Ligand Protein; Female; Immunohistochemistry; Lenalidomide; Mice; Mice, Inbred C3H; Microvessels; Platelet Endothelial Cell Adhesion Molecule-1; Thalidomide; Tumor Burden; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2013 |
Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.
Topics: CD8-Positive T-Lymphocytes; Cells, Cultured; Dendritic Cells; Electroporation; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Immunologic Factors; Lenalidomide; nef Gene Products, Human Immunodeficiency Virus; RNA, Messenger; Species Specificity; Thalidomide | 2012 |
Lenalidomide enhances anti-myeloma cellular immunity.
Topics: Antineoplastic Agents; Cancer Vaccines; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellular; Immunoblotting; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; T-Lymphocyte Subsets; T-Lymphocytes; Thalidomide | 2013 |
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1 | 2012 |
Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.
Topics: Adult; CD4-CD8 Ratio; Chemotaxis; HIV Infections; Humans; Interleukin-2; Lenalidomide; Male; Middle Aged; T-Lymphocytes; T-Lymphocytopenia, Idiopathic CD4-Positive; Thalidomide | 2012 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2012 |
Treatment of refractory prurigo nodularis with lenalidomide.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Pruritus; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide: second cancers.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pharmacovigilance; Thalidomide | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone; Humans; Lenalidomide; Longitudinal Studies; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Thalidomide; Treatment Failure; Treatment Outcome | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide; Threonine; Xenograft Model Antitumor Assays | 2012 |
Second to none.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2012 |
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Topics: Animals; Antigens, CD34; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Lenalidomide; Mice; MicroRNAs; Myelodysplastic Syndromes; RNA, Messenger; Thalidomide; Treatment Outcome | 2013 |
Pharmacokinetics and tissue disposition of lenalidomide in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chromatography, Liquid; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intravenous; Lenalidomide; Mice; Mice, Inbred ICR; Species Specificity; Tandem Mass Spectrometry; Thalidomide; Time Factors; Tissue Distribution | 2012 |
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Netherlands; Thalidomide; Treatment Outcome; White People | 2013 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second primary malignancies and myeloma therapy: fad or fact?
Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide | 2012 |
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Janus Kinase 2; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Sequence Deletion; Thalidomide | 2013 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facilities; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Specialization; Thalidomide; Thrombosis; Warfarin | 2013 |
Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma.
Topics: Adult; Aged; Biomarkers, Tumor; Cohort Studies; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Survival Analysis; Thalidomide | 2013 |
Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Topics: Adult; Aged; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Frameshift Mutation; Gene Expression Regulation, Leukemic; Humans; Immunologic Factors; K562 Cells; Lenalidomide; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; RNA, Neoplasm; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Topics: Azacitidine; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Topics: Aged; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; Thalidomide | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma; Secondary Prevention; Thalidomide | 2012 |
[Diagnosis and treatment for plasma cell leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide | 2012 |
Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization.
Topics: Antigens, CD34; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Receptors, CXCR4; Thalidomide; Up-Regulation | 2013 |
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2013 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL3; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Integrin alpha4; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Topics: Aged; Biopsy; Bone Marrow; Cytogenetic Analysis; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide | 2013 |
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Remission Induction; Thalidomide | 2013 |
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Cluster Analysis; Dexamethasone; Endothelial Cells; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Stress, Physiological; Thalidomide; Venous Thromboembolism | 2013 |
MDS: unraveling the mystery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2012 |
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Adult; Anemia, Refractory; Bone Marrow; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Female; Humans; Janus Kinase 2; Karyotype; Lenalidomide; Thalidomide; Thrombocytosis; Translocation, Genetic; Treatment Outcome | 2013 |
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; B-Cell CLL-Lymphoma 10 Protein; CARD Signaling Adaptor Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Guanylate Cyclase; Humans; Interferon Regulatory Factors; Interleukin-1 Receptor-Associated Kinases; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Mutation; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neoplasm Transplantation; NF-kappa B; Peptide Hydrolases; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2013 |
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies; Risk; Thalidomide | 2013 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Complementarity Determining Regions; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Recurrence; Remission Induction; Thalidomide; Time Factors; Young Adult | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel.
Topics: Antineoplastic Agents; Cancer Vaccines; Humans; Lenalidomide; Managed Care Programs; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Secondary Prevention; Sequence Analysis, DNA; Thalidomide | 2012 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Female; Humans; Indazoles; Inhibitory Concentration 50; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sulfonamides; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
[POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide | 2012 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment | 2013 |
Development and validation of LC-MS/MS method for the quantitation of lenalidomide in human plasma using Box-Behnken experimental design.
Topics: Angiogenesis Inhibitors; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; Immunologic Factors; Lenalidomide; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Thalidomide | 2013 |
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; cdc42 GTP-Binding Protein; Cell Movement; Coculture Techniques; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Function-Associated Antigen-1; Peptide Hydrolases; Primary Cell Culture; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2013 |
Can NKT cells extinguish smoldering myeloma?
Topics: Dendritic Cells; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2013 |
Lenalidomide-induced paronychia.
Topics: Adult; Angiogenesis Inhibitors; Female; Hodgkin Disease; Humans; Lenalidomide; Paronychia; Thalidomide | 2013 |
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Topics: Adult; Age Factors; Aged; Cyclophosphamide; Data Collection; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Practice Guidelines as Topic; Retrospective Studies; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Positron-Emission Tomography; Radiography; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Survival; Coculture Techniques; Drug Evaluation, Preclinical; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cells; Primary Cell Culture; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Cells, Cultured; Cross-Priming; Dendritic Cells; Female; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Ovalbumin; Thalidomide | 2013 |
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
Topics: Activins; Angiogenesis Inhibitors; Antibodies, Neutralizing; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Humans; Lenalidomide; MAP Kinase Signaling System; Multiple Myeloma; Osteoblasts; Stromal Cells; Thalidomide | 2013 |
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Chromosome Deletion; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Genetic; Risk; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2013 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia; Thalidomide; Time Factors; Tomography, X-Ray Computed | 2013 |
Non-Hodgkin's lymphomas, version 1.2013.
Topics: Antineoplastic Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thalidomide; Virus Activation | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
Topics: Angiogenesis Inhibitors; Focal Nodular Hyperplasia; Humans; Infarction; Lenalidomide; Liver; Liver Cirrhosis; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
[Molecular target therapy for myelodysplastic syndrome].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyneuropathies; Prospective Studies; Severity of Illness Index; Thalidomide | 2013 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Topics: Aged; Aged, 80 and over; Anemia; Austria; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukopenia; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cooperative Behavior; Humans; Lenalidomide; Multiple Myeloma; National Cancer Institute (U.S.); Survival Analysis; Thalidomide; United States | 2013 |
Use of lenalidomide in treating refractory prurigo nodularis.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-induced acute lung injury in case of multiple myeloma.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Radiography; Thalidomide; Treatment Outcome | 2013 |
T cells in CLL: lost in migration.
Topics: Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Function-Associated Antigen-1; rho GTP-Binding Proteins; Signal Transduction; T-Lymphocytes; Thalidomide | 2013 |
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Bone Marrow; Dexamethasone; Humans; Interferon Regulatory Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peptide Hydrolases; Plasma Cells; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2013 |
Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Topics: Apoptosis; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytokines; Dasatinib; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lysosomal-Associated Membrane Protein 1; Lysosomal-Associated Membrane Protein 2; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Thalidomide; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2013 |
Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma.
Topics: Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Topics: Humans; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2013 |
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Female; Humans; Inflammation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Th1 Cells; Th2 Cells; Thalidomide; Treatment Outcome | 2013 |
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Topics: Aged; Aged, 80 and over; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome | 2013 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Designs for randomized phase II clinical trials with two treatment arms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bias; Clinical Trials, Phase II as Topic; Endpoint Determination; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Recurrence; Research Design; Rituximab; Thalidomide; Treatment Outcome | 2013 |
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Insulin-Like Growth Factor I; Interleukin-8; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Multiple Myeloma; Quality of Life; Thalidomide | 2013 |
Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy.
Topics: Adolescent; Animals; Astrocytes; Case-Control Studies; Child; Epilepsy, Temporal Lobe; Female; Hippocampus; Humans; Lenalidomide; Lipopolysaccharides; Lithium Chloride; Male; MicroRNAs; Pilocarpine; Rats; Rats, Sprague-Dawley; Status Epilepticus; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
Topics: Diagnosis, Differential; Humans; Immunologic Factors; Keratosis; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Thalidomide | 2014 |
Jump-starting the T cells in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Humans; Immunological Synapses; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes; Thalidomide | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Thalidomide | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |
Efficacy of lenalidomide in refractory lupus pernio.
Topics: Chilblains; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Middle Aged; Thalidomide | 2013 |
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.
Topics: Aged; Cell Proliferation; Coculture Techniques; Cohort Studies; Female; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Very low-dose lenalidomide therapy for elderly multiple myeloma patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Disease; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; NF-kappa B; Polymorphism, Single Nucleotide; Protein Subunits; Pulmonary Embolism; Thalidomide; Venous Thrombosis | 2013 |
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Humans; Hyaluronan Receptors; Hyaluronic Acid; Immunologic Factors; Lenalidomide; Mice; Multiple Myeloma; Protein Binding; Thalidomide; Tretinoin; Xenograft Model Antitumor Assays | 2014 |
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Topics: Animals; Antibodies; Antibody Specificity; Antineoplastic Agents; Cancer Vaccines; Disease Models, Animal; Female; Humans; Immunologic Factors; Immunologic Memory; Lenalidomide; Lymphoma; Mice; T-Lymphocyte Subsets; Thalidomide; Tumor Burden | 2014 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Can lenalidomide play a role in the management of scleritis?
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Scleritis; Thalidomide | 2013 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
[Synergistic effect and mechanism of baicalein in combination with lenalidomide-induced apoptosis of myeloma cells].
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Flavanones; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2013 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Topics: Angiogenesis Inhibitors; Animals; Chick Embryo; Chickens; Lenalidomide; Neovascularization, Physiologic; Neurites; Neurotoxins; Species Specificity; Teratogens; Thalidomide; Zebrafish | 2013 |
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
Topics: Administration, Oral; Adult; Biopsy, Needle; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Immunohistochemistry; Lenalidomide; Male; Scleromyxedema; Severity of Illness Index; Thalidomide; Treatment Outcome | 2013 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Minimal change disease and lenalidomide.
Topics: Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Nephrosis, Lipoid; Thalidomide | 2013 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis | 2014 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide | 2014 |
[Successful treatment of an HIV-positive multiple myeloma patient with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and maintenance therapy with lenalidomide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.
Topics: Aged; Allografts; Amyloidosis; Combined Modality Therapy; Female; Graft Rejection; Heart Diseases; Heart Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Kidney Diseases; Kidney Transplantation; Lenalidomide; Prognosis; Thalidomide | 2013 |
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2013 |
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Female; Humans; Lenalidomide; Male; Medicare; Myelodysplastic Syndromes; Practice Patterns, Physicians'; Thalidomide; Treatment Outcome; United States | 2013 |
Synthesis and stability of oxetane analogs of thalidomide and lenalidomide.
Topics: Animals; Drug Discovery; Ethers, Cyclic; Hepatocytes; Humans; Lenalidomide; Mice; Microsomes, Liver; Molecular Structure; Rats; Thalidomide | 2013 |
Memory loss during lenalidomide treatment: a report on two cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Male; Memory Disorders; Multiple Myeloma; Thalidomide; Tomography, Emission-Computed, Single-Photon | 2013 |
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Topics: Adolescent; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Phenotype; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribosomal Proteins; Thalidomide | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
[II. Immunomodulation for multiple myeloma].
Topics: Bone Marrow Transplantation; Glucosides; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma; Phenols; Thalidomide | 2013 |
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Thalidomide | 2014 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation.
Topics: Adult; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Lenalidomide; Male; Paraproteinemias; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Culture Media, Conditioned; Female; Humans; Interleukin-6; Killer Cells, Natural; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Thalidomide; Transforming Growth Factor beta1; Tumor Microenvironment | 2013 |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Dexamethasone; Female; Greece; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Osteogenesis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Dose-Response Relationship, Drug; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Drug Hypersensitivity Syndrome; Female; Humans; Lenalidomide; Nephritis, Interstitial; Thalidomide | 2014 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Topics: Base Sequence; Dexamethasone; Drug Resistance; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lenalidomide; Molecular Sequence Data; Myelodysplastic Syndromes; Oligonucleotides; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Topics: HMGB1 Protein; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Stevens-Johnson Syndrome; Thalidomide; Thrombomodulin | 2013 |
Lenalidomide as first-line therapy for elderly CLL patients.
Topics: Aged; Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2013 |
Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Pharmacovigilance; Thalidomide; Young Adult | 2013 |
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Compassionate Use Trials; HIV-1; Humans; Lenalidomide; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Sarcoma, Kaposi; Thalidomide; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Viral Load | 2013 |
Light chain amyloidosis: the heart of the problem.
Topics: Amyloidosis; Animals; Cardiovascular Diseases; Death; Dexamethasone; Humans; Lenalidomide; Thalidomide | 2013 |
Lenalidomide-induced photosensitivity.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Photosensitivity Disorders; Thalidomide | 2013 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].
Topics: Acute Disease; Aged; Comorbidity; Dexamethasone; Dyspnea; Hematopoietic Stem Cell Transplantation; Humans; Hypothermia; Lenalidomide; Lung; Male; Multiple Myeloma; Neoplasm Staging; Pulmonary Diffusing Capacity; Radiotherapy, Adjuvant; Remission Induction; Respiratory Function Tests; Shivering; Thalidomide | 2014 |
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2014 |
Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Disease Models, Animal; Humans; Lenalidomide; Lymphangiogenesis; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; DNA-Binding Proteins; Humans; Lenalidomide; Mutation; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Topics: B-Lymphocytes; Female; Hodgkin Disease; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture.
Topics: Animals; Astrocytes; Brain; Calgranulin A; Cells, Cultured; Gene Expression Regulation; Inflammation; Lenalidomide; Lipopolysaccharides; Male; MicroRNAs; Rats; Rats, Sprague-Dawley; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Female; Gene Expression; Heterografts; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Protein Binding; Protein Stability; Thalidomide; Tumor Burden | 2014 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Topics: Adult; Antigens, Surface; Antineoplastic Agents; Case-Control Studies; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Homeostasis; Humans; Immunophenotyping; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Staging; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Thymus Gland; Transplantation, Autologous; Treatment Outcome | 2014 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corneal Opacity; Crystallization; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney Failure, Chronic; Lenalidomide; Male; Melphalan; Middle Aged; Paraproteinemias; Paraproteins; Phacoemulsification; Postoperative Complications; Prednisone; Slit Lamp; Thalidomide | 2013 |
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Withholding Treatment | 2014 |
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Proteolysis; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Proteolysis; T-Lymphocytes; Thalidomide; Ubiquitination | 2014 |
A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.
Topics: Animals; Cattle; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immune Sera; Lenalidomide; Multiple Myeloma; Rabbits; Sensitivity and Specificity; Serum Albumin, Bovine; Thalidomide | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Topics: Aged, 80 and over; Anemia, Refractory; Bone Marrow; Erythrocytes, Abnormal; Female; Humans; Immunologic Factors; Lenalidomide; Thalidomide; Thrombocytosis; Treatment Outcome | 2014 |
Potential new risks of lenalidomide.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome | 2014 |
Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner.
Topics: Aged; Angiogenesis Inhibitors; Cryoglobulinemia; Hemangioendothelioma; Humans; Lenalidomide; Male; Running; Skin Neoplasms; Thalidomide | 2013 |
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
Topics: Acyclovir; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotic Prophylaxis; Antiviral Agents; Encephalitis, Varicella Zoster; Female; Germany; Herpes Simplex; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polyradiculopathy; Risk Factors; Simplexvirus; Thalidomide | 2014 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning | 2013 |
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Peptide Hydrolases; Proteasome Endopeptidase Complex; T-Lymphocytes; Thalidomide; Transcription Factors; Transfection; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors | 2014 |
[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Fatal Outcome; Humans; Lenalidomide; Male; Stevens-Johnson Syndrome; Thalidomide | 2013 |
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Killer Cells, Natural; Lenalidomide; Liver Neoplasms; Lung Neoplasms; Mutation; Pelvic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Thalidomide | 2014 |
Multiple myeloma and other malignancies: a pilot study from the Houston VA.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pilot Projects; Proportional Hazards Models; Registries; Retrospective Studies; Survivors; Texas; Thalidomide; United States; United States Department of Veterans Affairs | 2014 |
Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Glycosylation; GPI-Linked Proteins; Humans; Immunotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Side-Population Cells; Thalidomide; Up-Regulation | 2013 |
Case of angioedema and urticaria induced by lenalidomide.
Topics: Aged; Angioedema; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Urticaria | 2014 |
Lenalidomide and T-cell homeostasis: tolerating immune reconstitution after autologous stem cell transplant.
Topics: Antineoplastic Agents; Homeostasis; Humans; Lenalidomide; Multiple Myeloma; T-Lymphocyte Subsets; Thalidomide | 2014 |
An overview of the progress in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide | 2014 |
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide | 2014 |
Medicine. How thalidomide works against cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide | 2014 |
Multiple myeloma and second malignancies.
Topics: Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Registries; Thalidomide | 2014 |
Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Male; Purines; Quinazolinones; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thalidomide; Vidarabine | 2014 |
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Surface; Apoptosis; beta 2-Microglobulin; Cell Proliferation; Complement System Proteins; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Male; Mesenchymal Stem Cells; Mice; Mice, SCID; Multiple Myeloma; RNA Interference; RNA, Small Interfering; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9 | 2014 |
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones | 2014 |
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.
Topics: Aged; Bone Marrow; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Positron-Emission Tomography; Recurrence; Thalidomide; Tomography, X-Ray Computed; Transplantation, Homologous | 2014 |
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Rituximab; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Necrobiotic Xanthogranuloma; Orbital Neoplasms; Thalidomide | 2013 |
Lenalidomide and second malignancies in myeloma patients.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2014 |
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Gene Expression Regulation, Leukemic; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Receptors, Immunologic; T-Lymphocytes; Thalidomide | 2014 |
A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Area Under Curve; Asian People; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Maturation Antigen; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Immunologic Factors; Immunotoxins; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide | 2014 |
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.
Topics: Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Interactions; Glucuronosyltransferase; Humans; Lenalidomide; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Thalidomide | 2014 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Flow Cytometry; Hematopoiesis; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Time Factors; Treatment Outcome; Young Adult | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.
Topics: Adjuvants, Immunologic; Cell Differentiation; Cells, Cultured; Humans; In Vitro Techniques; Lenalidomide; Mesenchymal Stem Cells; Osteoblasts; Thalidomide | 2014 |
Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Radiography; Thalidomide; Treatment Outcome | 2014 |
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Topics: Aged; Female; Humans; Immunologic Factors; Immunologic Memory; Immunomodulation; Immunophenotyping; Lenalidomide; Lymphocyte Activation; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phenotype; T-Lymphocyte Subsets; Thalidomide | 2014 |
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Evaluation; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Humans; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Proteasome Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Thalidomide | 2014 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide | 2014 |
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Tumour necrosis factor-α inhibition with lenalidomide alleviates tissue oxidative injury and apoptosis in ob/ob obese mice.
Topics: Animals; Apoptosis; Blood Glucose; Gene Expression Regulation; Glucose; Immunologic Factors; Intestine, Small; Kidney; Lenalidomide; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Oxidative Stress; Thalidomide; Tumor Necrosis Factor-alpha | 2014 |
Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient.
Topics: Angiogenesis Inhibitors; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; Crystallography, X-Ray; Delayed-Action Preparations; Drug Carriers; Excipients; Humans; Hydrophobic and Hydrophilic Interactions; Lenalidomide; Light; MCF-7 Cells; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms; Particle Size; Powder Diffraction; Scattering, Radiation; Solubility; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Thalidomide; Thermogravimetry | 2014 |
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Response of cutaneous lesion of mantle cell lymphoma to lenalidomide.
Topics: Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Male; Skin; Skin Neoplasms; Thalidomide | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Successful management of refractory pediatric-onset complex aphthosis with lenalidomide.
Topics: Adolescent; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Recurrence; Stomatitis, Aphthous; Thalidomide | 2014 |
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Humans; Lenalidomide; Neoplasm Recurrence, Local; Plasmacytoma; Thalidomide; Treatment Outcome | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide.
Topics: Aged; Blood Cell Count; Bone Marrow; Drug Therapy, Combination; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nitrosourea Compounds; Skin; Sweet Syndrome; Thalidomide; Thrombocythemia, Essential; Treatment Outcome | 2014 |
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunophenotyping; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Fc; Risk Factors; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Topics: Angiogenesis Inhibitors; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2014 |
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; alpha Karyopherins; Anti-Inflammatory Agents; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Flow Cytometry; Follow-Up Studies; Humans; Ikaros Transcription Factor; Immunologic Factors; Immunoprecipitation; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Prognosis; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Paraproteinemias; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.
Topics: Aged; Angiogenesis Inhibitors; Antigens, CD34; Biomarkers, Tumor; Biopsy; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Lenalidomide; Liver Neoplasms; Magnetic Resonance Imaging; Male; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2014 |
Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2014 |
A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Birefringence; Bone Marrow Examination; Fatal Outcome; Female; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Microscopy, Polarization; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
The preclinical activity of lenalidomide in indolent urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cerebrosides; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lenalidomide; Mice; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Pathologic; Thalidomide; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Cell Count; Fatal Outcome; Humans; Knee; Lenalidomide; Male; Multiple Myeloma; Pyoderma Gangrenosum; Skin; Thalidomide | 2015 |
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Leukemic; HeLa Cells; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Peptide Hydrolases; Signal Transduction; Thalidomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
[Myelodysplastic syndromes (MDS)].
Topics: Azacitidine; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide | 2014 |
[Immunomodulatory drugs (IMiDs)].
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatigue; Humans; Hypertension, Renal; Immunoglobulin Light Chains; Kidney; Kidney Failure, Chronic; Lenalidomide; Male; Myalgia; Paraproteinemias; Proteinuria; Remission Induction; Thalidomide | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Survival Rate; Tertiary Care Centers; Thalidomide; Treatment Outcome; Young Adult | 2015 |
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Topics: Adaptor Proteins, Signal Transducing; Crystallography, X-Ray; DNA-Binding Proteins; Homeodomain Proteins; Humans; Lenalidomide; Models, Molecular; Multiprotein Complexes; Peptide Hydrolases; Protein Binding; Structure-Activity Relationship; Substrate Specificity; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2014 |
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Topics: Fatal Outcome; Humans; Immunologic Factors; Leg; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Transplantation; Nerve Tissue Proteins; Plasmacytoma; Signal Transduction; Thalidomide; Trans-Activators | 2015 |
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2015 |
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Crystallography, X-Ray; DNA-Binding Proteins; Humans; Lenalidomide; Mice; Molecular Docking Simulation; Molecular Sequence Data; Peptide Hydrolases; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Sequence Alignment; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
Topics: Adult; Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Thalidomide | 2015 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide | 2014 |
Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Cholecalciferol; CpG Islands; Drug Synergism; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Membrane Proteins; Middle Aged; Mitochondrial Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Thalidomide; Tumor Cells, Cultured | 2014 |
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Thalidomide | 2014 |
Current treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2014 |
[Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Plasmapheresis; Thalidomide | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide, an antiproliferative CLL drug.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunologic Factors; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Thalidomide | 2015 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Immunoglobulin A; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bortezomib; Dexamethasone; Doxorubicin; Erythema; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Renal Dialysis; Thalidomide; Vincristine | 2014 |
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Radiotherapy, Adjuvant; Recurrence; Rituximab; Salvage Therapy; Thalidomide | 2014 |
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Cell Count; Drug Therapy, Combination; Female; Filgrastim; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2015 |
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Single Nucleotide; RNA Splicing; RNA, Messenger; Signal Transduction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2015 |
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Topics: Aged; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome-Wide Association Study; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Primary Cell Culture; RNA Splicing; Signal Transduction; Thalidomide | 2015 |
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.
Topics: Aged; Bile Acids and Salts; Diarrhea; Female; Humans; Lenalidomide; Malabsorption Syndromes; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; CD4-Positive T-Lymphocytes; Cell Proliferation; Humans; Immunomodulation; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Thalidomide; Tumor Cells, Cultured | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
Topics: Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Recurrence; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors; Treatment Outcome | 2015 |
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; Indoles; Lenalidomide; Lymphoma, Mantle-Cell; Male; Signal Transduction; Thalidomide | 2015 |
Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type.
Topics: Aged; Female; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Thalidomide | 2015 |
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Topics: Angiogenesis Inhibitors; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; RNA, Small Interfering; Thalidomide; Tumor Cells, Cultured | 2015 |
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Animals; Antibody-Dependent Cell Cytotoxicity; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Immunotherapy; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Mice; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Thalidomide; Xenograft Model Antitumor Assays | 2015 |
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Topics: Actin Cytoskeleton; Angiogenesis Inhibitors; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Coculture Techniques; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Macrophages; Monocytes; Phagocytosis; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Recurrence; Thalidomide; Treatment Outcome | 2015 |
Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Topics: Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Alveoli; Thalidomide | 2015 |
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
Topics: Antigens, CD; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Drug Monitoring; Female; Gene Expression; Humans; Immunologic Factors; Immunophenotyping; Lenalidomide; Lymphocytes; Male; Myelodysplastic Syndromes; Myeloid Cells; Thalidomide | 2015 |
Towards a chemotherapy-free approach in indolent lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Rituximab; Thalidomide | 2014 |
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.
Topics: Actins; Aged; Aged, 80 and over; Amides; Cell Line, Tumor; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Female; Humans; Immunologic Factors; Lenalidomide; Male; Membrane Microdomains; Myelodysplastic Syndromes; Protein Multimerization; Pyridines; Receptors, Erythropoietin; rho-Associated Kinases; Signal Transduction; Thalidomide | 2014 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide | 2015 |
Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography.
Topics: Antineoplastic Agents; Chromatography, Micellar Electrokinetic Capillary; Lenalidomide; Models, Molecular; Stereoisomerism; Thalidomide; Thermodynamics | 2015 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytotoxicity, Immunologic; Drug Synergism; Flow Cytometry; Humans; Immunoglobulin G; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Receptors, IgG; Receptors, KIR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide | 2015 |
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myopathies, Nemaline; Neck Muscles; Thalidomide | 2015 |
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2015 |
[Suspected itchy rash secondary to lenalidomide].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; Lenalidomide; Prednisone; Thalidomide | 2014 |
Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells.
Topics: Antigens, CD20; Antineoplastic Agents; Cell Membrane; Gene Expression Regulation, Leukemic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2015 |
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Prospective Studies; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2015 |
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Adenine; Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Liquid-Liquid Extraction; Male; Piperidines; Plasma; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Thalidomide; Tolbutamide | 2015 |
A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Half-Life; Heterografts; Humans; Lenalidomide; Male; Mice, Inbred ICR; Mice, SCID; Multiple Myeloma; Nuclear Proteins; Nucleophosmin; Osteoclasts; Phthalimides; Thalidomide | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
[Immunomodulatory effects of lenalidomide].
Topics: Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Myeloid Cells; T-Lymphocytes; Thalidomide | 2015 |
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2015 |
Late onset perforating folliculitis induced by lenalidomide: a case report.
Topics: Drug Eruptions; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Thalidomide | 2015 |
Lenalidomide-associated hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Treatment Outcome | 2015 |
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Drug Synergism; Humans; Immunoglobulin kappa-Chains; Immunophenotyping; Lenalidomide; Leukocytes, Mononuclear; Multiple Myeloma; Phenotype; Plasma Cells; Protein Binding; Thalidomide | 2015 |
R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Thalidomide; Vincristine | 2014 |
Myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2015 |
Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Plasmablastic Lymphoma; Retreatment; Stomach Neoplasms; Thalidomide; Treatment Outcome | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Severe hypocalcemia due to lenalidomide.
Topics: Aged; Calcium; Humans; Hypocalcemia; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Severity of Illness Index; Thalidomide | 2015 |
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2015 |
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Function Tests | 2015 |
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Cytokines; Female; Flow Cytometry; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Thalidomide | 2015 |
When less is more: results Herald 'paradigm shift' in treating newly diagnosed multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Congresses as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2014 |
Zeroing in on cereblon.
Topics: Adaptor Proteins, Signal Transducing; Carrier Proteins; Cullin Proteins; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; NF-kappa B; Peptide Hydrolases; Protein Binding; Signal Transduction; Thalidomide; Transcription Factor 3; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2015 |
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2015 |
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Bortezomib; Cryoprotective Agents; Dexamethasone; Dimethyl Sulfoxide; Electrocardiography; Humans; Isotonic Solutions; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Ventricular Premature Complexes | 2015 |
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Follow-Up Studies; Gene Expression; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Topics: ADP-ribosyl Cyclase 1; Animals; Bortezomib; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2015 |
Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
Topics: Angiogenesis Inhibitors; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; MicroRNAs; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Sequence Deletion; Thalidomide | 2015 |
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Ital
Topics: Aged; Aging; Antigens, CD34; Biomarkers; Cell Count; Cell Separation; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Failure | 2015 |
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Netherlands; Quality-Adjusted Life Years; Survival Analysis; Thalidomide | 2016 |
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Lenalidomide; Mesenchymal Stem Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thalidomide; Tretinoin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
New treatments highlighted for lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Oligopeptides; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic Diseases; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Pain; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Humans; Immunologic Factors; Lenalidomide; Plasma Exchange; Rituximab; Severity of Illness Index; Splenectomy; Steroids; Thalidomide; Time-to-Treatment; Treatment Outcome | 2015 |
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Line, Transformed; Cytokines; Disease Models, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunologic Factors; Lenalidomide; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Parkinson Disease; RNA, Messenger; Signal Transduction; Thalidomide | 2015 |
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Topics: Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Proteolysis; Thalidomide | 2015 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Immunomodulation; In Vitro Techniques; Lenalidomide; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thalidomide; Transfection; Vorinostat | 2015 |
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antigen-Presenting Cells; B7-H1 Antigen; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Humans; Interferon-gamma; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Microenvironment | 2015 |
Lenalidomide in treating patients with castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lenalidomide; Male; Meta-Analysis as Topic; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Thalidomide | 2015 |
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Down-Regulation; Gene Silencing; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; Thalidomide; Up-Regulation; Vincristine | 2015 |
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.
Topics: Actin Cytoskeleton; Actins; Cells, Cultured; GPI-Linked Proteins; Humans; Immunological Synapses; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; NK Cell Lectin-Like Receptor Subfamily K; Receptors, IgG; Thalidomide | 2015 |
Plasma cell leukemia mimicking hairy cell leukemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Hairy Cell; Leukemia, Plasma Cell; Plasma Cells; Thalidomide | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome | 2015 |
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Purpura, Thrombotic Thrombocytopenic; Thalidomide | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Down-Regulation; Female; Humans; Immunologic Factors; Inducible T-Cell Co-Stimulator Ligand; Lenalidomide; Male; Middle Aged; Multiple Myeloma; T-Lymphocytes, Regulatory; Thalidomide | 2015 |
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2015 |
[Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Beijing; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2015 |
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Mice; Nuclear Proteins; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Thalidomide; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Topics: Amino Acid Sequence; Animals; Casein Kinase I; Cell Line; Gene Expression Regulation; HEK293 Cells; Humans; Immunologic Factors; Jurkat Cells; K562 Cells; Lenalidomide; Mice; Molecular Sequence Data; Myelodysplastic Syndromes; Peptide Hydrolases; Proteolysis; Sequence Alignment; Sequence Deletion; Species Specificity; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2015 |
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Poland; Retrospective Studies; Thalidomide; Treatment Outcome | 2015 |
Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration.
Topics: Adsorption; Angiogenesis Inhibitors; Chromatography, High Pressure Liquid; Deglutition Disorders; Drug Compounding; Drug Stability; Feasibility Studies; Lenalidomide; Particle Size; Solvents; Spectrophotometry, Ultraviolet; Suspensions; Tablets; Temperature; Thalidomide | 2016 |
Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Lenalidomide; Lymph Nodes; Male; Mediastinal Neoplasms; Mediastinum; Melphalan; Middle Aged; Plasma Cells; Plasmacytoma; Syndecan-1; Thalidomide | 2016 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Glomerular Basement Membrane; Glomerular Filtration Rate; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney Diseases; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteinuria; Retrospective Studies; Survival Rate; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2015 |
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2017 |
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; HEK293 Cells; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Lung; Sarcoidosis, Pulmonary; Thalidomide; Tomography, X-Ray Computed | 2015 |
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Choroidal Neovascularization; Diabetic Retinopathy; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inflammation Mediators; Lenalidomide; Macaca mulatta; Mice; Retinal Neovascularization; Retinal Vessels; Thalidomide; Vascular Endothelial Growth Factor A | 2015 |
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Transplantation, Homologous | 2015 |
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antigens, Differentiation, T-Lymphocyte; Cell Line, Tumor; Female; Histocompatibility Antigens Class I; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Killer Cells, Natural; Lenalidomide; Ligands; Lymphocyte Activation; Male; Middle Aged; Multiple Myeloma; NK Cell Lectin-Like Receptor Subfamily K; Promoter Regions, Genetic; Receptors, Virus; Thalidomide | 2015 |
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide | 2016 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.
Topics: Analysis of Variance; Animals; Autoimmunity; Cells, Cultured; Central Nervous System; Cerium; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Flow Cytometry; Gene Expression Regulation; Immunologic Factors; Lenalidomide; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; RNA, Messenger; Thalidomide; Time Factors | 2015 |
Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Female; Humans; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Thalidomide; Tumor Suppressor Protein p53 | 2015 |
Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.
Topics: Adult; B-Lymphocytes; Biopsy; Epstein-Barr Virus Infections; Female; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoproliferative Disorders; Remission Induction; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Health Care Costs; Humans; Lenalidomide; Models, Economic; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Technology Assessment, Biomedical; Thalidomide | 2016 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide | 2015 |
[A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Topics: Aged; Female; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pancreatic Neoplasms; Thalidomide; Tomography, X-Ray Computed | 2015 |
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Female; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Mice, Inbred BALB C; Multiple Myeloma; Spleen; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2015 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Heparin; Humans; Lenalidomide; Magnetic Resonance Imaging; Metronidazole; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Dexamethasone; Humans; Leishmaniasis, Visceral; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide | 2015 |
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom | 2015 |
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Quality of Life; Thalidomide; Treatment Outcome | 2015 |
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Clinical Trials, Phase II as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thalidomide | 2015 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Lenalidomide; Mice; Mice, Nude; Multiple Myeloma; Phenylbutyrates; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunoblotting; Immunohistochemistry; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Signal Transduction; Thalidomide | 2015 |
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Retrospective Studies; Thalidomide; Treatment Failure; Treatment Outcome | 2015 |
CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; CD4-Positive T-Lymphocytes; Immunomodulation; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Multiple Myeloma; Thalidomide | 2015 |
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Glioma; Humans; Immunologic Factors; Immunological Synapses; Immunotherapy, Adoptive; Interferon-gamma; Interleukin Receptor Common gamma Subunit; Lenalidomide; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; Single-Chain Antibodies; T-Lymphocytes; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.
Topics: Aged; Aged, 80 and over; Disease Management; Drug Therapy; Erythrocyte Transfusion; Female; Geriatric Assessment; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Precision Medicine; Thalidomide; Thrombopoiesis | 2015 |
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2016 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report.
Topics: Adult; Histiocytosis, Sinus; Humans; Immunologic Factors; Lenalidomide; Male; Thalidomide; Treatment Outcome | 2016 |
Extensive purpuric lesions on the face.
Topics: Aged, 80 and over; Amyloidosis; Diagnosis, Differential; Face; Facial Dermatoses; Female; Humans; Immunologic Factors; Lenalidomide; Thalidomide | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Cycle; Cyclophosphamide; Dexamethasone; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Peptide Hydrolases; Polymorphism, Single Nucleotide; Thalidomide; Ubiquitin-Protein Ligases; Wnt Signaling Pathway | 2015 |
Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Bortezomib; Cell Line, Tumor; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2015 |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; DNA, Neoplasm; Female; Germ-Line Mutation; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Receptors, Interleukin-1; Survival Analysis; Thalidomide; Toll-Like Receptor 4 | 2016 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide | 2016 |
Continued role for ASCT in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
POEMS syndrome: complex factors contributing to a delayed diagnosis.
Topics: Delayed Diagnosis; Dexamethasone; Diagnosis, Differential; Electromyography; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Neural Conduction; POEMS Syndrome; Thalidomide | 2015 |
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Community Pharmacy Services; Fees, Pharmaceutical; Female; Humans; Lenalidomide; Male; Medication Adherence; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Topics: Animals; Caspase 3; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Plasma Cells; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thalidomide; Trans-Activators | 2016 |
Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Interleukin-6; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphorylation; STAT3 Transcription Factor; Syndecan-1; Thalidomide | 2016 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2016 |
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bortezomib; Dexamethasone; Erythrocyte Indices; Erythroid Cells; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Lenalidomide; Lymphocytes; Remission Induction; Rituximab; Thalidomide; Treatment Outcome | 2016 |
CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Gene Expression; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Registries; SEER Program; Thalidomide; Young Adult | 2016 |
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2015 |
The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Count; Retrospective Studies; Risk Factors; Thalidomide; Thrombocytopenia | 2015 |
[Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Quality of Life; Surveys and Questionnaires; Thalidomide | 2015 |
Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Necrobiotic Xanthogranuloma; Paraproteinemias; Thalidomide; Treatment Outcome | 2016 |
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Topics: Angiogenesis Inhibitors; Antibodies; Apoptosis; Base Sequence; Binding Sites; Cell Line, Tumor; Cullin Proteins; Down-Regulation; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Positive Regulatory Domain I-Binding Factor 1; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA, Small Interfering; Thalidomide; Ubiquitination | 2016 |
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Second Primary; Thalidomide | 2015 |
Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Cells, Cultured; Clustered Regularly Interspaced Short Palindromic Repeats; Immunologic Factors; Immunosuppression Therapy; Inflammation; Interferon Regulatory Factor-3; Interferon Type I; Lenalidomide; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Signal Transduction; Thalidomide; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2016 |
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Topics: Academic Medical Centers; Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Panniculitis, Lupus Erythematosus; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Thalidomide; Time Factors; Treatment Outcome | 2016 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas.
Topics: Antineoplastic Agents; Dendritic Cells; Drug Screening Assays, Antitumor; Glioma; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Leukocytes, Mononuclear; Molecular Structure; Structure-Activity Relationship; Thalidomide; Tumor Cells, Cultured | 2016 |
Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Topics: Binding Sites; Casein Kinase Ialpha; Catalytic Domain; Crystallography, X-Ray; Humans; Ikaros Transcription Factor; Lenalidomide; Models, Molecular; Protein Binding; Proteolysis; Structure-Activity Relationship; Substrate Specificity; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Lenalidomide; Mice, SCID; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Disease Management; Exanthema; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide in adult T-cell leukaemia-lymphoma.
Topics: Adult; Antineoplastic Agents; Humans; Lenalidomide; Leukemia; Leukemia-Lymphoma, Adult T-Cell; T-Lymphocytes; Thalidomide; Treatment Outcome | 2016 |
A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies.
Topics: Angiogenesis Inhibitors; Chromatography, High Pressure Liquid; Humans; Lenalidomide; Plasma; Thalidomide | 2016 |
Lenalidomide potentiates CD4
Topics: Adult; Aged; B-Lymphocytes; Blood Donors; CD4 Antigens; Cell Proliferation; Cells, Cultured; Female; Humans; Immunologic Factors; Interleukin-2 Receptor alpha Subunit; Lenalidomide; Lymphoma; Male; Middle Aged; Sirolimus; T-Lymphocytes, Regulatory; Thalidomide | 2017 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Remission Induction; Thalidomide; Treatment Outcome; von Willebrand Diseases; von Willebrand Factor | 2016 |
Monoclonal gammopathy-associated pure red cell aplasia.
Topics: Adult; Aged; Bone Marrow; Dexamethasone; Diagnosis, Differential; Female; Humans; Immunoglobulins; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Plasma Cells; Red-Cell Aplasia, Pure; Reticulocyte Count; Reticulocytes; Thalidomide; Young Adult | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinolines; Thalidomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; Edema; Emergencies; Heart; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Nephrotic Syndrome; Paraproteinemias; Paraproteins; Recurrence; Syncope; Thalidomide; Torsades de Pointes; Transplantation, Autologous | 2016 |
Differential effects of lenalidomide during plasma cell differentiation.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Thalidomide | 2016 |
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide - the new melphalan?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide | 2016 |
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide | 2016 |
Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond.
Topics: Adult; Diagnosis, Differential; Disease Progression; Genetic Markers; Genetic Testing; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; POEMS Syndrome; Thalidomide | 2016 |
A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Chromosomes, Human, Pair 1; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exosomes; Female; Gene Amplification; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Microarray Analysis; MicroRNAs; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Risk Factors; Thalidomide; Tumor Microenvironment | 2016 |
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Argonaute Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; MicroRNAs; Multiple Myeloma; Peptide Hydrolases; Protein Binding; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lenalidomide; Mice; Mice, SCID; Neoplasm Metastasis; Neovascularization, Pathologic; Perfusion; Pericytes; Thalidomide; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Cholangiocarcinoma; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
[Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2016 |
[Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Ifosfamide; Lenalidomide; Multiple Myeloma; Remission Induction; Thalidomide | 2016 |
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Internationality; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Prospective Studies; Salvage Therapy; Thalidomide | 2016 |
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Topics: Adult; Chronic Disease; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Retreatment; Thalidomide | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.
Topics: Adaptor Proteins, Signal Transducing; Cells, Cultured; Humans; Janus Kinase 2; Lenalidomide; Peptide Hydrolases; Receptors, Erythropoietin; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Vitamin K | 2016 |
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Oligopeptides; Quality of Life; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States | 2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylate Cyclase; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Signal Transduction; Thalidomide; Transfection | 2016 |
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Humans; L-Selectin; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Analysis; Thalidomide; Vascular Cell Adhesion Molecule-1 | 2016 |
Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.
Topics: Aged; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2016 |
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Thalidomide; Treatment Outcome | 2016 |
Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
Topics: Acute Kidney Injury; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Topics: B-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Expression Profiling; Humans; Immunologic Factors; Interleukins; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Phospholipase C gamma; Phosphorylation; Receptors, Interleukin-21; Syk Kinase; T-Lymphocytes; Thalidomide | 2016 |
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Calcium; Calcium-Binding Proteins; Calpain; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Peptide Hydrolases; Receptors, G-Protein-Coupled; RNA Interference; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |
Prolonged Response in Patient With Multiply Relapsed B-cell Acute Lymphoblastic Leukemia and Monosomy-7 to Bortezomib, Lenalidomide, and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Chromosome Deletion; Chromosomes, Human, Pair 7; Dexamethasone; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2016 |
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy.
Topics: Aged; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Survival Rate; Thalidomide | 2017 |
Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.
Topics: Adult; Aged; Dexamethasone; Female; Humans; Hypogonadism; Immunologic Factors; Lenalidomide; Male; Middle Aged; POEMS Syndrome; Prospective Studies; Sexual Dysfunction, Physiological; Thalidomide; Young Adult | 2016 |
Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions.
Topics: Adult; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Retreatment; Skin Diseases; Thalidomide | 2016 |
Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, AIDS-Related; Maxillary Sinus Neoplasms; Plasmablastic Lymphoma; Poverty; Prednisolone; Remission Induction; Thalidomide; Vincristine | 2016 |
LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Chromatography, Liquid; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Monitoring; Humans; Immunosuppressive Agents; Lenalidomide; Limit of Detection; Multiple Myeloma; Tandem Mass Spectrometry; Thalidomide | 2016 |
Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
Topics: Antineoplastic Agents; Bortezomib; Canada; Combined Modality Therapy; Costs and Cost Analysis; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2016 |
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phenotype; Thalidomide | 2016 |
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Secondary Prevention; Thalidomide; Treatment Outcome | 2016 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Odds Ratio; Population Surveillance; Retrospective Studies; Risk Factors; Thalidomide | 2017 |
Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hemoglobins; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Risk Factors; Thalidomide | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine | 2016 |
Pleural effusion as a manifestation of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Kidney Failure, Chronic; Lenalidomide; Lung Neoplasms; Male; Multiple Myeloma; Pleural Effusion; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Multiple Medium Amoebic Liver Abscesses Successfully Treated with Medication and Comprehensive Percutaneous Catheter Drainage.
Topics: Catheterization; Drainage; Female; Humans; Immunologic Factors; Lenalidomide; Liver Abscess, Amebic; Metronidazole; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Prospective Studies; Recurrence; Sensory Receptor Cells; Severity of Illness Index; Thalidomide; Time Factors | 2016 |
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Topics: Aged; Erythema Nodosum; Humans; Immunologic Factors; Janus Kinase 2; Lenalidomide; Male; Panniculitis; Primary Myelofibrosis; Thalidomide | 2016 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Panobinostat; Proportional Hazards Models; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Prognosis; Recurrence; Remission Induction; Thalidomide | 2017 |
Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.
Topics: Antineoplastic Agents; Biopsy; Bone Marrow; Female; Humans; Immunophenotyping; Lenalidomide; Lymphoma, Follicular; Middle Aged; Skin; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous | 2017 |
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cohort Studies; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Thalidomide; Young Adult | 2016 |
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dexamethasone; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Staging; Proportional Hazards Models; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2016 |
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Drug Monitoring; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Thalidomide; Treatment Outcome | 2016 |
Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.
Topics: Adaptor Proteins, Signal Transducing; Binding Sites; Gene Knockdown Techniques; Guanine Nucleotide Exchange Factors; Humans; Immunity, Cellular; Immunologic Factors; Interferon Type I; Lenalidomide; Multiprotein Complexes; Peptide Hydrolases; Protein Binding; Thalidomide; Toll-Like Receptors; Ubiquitin-Protein Ligases | 2016 |
Maintenance lenalidomide after transplantation: How much is enough?
Topics: Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2016 |
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2016 |
Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Gene Knockdown Techniques; Humans; Isoenzymes; Lenalidomide; MAP Kinase Signaling System; Multiple Myeloma; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; ras Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; TOR Serine-Threonine Kinases | 2017 |
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Enzyme Activation; Female; Humans; Immunoglobulin Isotypes; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Oligopeptides; Proteasome Endopeptidase Complex; Thalidomide; Treatment Outcome | 2017 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
Anaemia with inflammation responding to lenalidomide.
Topics: Aged; Anemia; Female; Humans; Immunologic Factors; Inflammation; Lenalidomide; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression; Humans; Lenalidomide; Liver Neoplasms; Neovascularization, Pathologic; Thalidomide; Vascular Endothelial Growth Factor A | 2016 |
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2017 |
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Vorinostat | 2016 |
RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.
Topics: Actins; Adolescent; Angiogenesis Inhibitors; B-Lymphocytes; Cell Movement; Cell Proliferation; Child; Cytoskeleton; Cytotoxicity, Immunologic; DNA Mutational Analysis; DNA-Binding Proteins; Dyneins; Female; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunoglobulin Class Switching; Immunologic Deficiency Syndromes; Jurkat Cells; Killer Cells, Natural; Lenalidomide; Male; Mutation; Pedigree; RNA, Small Interfering; T-Lymphocytes; Thalidomide | 2016 |
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disease Progression; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Prospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Heart Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Propensity Score; Proportional Hazards Models; Risk; Thalidomide | 2017 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Prednisolone; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2017 |
Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, T-Cell; Male; Positron Emission Tomography Computed Tomography; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marrow; Bortezomib; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Radiation Dosage; Retrospective Studies; Sensitivity and Specificity; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2016 |
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Topics: Chromosome Aberrations; Cohort Studies; Computational Biology; Computer Simulation; Drug Resistance, Neoplasm; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Interaction Maps; Retrospective Studies; Thalidomide; Treatment Outcome | 2017 |
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Dapsone; Humans; Immunosuppressive Agents; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Practice Guidelines as Topic; Retinoids; Thalidomide | 2017 |
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Thalidomide; Treatment Outcome | 2017 |
Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Immunologic Factors; Immunomodulation; Lenalidomide; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prostatic Neoplasms; Thalidomide | 2017 |
Lenalidomide in Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Thalidomide; Treatment Outcome | 2016 |
Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Dexamethasone; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Survival Rate; Thalidomide; United States; Young Adult | 2017 |
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Topics: Aged; Antigens, CD34; Blood Cells; Bone Marrow Cells; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Thalidomide | 2017 |
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Topics: Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Computational Biology; Disease Progression; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Stem Cell Niche; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Topics: Biomarkers; Cell Survival; Cytokines; Dendritic Cells; Humans; Immunologic Factors; Immunomodulation; Immunophenotyping; Lenalidomide; Multiple Myeloma; Phenotype; T-Lymphocyte Subsets; Thalidomide | 2017 |
Treatment of prurigo nodularis with lenalidomide.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunoglobulins; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2017 |
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Outpatient Clinics, Hospital; Retrospective Studies; Survival Rate; Thalidomide | 2017 |
OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Papilledema; POEMS Syndrome; Prospective Studies; Thalidomide; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Topics: Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2017 |
Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.
Topics: Blood Platelets; Cell Proliferation; Culture Media; Female; Humans; Immunoglobulins; Killer Cells, Natural; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2017 |
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Renal Dialysis; Thalidomide | 2017 |
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
Topics: Administration, Oral; Adult; Aged; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Registries; Thalidomide; Time Factors | 2017 |
Multiple myeloma cells' capacity to decompose H
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Humans; Hydrogen Peroxide; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxidative Stress; Peptide Hydrolases; Peroxidase; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2017 |
Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Body Surface Area; Creatinine; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Thalidomide | 2017 |
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Dexamethasone; Gene Expression; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Thalidomide | 2017 |
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Gliosis; Humans; Immunotherapy; Lenalidomide; Mice, Transgenic; Multiple System Atrophy; Proto-Oncogene Proteins c-akt; Signal Transduction; Single-Chain Antibodies; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Topics: Antibodies, Monoclonal; Cancer Vaccines; Cell Cycle Checkpoints; Humans; Immunomodulation; Immunotherapy; Ipilimumab; Lenalidomide; Male; Nivolumab; Programmed Cell Death 1 Receptor; Prostatic Neoplasms; Quinolines; Quinolones; Thalidomide; Tissue Extracts; Vaccines, Synthetic | 2016 |
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
Topics: Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide | 2016 |
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status.
Topics: Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Risk Factors; Thalidomide | 2016 |
Recommend maintenance therapy with lenalidomide in multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2016 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bortezomib; Humans; Lenalidomide; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Thalidomide; Thoracic Vertebrae; Treatment Outcome | 2017 |
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.
Topics: Adolescent; Adult; Child; Comprehension; Contraception; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Lenalidomide; Male; Patient Compliance; Patient Education as Topic; Pregnancy; Risk Evaluation and Mitigation; Surveys and Questionnaires; Teratogens; Thalidomide; Young Adult | 2017 |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Evaluation, Preclinical; Humans; Immunoconjugates; Lenalidomide; Maytansine; Mice; Multiple Myeloma; Syndecan-1; Thalidomide | 2017 |
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Survival; Dexamethasone; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Protein Binding; Proteolysis; Proto-Oncogene Proteins c-abl; Thalidomide; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computed Tomography Angiography; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; HIV Seronegativity; Humans; Lenalidomide; Male; Plasmablastic Lymphoma; Prognosis; Remission Induction; Sigmoid Neoplasms; Thalidomide | 2017 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocytosis, Langerhans-Cell; Humans; Infant; Lenalidomide; Male; Pituitary Gland, Posterior; Prednisolone; Pulse Therapy, Drug; Remission Induction; Salvage Therapy; Skull Base; Thalidomide; Thoracic Vertebrae; Vinblastine | 2017 |
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Bortezomib; Casein Kinase I; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Tumor Suppressor Protein p53 | 2017 |
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen Type II; Dextran Sulfate; Disease Models, Animal; Immunologic Factors; Inflammatory Bowel Diseases; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Thalidomide; Trinitrobenzenesulfonic Acid | 2017 |
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2017 |
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antilymphocyte Serum; Deprescriptions; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Mycophenolic Acid; Polycystic Kidney, Autosomal Dominant; Tacrolimus; Thalidomide | 2017 |
Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy.
Topics: Aged; Factor Xa Inhibitors; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Treatment Outcome; Venous Thromboembolism | 2017 |
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.
Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalidomide; Multiple Organ Failure; Myelodysplastic Syndromes; Neutrophils; Paraneoplastic Syndromes; Prednisone; Thalidomide | 2017 |
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Approval; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Drug Resistance, Neoplasm; Europe; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Case of lymphadenopathy with lytic bone lesions.
Topics: Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Incidental Findings; Lenalidomide; Lymphadenopathy; Male; Middle Aged; Multiple Myeloma; Osteolysis; Thalidomide; Treatment Outcome | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis.
Topics: Animals; Cell Movement; Gene Expression Regulation; Glycoproteins; Human Umbilical Vein Endothelial Cells; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Mice; Neovascularization, Pathologic; Osteoarthritis; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
Topics: Adult; Castleman Disease; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymph Nodes; Male; Middle Aged; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Drug Resistance, Viral; Female; Humans; Lenalidomide; Lymphoma, AIDS-Related; Thalidomide; Treatment Outcome | 2017 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
Crystalglobulinemia manifesting as chronic arthralgia and acute limb ischemia: A clinical case report.
Topics: Amputation, Surgical; Arterial Occlusive Diseases; Arthralgia; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Thalidomide | 2017 |
Clonal evolution in myelodysplastic syndromes.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow Cells; Clonal Evolution; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lenalidomide; Male; Membrane Proteins; Middle Aged; Monitoring, Physiologic; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins p21(ras); Thalidomide; Tumor Suppressor Protein p53 | 2017 |
Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
Topics: Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Cytokines; Dendritic Cells; Disease Models, Animal; Female; Gene Expression; Immunity; Immunotherapy; Killer Cells, Natural; Lenalidomide; Mice; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Vaccination | 2017 |
Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission.
Topics: Aged; Female; Hepatitis E; Humans; Immunologic Factors; Lenalidomide; Liver Function Tests; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transaminases | 2017 |
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lenalidomide; Leukemoid Reaction; Multiple Myeloma; Plasma Cells; Thalidomide | 2017 |
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Cell Cycle Checkpoints; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Knockdown Techniques; Humans; Interleukin-6; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Peptide Hydrolases; Phosphatidylinositol 3-Kinases; Signal Transduction; STAT3 Transcription Factor; Survival Analysis; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2017 |
Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Databases, Factual; Drug Administration Schedule; Drug Costs; Eligibility Determination; Female; Health Expenditures; Health Services Accessibility; Healthcare Disparities; Humans; Immunologic Factors; Insurance Benefits; Lenalidomide; Male; Medicare Part D; Models, Economic; Multiple Myeloma; Process Assessment, Health Care; SEER Program; Thalidomide; Time Factors; Treatment Outcome; United States | 2017 |
Lenalidomide acts as an adjuvant for HCV DNA vaccine.
Topics: Adjuvants, Immunologic; Animals; Cell Line, Tumor; Female; Humans; Killer Cells, Natural; Lenalidomide; Mice, Inbred BALB C; Neoplasms; T-Lymphocytes, Cytotoxic; Thalidomide; Vaccines, DNA; Viral Hepatitis Vaccines | 2017 |
Lenalidomide-responsive anti-myelin-associated glycoprotein neuropathy.
Topics: Aged; Female; Humans; Immunoglobulin M; Lenalidomide; Myelin-Associated Glycoprotein; Peripheral Nervous System Diseases; Rituximab; Thalidomide; Treatment Outcome | 2017 |
Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.
Topics: Adult; Aged; Aged, 80 and over; Australia; Electronic Prescribing; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pharmacy Service, Hospital; Queensland; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous | 2017 |
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide | 2017 |
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Microsatellite Repeats; Middle Aged; Multiplex Polymerase Chain Reaction; Myelodysplastic Syndromes; Reproducibility of Results; Thalidomide; Uniparental Disomy | 2017 |
MODULATION OF ANTITUMOR IMMUNE RESPONSE IN MOUSE PROSTATE CANCER MODEL.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Immunologic Factors; Interleukin-12; Interleukin-15; Lenalidomide; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Prostatic Neoplasms; Thalidomide | 2017 |
Low Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant.
Topics: Adjuvants, Immunologic; Animals; Antigens; Cells, Cultured; Cytotoxicity, Immunologic; Female; Humans; K562 Cells; Killer Cells, Natural; L-Lactate Dehydrogenase; Lenalidomide; Lymphocyte Activation; Mice; Thalidomide | 2017 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HIV Seropositivity; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Paraproteinemias; Recurrence; Thalidomide; Treatment Outcome | 2017 |
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy.
Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Peripheral Nervous System Diseases; Plasmacytoma; POEMS Syndrome; Sacrum; Thalidomide | 2017 |
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Intention to Treat Analysis; Lenalidomide; Multiple Myeloma; Quality of Life; Reproducibility of Results; Thalidomide; Time Factors; Treatment Outcome | 2018 |
MUC1-C is a target in lenalidomide resistant multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Lenalidomide; Molecular Targeted Therapy; Mucin-1; Multiple Myeloma; Oxidation-Reduction; Peptides; Reactive Oxygen Species; Thalidomide; Tumor Cells, Cultured | 2017 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Stromal Cells; Thalidomide; Time Factors | 2017 |
JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
Topics: Algorithms; Allografts; Azacitidine; Blood Transfusion; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Japan; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Prognosis; Risk; Thalidomide | 2017 |
Impact of lenalidomide-based induction therapy on the mobilization of CD34
Topics: Aged; Antigens, CD34; Case-Control Studies; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Thalidomide | 2017 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Disease Models, Animal; Female; Lenalidomide; Lymphangiogenesis; Lymphatic Vessels; Mice; Mice, Inbred C57BL; Photochemotherapy; Photosensitizing Agents; Porphyrins; Thalidomide; Vascular Endothelial Growth Factor Receptor-3; Verteporfin | 2017 |
Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better.
Topics: Aged; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.
Topics: Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Immunologic Factors; Japan; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2017 |
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Topics: Acetamides; Aged; Aged, 80 and over; Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Disease Models, Animal; Drug Synergism; Female; Gene Expression Profiling; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Mice; Middle Aged; Multiple Myeloma; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; Lenalidomide; Models, Molecular; Molecular Structure; Neovascularization, Pathologic; Sincalide; Structure-Activity Relationship; Thalidomide | 2017 |
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating MicroRNA; Dexamethasone; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Reproducibility of Results; Retreatment; ROC Curve; Thalidomide; Treatment Outcome | 2017 |
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Medicare; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Thalidomide; United States | 2017 |
Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm.
Topics: Aged; Bone Marrow Neoplasms; Fatal Outcome; Female; Humans; Immunologic Factors; Janus Kinase 2; Lenalidomide; Myeloproliferative Disorders; Thalidomide; Thrombosis | 2017 |
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors | 2017 |
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cerebrosides; Female; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Thalidomide; Treatment Outcome | 2018 |
Eosinophilia secondary to lenalidomide therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cyclophosphamide; Dexamethasone; Eosinophilia; Female; Humans; Lenalidomide; Middle Aged; POEMS Syndrome; Thalidomide | 2018 |
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Statistical; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Risk Assessment; ROC Curve; Survival Rate; Thalidomide | 2017 |
Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2017 |
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thalidomide | 2017 |
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasm Proteins; NIH 3T3 Cells; Peptide Hydrolases; Proteolysis; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2017 |
Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Thalidomide | 2017 |
Maintenance lenalidomide could be most relevant after first-line therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
A case of multiple myeloma with navicular bone involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Osteolysis; Plasma Cells; Remission Induction; Stem Cell Transplantation; Tarsal Bones; Thalidomide | 2017 |
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2017 |
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
Topics: Calgranulin B; Erythropoiesis; Erythropoietin; Hep G2 Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: A case report.
Topics: Arthritis, Rheumatoid; Cell Proliferation; Diagnosis, Differential; Female; Humans; Immunoelectrophoresis; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Systemic; Middle Aged; Neurologic Examination; Osteosclerosis; Plasma Cells; POEMS Syndrome; Sjogren's Syndrome; Thalidomide; Treatment Outcome | 2017 |
Necrobiotic xanthogranuloma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Dermatologic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Necrobiotic Xanthogranuloma; Thalidomide | 2018 |
Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; G1 Phase; Heme Oxygenase-1; Histone Deacetylase Inhibitors; Humans; Janus Kinase 2; Lenalidomide; Multiple Myeloma; Resting Phase, Cell Cycle; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2018 |
Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.
Topics: Aged, 80 and over; Aging; Antigens, CD; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lenalidomide; Lymph Nodes; Lymphoproliferative Disorders; Male; Plasma Cells; Positron Emission Tomography Computed Tomography; Thalidomide | 2018 |
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Case-Control Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Time Factors | 2017 |
Necrotizing autoimmune myopathy associated with POEMS syndrome report.
Topics: Autoimmune Diseases; Dexamethasone; Electromyography; Humans; Lenalidomide; Male; Middle Aged; Muscular Diseases; POEMS Syndrome; Thalidomide | 2018 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide | 2017 |
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian; Black or African American; Bortezomib; Female; Health Services Accessibility; Healthcare Disparities; Hispanic or Latino; Humans; Lenalidomide; Male; Medicare; Multiple Myeloma; Process Assessment, Health Care; Proportional Hazards Models; Risk Factors; SEER Program; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome; United States; White People | 2017 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
[Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Topics: Consensus; Creatinine; Dexamethasone; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Renal Insufficiency, Chronic; Thalidomide | 2017 |
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Lenalidomide plus dexamethasone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2018 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors.
Topics: Chromatography, High Pressure Liquid; Cyclodextrins; Electrophoresis, Capillary; Lenalidomide; Molecular Structure; Polysaccharides; Quantum Theory; Thalidomide | 2018 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Immunologic Factors; Interferon Type I; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2018 |
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Topics: Adult; Aged; Autografts; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide; Time Factors; Transplantation, Autologous | 2018 |
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Cytogenetic Analysis; Hematologic Neoplasms; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Lenalidomide; Megakaryocyte-Erythroid Progenitor Cells; Megakaryocytes; Remission Induction; Thalidomide; Treatment Outcome | 2018 |
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature
.
Topics: Aged, 80 and over; Female; Humans; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Nephrotic Syndrome; Thalidomide | 2018 |
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Adult; Brain; Brain Infarction; Dexamethasone; Female; Humans; Immunologic Factors; Ischemic Attack, Transient; Lenalidomide; Oligopeptides; POEMS Syndrome; Thalidomide | 2018 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Thalidomide | 2018 |
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Retrospective Studies; Thalidomide; von Willebrand Diseases | 2018 |
Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Conserved Sequence; Cullin Proteins; Humans; Immunologic Factors; Lenalidomide; Ligands; Mice; Molecular Probes; Nuclear Proteins; Peptide Hydrolases; Proteasome Endopeptidase Complex; Proteolysis; T-Lymphocytes; Thalidomide; Transcription Factors; Triazoles; Ubiquitin; Ubiquitin-Protein Ligases | 2018 |
Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme.
Topics: Adult; Chronic Disease; Drug Substitution; Erythema Multiforme; Female; Humans; Immunologic Factors; Lenalidomide; Recurrence; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2019 |
[Treatment of systemic AL amyloidosis: about 25 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Hospitals, Military; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Effect of lenalidomide on the human gastric cancer cell line SGC7901/vincristine Notch signaling.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lenalidomide; Receptors, Notch; RNA, Small Interfering; Signal Transduction; Thalidomide; Vincristine | 2018 |
Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Angiogenesis Inhibitors; Animals; Blood Vessels; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Inflammation; Intracranial Arteriovenous Malformations; Intracranial Hemorrhages; Lenalidomide; Lymphokines; Mice; Microvessels; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pericytes; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; Thalidomide | 2018 |
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.
Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Pyrimidines; Thalidomide | 2018 |
Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Topics: Antineoplastic Agents; Female; Graft Rejection; Humans; Kidney Transplantation; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Gene mutations in lenalidomide-treated CLL.
Topics: Genes, Neoplasm; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Thalidomide | 2018 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down-Regulation; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Interleukin-6; Lenalidomide; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/NF-κB/RANKL signaling.
Topics: Animals; Cell Line; Cells, Cultured; Immunologic Factors; Interleukin-1beta; Lenalidomide; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteocytes; Osteogenesis; RANK Ligand; Signal Transduction; Thalidomide | 2018 |
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide | 2018 |
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; CD56 Antigen; Cells, Cultured; Cytotoxicity, Immunologic; Genes, MHC Class I; Humans; Immunologic Factors; K562 Cells; Killer Cells, Natural; Lenalidomide; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Monitoring, Immunologic; Natural Cytotoxicity Triggering Receptor 3; Thalidomide; Xenograft Model Antitumor Assays | 2018 |
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Hemorrhage; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Thromboembolism; Thrombophilia | 2019 |
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Czech Republic; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2018 |
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Topics: Adult; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Prescriptions; Female; Health Expenditures; Humans; Imatinib Mesylate; Lenalidomide; Male; Middle Aged; Neoplasms; Prescription Fees; Retrospective Studies; Survival Analysis; Thalidomide; United States; Young Adult | 2018 |
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Structure-Activity Relationship; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.
Topics: Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Humans; Lenalidomide; Liver; Mice; Models, Animal; RNA; Serum Albumin, Human; Thalidomide | 2018 |
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Topics: Casein Kinase Ialpha; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Lymphoma, Primary Effusion; Molecular Targeted Therapy; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Prospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Second-generation immunomodulatory drugs in leptomeningeal myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunologic Factors; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2019 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Fatigue; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Polyneuropathies; Prednisone; Thalidomide | 2018 |
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Casein Kinase I; Disease Models, Animal; Female; Hematopoiesis; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Myelodysplastic Syndromes; Nerve Tissue Proteins; Point Mutation; Thalidomide | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\
refractory multiple myeloma: a real-life experience
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Pregnancy; Prognosis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey | 2018 |
Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cholesterol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lenalidomide; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Protein Interaction Mapping; Protein Interaction Maps; Signal Transduction; Thalidomide; Transcriptome | 2018 |
Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lenalidomide; Lymphoma, Follicular; Prednisone; Rituximab; Thalidomide; Vincristine | 2018 |
CRISPRing the CRL4
Topics: Adaptor Proteins, Signal Transducing; Cullin Proteins; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Female; Finland; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival; Thalidomide; Treatment Outcome | 2018 |
Advances in POEMS treatment and the need to define standardised outcome measures.
Topics: Biomarkers; Humans; Lenalidomide; Melphalan; Outcome Assessment, Health Care; POEMS Syndrome; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; CYS2-HIS2 Zinc Fingers; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Peptide Hydrolases; Proteolysis; Proteome; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.
Topics: Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide | 2019 |
Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
The shrinking biotech bazaar.
Topics: Biotechnology; Commerce; Drug Industry; Lenalidomide; Thalidomide | 2019 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Health Care Costs; Health Resources; Hospitalization; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Portugal; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2019 |
Response to the Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma".
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2019 |
[Skin Changes in POEMS Syndrome].
Topics: Humans; Lenalidomide; POEMS Syndrome; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myopathies, Nemaline; Paraproteinemias; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2019 |
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Topics: Apoptosis; Benzene Derivatives; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2019 |
Facing lenalidomide-refractory myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Xenograft Model Antitumor Assays | 2020 |
Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis.
Topics: Bayes Theorem; Computer Simulation; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Placebos; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Factors; Thalidomide | 2019 |
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Immunoglobulin D; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Failure | 2020 |
The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues.
Topics: Angiogenesis Inhibitors; Brazil; Cost-Benefit Analysis; Drug and Narcotic Control; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Leukocytes, Mononuclear; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2020 |
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome; United Kingdom | 2020 |
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
Topics: Cell Cycle Proteins; Cell Line; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; HL-60 Cells; Humans; Lenalidomide; Models, Molecular; Molecular Structure; Quinazolinones; Structure-Activity Relationship; Thalidomide; THP-1 Cells; Transcription Factors | 2020 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Dosage Calculations; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Progression-Free Survival; Thalidomide | 2019 |
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Piperacillin, Tazobactam Drug Combination; Pyoderma Gangrenosum; Thalidomide | 2020 |
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2020 |
Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes.
Topics: Cell Respiration; Cytokines; Energy Metabolism; Glycolysis; Humans; Immunologic Factors; Lenalidomide; Lipopolysaccharides; Monocytes; Oxidative Phosphorylation; Thalidomide; Toll-Like Receptor 4 | 2020 |
Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antibodies, Monoclonal; B7-H1 Antigen; Dendritic Cells; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Thalidomide | 2020 |
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Topics: Erythrocyte Transfusion; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2020 |
Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carrier Proteins; Cullin Proteins; DNA-Binding Proteins; Humans; Induced Pluripotent Stem Cells; Lenalidomide; Limb Deformities, Congenital; Mice; Multiprotein Complexes; Mutation; Proteolysis; Rats; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2020 |
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Treatment Outcome; United Kingdom | 2020 |
Tuberculosis during lenalidomide maintenance in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous; Tuberculosis | 2021 |
[Proteinuria in multiple myeloma: Be careful to iatrogeny].
Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomerulosclerosis, Focal Segmental; Humans; Iatrogenic Disease; Kidney; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteinuria; Thalidomide; Thrombotic Microangiopathies; Withholding Treatment | 2020 |
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients.
Topics: Ataxia Telangiectasia; Autoimmune Diseases of the Nervous System; Biomarkers; Cell Line; Cell Proliferation; Cell Survival; Clinical Decision-Making; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance; Genetic Predisposition to Disease; Humans; Immunologic Factors; Induced Pluripotent Stem Cells; Lenalidomide; Mercaptopurine; Nervous System Malformations; Phenotype; Precision Medicine; Predictive Value of Tests; Quinacrine; Thalidomide; Thioguanine | 2020 |
Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Contai
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2020 |
A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Topics: Adaptor Proteins, Signal Transducing; Cell Line; Histone Deacetylase 6; Humans; Lenalidomide; Ligands; Protein Binding; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Thalidomide; Treatment Outcome | 2020 |
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2020 |
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Pleural Neoplasms; Prednisolone; Thalidomide | 2020 |
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Topics: Cell Line, Tumor; Chemokine CCL5; Coculture Techniques; Humans; Interferon Regulatory Factors; Intramolecular Oxidoreductases; Lenalidomide; Macrophage Migration-Inhibitory Factors; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Thalidomide | 2020 |
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2021 |
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Treatment Outcome | 2021 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Dexamethasone; Disease Progression; Female; Humans; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pandemics; Pneumonia, Viral; Prognosis; Remission Induction; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2020 |
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Taiwan; Thalidomide; Treatment Outcome | 2020 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Topics: Animals; Humans; Immunomodulation; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Pharmaceutical Preparations; Thalidomide | 2020 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide | 2020 |
ARID2 is a pomalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Lenalidomide; Multiple Myeloma; Mutation; Protein Binding; Proteolysis; RNA, Messenger; RNA, Small Interfering; Thalidomide; Time Factors; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Doxorubicin; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Nervous System Diseases; Progression-Free Survival; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous; Vincristine | 2020 |
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Point Mutation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
[Multiple myeloma with light chain deposition disease showing needle-like crystal inclusions in plasma cells and macrophages in multiple organs].
Topics: Humans; Lenalidomide; Macrophages; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Thalidomide | 2020 |
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
Topics: Animals; Cell Proliferation; Drug Design; Female; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Sulfides; Thalidomide; Xenograft Model Antitumor Assays | 2021 |
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
Topics: Aged; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2020 |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Taiwan; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2021 |
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Drug Resistance, Neoplasm; Genetic Variation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Targeting cereblon in AML.
Topics: Humans; Lenalidomide; Leukemia, Myeloid, Acute; Stem Cells; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Organ Specificity; Retrospective Studies; Thalidomide | 2021 |
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States.
Topics: Aged; Anemia, Refractory; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Medicare; Methyltransferases; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; United States | 2021 |
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Topics: DNA-Binding Proteins; Hematologic Neoplasms; Humans; Lenalidomide; Oncogene Proteins; Thalidomide; Transcription Factors | 2021 |
Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Health Expenditures; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Young Adult | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction.
Topics: Apoptosis; Cell Line, Transformed; Humans; Lenalidomide; Male; Muscle Contraction; Muscle, Smooth; Prostate; Stromal Cells; Thalidomide | 2021 |
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Topics: Animals; Cell Proliferation; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Half-Life; Humans; K562 Cells; Lenalidomide; Ligands; Mice; Neoplasms; Protein Kinase Inhibitors; Proteolysis; Structure-Activity Relationship; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2021 |
A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis.
Topics: Dexamethasone; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Thalidomide | 2021 |
Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lenalidomide; Microbial Sensitivity Tests; Thalidomide | 2021 |
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
Topics: China; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Therapeutic Equivalency | 2021 |
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Topics: Biomarkers; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2022 |
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Prognosis; Retrospective Studies; RNA Splicing Factors; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome.
Topics: Adult; Dexamethasone; Endothelial Cells; Humans; Kidney Diseases; Lenalidomide; Middle Aged; POEMS Syndrome; Thalidomide; Vascular Endothelial Growth Factor A | 2022 |
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; Disease Progression; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Lenalidomide; Male; Methotrexate; Pneumonia; Pneumonia, Pneumococcal; Rituximab; Thalidomide | 2022 |
[MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes].
Topics: Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2022 |
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Topics: Anemia; Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Macrophages; Mice; Myelodysplastic Syndromes; Thalidomide | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
Topics: Exanthema; Humans; Lenalidomide; Multiple Myeloma; Skin; Thalidomide | 2021 |
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Topics: Genes, p53; Hematopoietic Stem Cells; Humans; Lenalidomide; Mutation; Neoplasms, Second Primary; Thalidomide; Tumor Suppressor Protein p53 | 2022 |
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Thalidomide | 2022 |
Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Ferritins; Humans; Lenalidomide; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Treatment Outcome | 2022 |
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2022 |
Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.
Topics: Animals; Cell Membrane Permeability; Female; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Placenta; Pregnancy; Thalidomide | 2022 |
A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Leukemia, Neutrophilic, Chronic; Multiple Myeloma; Thalidomide | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2022 |
Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Topics: Child; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Thalidomide | 2023 |
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.
Topics: Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2022 |
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
Topics: Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Plasmacytoma; POEMS Syndrome; Thalidomide; Transplantation, Autologous | 2023 |
Dupilumab in Multiple Myeloma: A Case Series.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron.
Topics: Amino Acid Motifs; Asparagine; Cyclization; Dipeptides; Glutamine; Humans; Imides; Lenalidomide; Ligands; Peptide Hydrolases; Proteolysis; Proteome; Thalidomide; Ubiquitin-Protein Ligase Complexes; Ubiquitination | 2022 |
Connecting the dots: lenalidomide and t-MNs.
Topics: Lenalidomide; Thalidomide | 2022 |
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
Topics: Clonal Hematopoiesis; Hematopoiesis; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Embryo-fetal exposure and developmental outcome of lenalidomide following oral administration to pregnant cynomolgus monkeys.
Topics: Administration, Oral; Animals; Cesarean Section; Female; Lenalidomide; Macaca fascicularis; Placenta; Pregnancy; Thalidomide | 2022 |
Molecular and Structural Characterization of Lenalidomide-Mediated Sequestration of eIF3i.
Topics: Adaptor Proteins, Signal Transducing; Lenalidomide; Peptide Hydrolases; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases | 2022 |
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2022 |
Development and validation of a novel chiral chromatographic method for separation of lenalidomide enantiomers in human plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Lenalidomide; Reproducibility of Results; Stereoisomerism; Thalidomide | 2023 |
Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.
Topics: Lenalidomide; Peptide Hydrolases; Thalidomide; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitination | 2023 |
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2023 |
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Tertiary Care Centers; Thalidomide | 2023 |
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2023 |
Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2023 |
Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Patients; Psoriasis; Thalidomide | 2023 |
Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?
Topics: Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2023 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thalidomide | 2023 |
Lenalidomide maintenance based on a genetic profile.
Topics: Genetic Profile; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Topics: Bortezomib; Chemokine CXCL10; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Thalidomide derivatives as nanomolar human neutrophil elastase inhibitors: Rational design, synthesis, antiproliferative activity and mechanism of action.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lenalidomide; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Proteinase Inhibitory Proteins, Secretory; Structure-Activity Relationship; Thalidomide | 2023 |
[Access and safety of dexamethasone in multiple myeloma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2023 |
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Topics: Black or African American; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2023 |
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome | 2023 |
Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Cholestasis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide | 2023 |